WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Friday, March 12, 2004

Hide?	Set Name	Query	Hit Count
		DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ	
☐	L57	L56 AND L45	6
☐	L56	Zoghbi.IN.	35
☐	L55	L54 AND Hayden-Michael.IN.	1
☐	L54	L53 AND L45	56
☐	L53	(Hayden.IN.)	2457
☐	L52	L51 AND Burke-James-R.IN.	3
☐	L51	L50 AND L45	150
☐	L50	(Burke.IN.)	6987
☐	L49	L45 AND L47	7
☐	L48	L42 AND L47	5
☐	L47	(Housman.IN.)	174
☐	L46	L45 AND Kazantsev.IN.	8
☐	L45	aggregate OR aggregation	210298
☐	L44	aggregate OR aggregation	210298
☐	L43	L42 AND aggregate	4
☐	L42	(Kazantsev.IN.)	695
☐	L41	L40 NOT Rose-Craig-A.IN.	179
☐	L40	(huntingtin AND inhibition)	179
☐	L39	L38 AND polyglutamine	44
☐	L38	L37 AND intracellular	6120
☐	L37	(aggregate AND polypeptide AND inhibitor)	9147
☐	L36	(intrabody AND polyglutamine)	6
☐	L35	(intrabody AND huntingtin)	5
☐	L34	L32 NOT Rosen-Craig-A.IN.	78
☐	L33	L32 NOT Rosen-Craig-A.IN/	169
☐	L32	L31 AND aggregate	169
☐	L31	(intrabody)	656
☐	L30	L28 AND polyglutamine	51
☐	L29	L28 AND CAG repeat protein	0
☐	L28	L27 AND intracellular	7190
☐	L27	L25 AND polypeptide	12881
☐	L26	L25 AND polypeptid3e	0
☐	L25	aggregate	168711

☐	L24	L23 AND huntingtin	0
☐	L23	530/387.1.CCLS.	1980
☐	L22	L21 AND huntingtin	4
☐	L21	424/130.1,133.1.CCLS.	1687
☐	L20	424/130.1,133.	0
☐	L19	L18 AND huntingtin	4
☐	L18	424/130.1.CCLS.	1314
☐	L17	L16 AND huntingtin	6
☐	L16	L15 AND aggregate	956
☐	L15	514/1,2.CCLS.	6712
☐	L14	Lecerf-J.IN.	3
☐	L13	Lecerf-Jean-M.IN.	0
☐	L12	Lecerf-Jean.IN.	2
☐	L11	Lecerf-J-M.IN.	3
☐	L10	Lecerf-Jean-Michel.IN.	0
☐	L9	Lecerf.IN.	162
☐	L8	Messer-A.IN.	10
☐	L7	Messer-Anne.IN.	0
☐	L6	Messer.IN.	721
☐	L5	Huston-J.IN.	9
☐	L4	Huston-J-S.IN.	26
☐	L3	Huston-James.IN.	1
☐	L2	Huston-James-S.IN.	35
☐	L1	(Huston.IN.)	1255

END OF SEARCH HISTORY

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for huntingtin AND intrabody Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-2 of 2 One page.

1: Murphy RC, Messer A. Related Articles, Links

A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease.
Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):141-5.
PMID: 14969746 [PubMed - in process]

2: Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston JS Related Articles, Links

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4764-9.
PMID: 11296304 [PubMed - indexed for MEDLINE]

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books

Search PubMed for intrabody Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-53 of 53 One page.

1: Song JM, Xu D, Fan EJ, Xu SR, Li D, Zhao CH. Links

[Cyclin D2 expression in chronic myelogenous leukemia]
Zhonghua Xue Ye Xue Za Zhi. 2004 Feb;25(2):103-5. Chinese.
PMID: 14990053 [PubMed - in process]

2: Murphy RC, Messer A. Related Articles, Links

A single-chain Fv intrabody provides functional protection against the effects of mutant protein in an organotypic slice culture model of Huntington's disease.
Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):141-5.
PMID: 14969746 [PubMed - in process]

3: Secco P, Ferretti M, Gioia D, Cesaro P, Bozzo C, Marks JD, Santoro C. Related Articles, Links

Characterization of a single-chain intrabody directed against the human receptor tyrosine kinase Ron.
J Immunol Methods. 2004 Feb 1;285(1):99-109.
PMID: 14871539 [PubMed - in process]

4: Gennari F, Mehta S, Wang Y, St Clair Tallarico A, Palu G, Marasco WA. Related Articles, Links

Direct phage to intrabody screening (DPIS): demonstration by isolation of cytosolic intrabodies against the TES1 site of Epstein Barr virus latent membrane protein 1 (LMP1) that block NF-kappaB transactivation.
J Mol Biol. 2004 Jan 2;335(1):193-207.
PMID: 14659750 [PubMed - indexed for MEDLINE]

5: Reinman M, Jantti J, Alfthan K, Keranen S, Soderlund H, Takkinen K. Related Articles, Links

Functional inactivation of the conserved Sem1p in yeast by intrabodies.
Yeast. 2003 Sep;20(12):1071-84.
PMID: 12961755 [PubMed - indexed for MEDLINE]

6: Wheeler YY, Kute TE, Willingham MC, Chen SY, Sane DC. Related Articles, Links

Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis.
FASEB J. 2003 Sep;17(12):1733-5. Epub 2003 Jul 03.
PMID: 12958192 [PubMed - indexed for MEDLINE]

7: Jendreyko N, Popkov M, Beerli RR, Chung J, McGavern DB, Rader C, Barbas CF 3rd Related Articles, Links

Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors.
J Biol Chem. 2003 Nov 28;278(48):47812-9. Epub 2003 Aug 28.
PMID: 12947084 [PubMed - indexed for MEDLINE]

8: Wheeler YY, Chen SY, Sane DC. Related Articles, Links

Intrabody and intrakine strategies for molecular therapy.

Mol Ther. 2003 Sep;8(3):355-66. No abstract available.
PMID: 12946308 [PubMed - in process]

9: Tanaka T, Lobato MN, Rabbitts TH. Related Articles, Links

Single domain intracellular antibodies: a minimal fragment for direct in vivo selection of antigen-specific intrabodies.
J Mol Biol. 2003 Aug 29;331(5):1109-20.
PMID: 12927545 [PubMed - indexed for MEDLINE]

10: Nuttall SD, Krishnan UV, Doughty L, Pearson K, Ryan MT, Hoogenraad NJ, Hattarki M, Carmichael JA, Irving RA, Hudson PJ. Related Articles, Links

Isolation and characterization of an IgNAR variable domain specific for the human mitochondrial translocase receptor Tom70.
Eur J Biochem. 2003 Sep;270(17):3543-54.
PMID: 12919318 [PubMed - indexed for MEDLINE]

11: Xu D, Song JM, Hu Y, Guo H, Cao DJ, Wang P, Liu H, Zhao CH. Related Articles, Links

[Effects of anti-ABL tyrosine kinase intrabody on the growth of K562 cells in nude mice]
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002 Feb;24(1):11-4. Chinese.
PMID: 12905832 [PubMed - in process]

12: Wang T, Li JD, Li C, Liang MF, Li DX. Related Articles, Links

[Construction and stable expression of intracellular antibodies to glycoprotein of hantavirus]
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2003 Jun;17(2):116-20. Chinese.

PMID: 12869989 [PubMed - in process]

13: Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S, Canevari S. Related Articles, Links

Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies.
Gene Ther. 2003 Jun;10(12):1018-25.
PMID: 12776159 [PubMed - indexed for MEDLINE]

14: Robin C, Ottersbach K, de Bruijn M, Ma X, van der Horn K, Dzierzak E Related Articles, Links

Developmental origins of hematopoietic stem cells.
Oncol Res. 2003;13(6-10):315-21. Review.
PMID: 12725520 [PubMed - indexed for MEDLINE]

15: Zhang D, Murakami A, Johnson RP, Sui J, Cheng J, Bai J, Marasco WA. Related Articles, Links

Optimization of ex vivo activation and expansion of macaque primary CD4-enriched peripheral blood mononuclear cells for use in anti-HIV immunotherapy and gene therapy strategies.
J Acquir Immune Defic Syndr. 2003 Mar 1;32(3):245-54.
PMID: 12626883 [PubMed - indexed for MEDLINE]

16: Tanaka T, Rabbitts TH. Related Articles, Links

Intrabodies based on intracellular capture frameworks that bind the RAS protein with high affinity and impair oncogenic transformation.
EMBO J. 2003 Mar 3;22(5):1025-35.
PMID: 12606568 [PubMed - indexed for MEDLINE]

17: Tanaka T, Chung GT, Forster A, Lobato MN, Rabbitts TH. Related Articles, Links

De novo production of diverse intracellular antibody libraries.

Nucleic Acids Res. 2003 Mar 1;31(5):e23.
PMID: 12595572 [PubMed - indexed for MEDLINE]

18: Tamura S, Hirano M, Chen X, Sato Y, Narumi Y, Hori M, Takahashi S, Nakamura H. Related Articles, Links

Intrabody three-dimensional position sensor for an ultrasound endoscope.
IEEE Trans Biomed Eng. 2002 Oct;49(10):1187-94.
PMID: 12374344 [PubMed - indexed for MEDLINE]

19: der Maur AA, Zahnd C, Fischer F, Spinelli S, Honegger A, Cambillau C, Escher D, Pluckthun A, Barberis A. Related Articles, Links

Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework.
J Biol Chem. 2002 Nov 22;277(47):45075-85. Epub 2002 Sep 04.
PMID: 12215438 [PubMed - indexed for MEDLINE]

20: Goncalves J, Silva F, Freitas-Vieira A, Santa-Marta M, Malho R, Yang X, Gabuzda D, Barbas C 3rd. Related Articles, Links

Functional neutralization of HIV-1 Vif protein by intracellular immunization inhibits reverse transcription and viral replication.
J Biol Chem. 2002 Aug 30;277(35):32036-45. Epub 2002 May 30.
PMID: 12039955 [PubMed - indexed for MEDLINE]

21: Strube RW, Chen SY. Related Articles, Links

Characterization of anti-cyclin E single-chain Fv antibodies and intrabodies in breast cancer cells: enhanced intracellular stability of novel sFv-F(c) intrabodies.
J Immunol Methods. 2002 May 1;263(1-2):149-67.
PMID: 12009211 [PubMed - indexed for MEDLINE]

22: Scheffer GL, Reurs AW, Jutten B, Beiboer SH, van Amerongen R, Schoester M, Wiemer EA, Hoogenboom HR, Scheper RJ. Related Articles, Links

Selection and characterisation of a phage-displayed human antibody (Fab) reactive to the lung resistance-related major vault protein.
Br J Cancer. 2002 Mar 18;86(6):954-62.
PMID: 11953829 [PubMed - indexed for MEDLINE]

23: Mbashilkar AM, Doebis C, Seifert M, Busch A, Zani C, Soo Hoo J, Nagy M, Ritter T, Volk HD, Marasco WA. Related Articles, Links

Intrabody-mediated phenotypic knockout of major histocompatibility complex class I expression in human and monkey cell lines and in primary human keratinocytes.
Gene Ther. 2002 Mar;9(5):307-19.
PMID: 11938450 [PubMed - indexed for MEDLINE]

24: Huston JS, George AJ. Related Articles, Links

Engineered antibodies take center stage.
Hum Antibodies. 2001;10(3-4):127-42. Review.
PMID: 11847424 [PubMed - indexed for MEDLINE]

25: Auf der Maur A, Escher D, Barberis A. Related Articles, Links

Antigen-independent selection of stable intracellular single-chain antibodies.
FEBS Lett. 2001 Nov 23;508(3):407-12.
PMID: 11728462 [PubMed - indexed for MEDLINE]

26: Boucher M, Bhandari M, Kwok D. Related Articles, Links

Health-related quality of life after short segment instrumentation of lumbar burst fractures.

J Spinal Disord. 2001 Oct;14(5):417-26.
PMID: 11586142 [PubMed - indexed for MEDLINE]

27: Rajpal A, Turi TG. Related Articles, Links

Intracellular stability of anti-caspase-3 intrabodies determines efficacy in retargeting the antigen.
J Biol Chem. 2001 Aug 31;276(35):33139-46. Epub 2001 Jun 25.
PMID: 11425853 [PubMed - indexed for MEDLINE]

28: Lecerf JM, Shirley TL, Zhu Q, Kazantsev A, Amersdorfer P, Housman DE, Messer A, Huston JS Related Articles, Links

Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease.
Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4764-9.
PMID: 11296304 [PubMed - indexed for MEDLINE]

29: Arafat W, Gomez-Navarro J, Xiang J, Siegal GP, Alvarez RD, Curiel DT. Related Articles, Links

Antineoplastic effect of anti-erbB-2 intrabody is not correlated with scFv affinity for its target.
Cancer Gene Ther. 2000 Sep;7(9):1250-6.
PMID: 11023197 [PubMed - indexed for MEDLINE]

30: Alvarez RD, Barnes MN, Gomez-Navarro J, Wang M, Strong TV, Arafat W, Arani RB, Johnson MR, Roberts BL, Siegal GP, Curiel DT. Related Articles, Links

A cancer gene therapy approach utilizing an anti-erbB-2 single-chain antibody-encoding adenovirus (AD21): a phase I trial.
Clin Cancer Res. 2000 Aug;6(8):3081-7.
PMID: 10955787 [PubMed - indexed for MEDLINE]

31: Marasco WA, LaVecchio J, Winkler A. Related Articles, Links

Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS.
J Immunol Methods. 1999 Dec 10;231(1-2):223-38. Review.
PMID: 10648940 [PubMed - indexed for MEDLINE]

32: Zhu Q, Zeng C, Hubalov A, Yao J, Turi TG, Danley D, Hynes T, Cong Y, DiMattia D, Kennedy S, Daumy G, Schaeffer E, Marasco WA, Huston JS. Related Articles, Links

Extended half-life and elevated steady-state level of a single-chain Fv intrabody are critical for specific intracellular retargeting of its antigen, caspase-7.
J Immunol Methods. 1999 Dec 10;231(1-2):207-22.
PMID: 10648939 [PubMed - indexed for MEDLINE]

33: Steinberger P, Andris-Widhopf J, Buhler B, Torbett BE, Barbas CF 3rd. Related Articles, Links

Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion.
Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):805-10.
PMID: 10639161 [PubMed - indexed for MEDLINE]

34: Wirtz P, Steipe B. Related Articles, Links

Intrabody construction and expression III: engineering hyperstable V(H) domains.
Protein Sci. 1999 Nov;8(11):2245-50.
PMID: 10595527 [PubMed - indexed for MEDLINE]

35: Duff RJ, Deamond SF, Roby C, Zhou Y, Ts'o PO. Related Articles, Links

Intrabody tissue-specific delivery of antisense conjugates in animals: ligand-linker-antisense oligomer conjugates.
Methods Enzymol. 2000;313:297-321. No abstract available.
PMID: 10595363 [PubMed - indexed for MEDLINE]

36: Ohage EC, Wirtz P, Barnikow J, Steipe B. Related Articles, Links

Intrabody construction and expression. II. A synthetic catalytic Fv fragment.
J Mol Biol. 1999 Sep 3;291(5):1129-34.
PMID: 10518948 [PubMed - indexed for MEDLINE]

37: Ohage E, Steipe B. Related Articles, Links

Intrabody construction and expression. I. The critical role of VL domain stability.
J Mol Biol. 1999 Sep 3;291(5):1119-28.
PMID: 10518947 [PubMed - indexed for MEDLINE]

38: Mhashilkar AM, LaVecchio J, Eberhardt B, Porter-Brooks J, Boisot S, Dove JH, Pumphrey C, Li X, Weissmahr RN, Ring DB, Ramstedt U, Marasco WA. Related Articles, Links

Inhibition of human immunodeficiency virus type 1 replication in vitro in acutely and persistently infected human CD4+ mononuclear cells expressing murine and humanized anti-human immunodeficiency virus type 1 Tat single-chain variable fragment intrabodies.
Hum Gene Ther. 1999 Jun 10;10(9):1453-67.
PMID: 10395371 [PubMed - indexed for MEDLINE]

39: Cohen PA, Mani JC, Lane DP. Related Articles, Links

Characterization of a new intrabody directed against the N-terminal region of human p53.
Oncogene. 1998 Nov 12;17(19):2445-56.
PMID: 9824155 [PubMed - indexed for MEDLINE]

40: Hassanzadeh Gh G, Devoogdt N, Ghysen A, De Baetselier P, Muyldermans S, Dambly-Chaudiere C. Related Articles, Links

The regulated expression of an intrabody produces a mutant phenotype in Drosophila.
FEBS Lett. 1998 Oct 16;437(1-2):81-6.
PMID: 9804176 [PubMed - indexed for MEDLINE]

41: Hassanzadeh GH G, De Silva KS, Dambly-Chaudiere C, Brys L, Ghysen A, Hamers R, Muyldermans S, De Baetselier P. Related Articles, Links

Isolation and characterization of single-chain Fv genes encoding antibodies specific for Drosophila Poxn protein.
FEBS Lett. 1998 Oct 16;437(1-2):75-80. Erratum in: FEBS Lett 1999 Jan 22;443(1):80.
PMID: 9804175 [PubMed - indexed for MEDLINE]

42: Richardson JH, Hofmann W, Sodroski JG, Marasco WA. Related Articles, Links

Intrabody-mediated knockout of the high-affinity IL-2 receptor in primary human T cells using a bicistronic lentivirus vector.
Gene Ther. 1998 May;5(5):635-44.
PMID: 9797868 [PubMed - indexed for MEDLINE]

43: Chandraraj S, Briggs CA, Opeskin K. Related Articles, Links

Disc herniations in the young and end-plate vascularity.
Clin Anat. 1998;11(3):171-6.
PMID: 9579589 [PubMed - indexed for MEDLINE]

44: Mhashilkar AM, Biswas DK, LaVecchio J, Pardee AB, Marasco WA. Related Articles, Links

Inhibition of human immunodeficiency virus type 1 replication in vitro by a novel combination of anti-Tat single-chain intrabodies and NF-kappa B antagonists.
J Virol. 1997 Sep;71(9):6486-94.
PMID: 9261367 [PubMed - indexed for MEDLINE]

45: Levin R, Mhashilkar AM, Dorfman T, Bukovsky A, Zani C, Bagley J, Hinkula J, Niedrig M, Albert J, Wahren B, Gottlinger HG, Marasco WA. Related Articles, Links

Inhibition of early and late events of the HIV-1 replication cycle by cytoplasmic Fab intrabodies against the matrix protein, p17.
Mol Med. 1997 Feb;3(2):96-110.
PMID: 9085253 [PubMed - indexed for MEDLINE]

46: Medvinsky AL, Gan OI, Semenova ML, Samoylina NL. Related Articles, Links

Development of day-8 colony-forming unit-spleen hematopoietic progenitors during early murine embryogenesis: spatial and temporal mapping.
Blood. 1996 Jan 15;87(2):557-66.
PMID: 8555477 [PubMed - indexed for MEDLINE]

47: Mhashilkar AM, Bagley J, Chen SY, Szilvay AM, Helland DG, Marasco WA. Related Articles, Links

Inhibition of HIV-1 Tat-mediated LTR transactivation and HIV-1 infection by anti-Tat single chain intrabodies.
EMBO J. 1995 Apr 3;14(7):1542-51.
PMID: 7537216 [PubMed - indexed for MEDLINE]

48: Proshina LG. Related Articles, Links

[The ecological-morphological aspects of adaptation and the role of the macrophages in body dehydration]
Aviakosm Ekolog Med. 1995;29(3):31-5. Russian.
PMID: 7550165 [PubMed - indexed for MEDLINE]

49: Chen SY, Bagley J, Marasco WA. Related Articles, Links

Intracellular antibodies as a new class of therapeutic molecules for gene therapy.
Hum Gene Ther. 1994 May;5(5):595-601.
PMID: 7914435 [PubMed - indexed for MEDLINE]

50: Charlton B, Schindhelm K, Smeby LC, Farrell PC. Related Articles, Links

Analysis of immunoglobulin G kinetics in the non-steady state.
J Lab Clin Med. 1985 Mar;105(3):312-20.
PMID: 3973467 [PubMed - indexed for MEDLINE]

51: Ghelman B, Freiberger RH. Related Articles, Links

The limbus vertebra: an anterior disc herniation demonstrated by discography.
Am J Roentgenol. 1976 Nov;127(5):854-5.
PMID: 973676 [PubMed - indexed for MEDLINE]

52: Martel W, Seeger JF, Wicks JD, Washburn RL. Related Articles, Links

Traumatic lesions of the discovertebral junction in the lumbar spine.
Am J Roentgenol. 1976 Sep;127(3):457-64.
PMID: 183533 [PubMed - indexed for MEDLINE]

Kurokawa T. Related Articles, Links

☐ 53:

[Effect of antibiotics and chemotherapeutics on the fetus and neonate with special reference to intrabody transference]
Nippon Sanka Fujinka Gakkai Zasshi. 1967 Mar;19(3):203-12. Japanese. No abstract available.
PMID: 6070772 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Items 1-53 of 53 One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Boo

Search PubMed for intrabody AND review Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-3 of 3 One page.

1: Robin C, Ottersbach K, de Bruijn M, Ma X, van der Horn K, Dzierzak E. Related Articles, Links

Developmental origins of hematopoietic stem cells.
Oncol Res. 2003;13(6-10):315-21. Review.
PMID: 12725520 [PubMed - indexed for MEDLINE]

2: Huston JS, George AJ. Related Articles, Links

Engineered antibodies take center stage.
Hum Antibodies. 2001;10(3-4):127-42. Review.
PMID: 11847424 [PubMed - indexed for MEDLINE]

3: Marasco WA, LaVecchio J, Winkler A. Related Articles, Links

Human anti-HIV-1 tat sFv intrabodies for gene therapy of advanced HIV-1-infection and AIDS.
J Immunol Methods. 1999 Dec 10;231(1-2):223-38. Review.
PMID: 10648940 [PubMed - indexed for MEDLINE]

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25

NCBI PubMed National Library of Medicine NLM

Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for polyglutamine AND inhibition Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Privacy Policy

Display Summary Show: 500 Sort Send to Text

Items 1-56 of 56 One page.

1: Lai TS, Tucker T, Burke JR, Strittmatter WJ, Greenberg CS. Links

Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats.
J Neurochem. 2004 Mar;88(5):1253-60.
PMID: 15009681 [PubMed - in process]

2: Thakur AK, Yang W, Wetzel R. Links

Inhibition of polyglutamine aggregate cytotoxicity by a structure-based elongation inhibitor.
FASEB J. 2004 Mar 4 [Epub ahead of print]
PMID: 15001566 [PubMed - as supplied by publisher]

3: Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, Ellerby LM. Related Articles, Links

Inhibition of calpain cleavage of Huntingtin reduces toxicity: Accumulation of calpain/caspase fragments in the nucleus.
J Biol Chem. 2004 Feb 23 [Epub ahead of print]
PMID: 14981075 [PubMed - as supplied by publisher]

4: Ruan Q, Lesort M, MacDonald ME, Johnson GV. Related Articles, Links

Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway.
Hum Mol Genet. 2004 Apr 1;13(7):669-81. Epub 2004 Feb 12.
PMID: 14962977 [PubMed - in process]

5: Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N. Related Articles, Links

Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease.
Nat Med. 2004 Feb;10(2):148-54. Epub 2004 Jan 18.
PMID: 14730359 [PubMed - in process]

6: Pountney DL, Huang Y, Burns RJ, Haan E, Thompson PD, Blumbergs PC, Gai WP. Related Articles, Links

SUMO-1 marks the nuclear inclusions in familial neuronal intranuclear inclusion disease.
Exp Neurol. 2003 Nov;184(1):436-46.
PMID: 14637113 [PubMed - indexed for MEDLINE]

7: Tarlac V, Storey E. Related Articles, Links

Role of proteolysis in polyglutamine disorders.
J Neurosci Res. 2003 Nov 1;74(3):406-16. Review.
PMID: 14598317 [PubMed - indexed for MEDLINE]

8: Miller LC, Swayne LA, Chen L, Feng ZP, Wacker JL, Muchowski PJ, Zamponi GW, Braun JE. Related Articles, Links

Cysteine string protein (CSP) inhibition of N-type calcium channels is

blocked by mutant huntingtin.
J Biol Chem. 2003 Dec 26;278(52):53072-81. Epub 2003 Oct 21.
PMID: 14570907 [PubMed - indexed for MEDLINE]

9: Meriin AB, Zhang X, Miliaras NB, Kazantsev A, Chernoff YO, McCaffery JM, Wendland B, Sherman MY. Related Articles, Links

Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis.
Mol Cell Biol. 2003 Nov;23(21):7554-65.
PMID: 14560003 [PubMed - indexed for MEDLINE]

10: Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, Stenoien DL, Young M, Faber PW, MacDonald ME, McPhaul MJ, Brady ST. Related Articles, Links

Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport.
Neuron. 2003 Sep 25;40(1):41-52.
PMID: 14527432 [PubMed - indexed for MEDLINE]

11: Kanuka H, Kuranaga E, Hiratou T, Igaki T, Nelson B, Okano H, Miura M. Related Articles, Links

Cytosol-endoplasmic reticulum interplay by Sec61alpha translocon in polyglutamine-mediated neurotoxicity in Drosophila.
Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11723-8. Epub 2003 Sep 22.
PMID: 14504396 [PubMed - indexed for MEDLINE]

12: Ardley HC, Scott GB, Rose SA, Tan NG, Markham AF, Robinson PA. Related Articles, Links

Inhibition of proteasomal activity causes inclusion formation in neuronal and non-neuronal cells overexpressing Parkin.
Mol Biol Cell. 2003 Nov;14(11):4541-56. Epub 2003 Aug 22.
PMID: 12937272 [PubMed - in process]

13: Snider BJ, Moss JL, Revilla FJ, Lee CS, Wheeler VC, Macdonald ME, Choi DW. Related Articles, Links

Neocortical neurons cultured from mice with expanded CAG repeats in the huntingtin gene: unaltered vulnerability to excitotoxins and other insults.
Neuroscience. 2003;120(3):617-25.
PMID: 12895502 [PubMed - indexed for MEDLINE]

14: Li SH, Yu ZX, Li CL, Nguyen HP, Zhou YX, Deng C, Li XJ. Related Articles, Links

Lack of huntingtin-associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease.
J Neurosci. 2003 Jul 30;23(17):6956-64.
PMID: 12890790 [PubMed - indexed for MEDLINE]

15: LaFevre-Bernt MA, Ellerby LM. Related Articles, Links

Kennedy's disease. Phosphorylation of the polyglutamine-expanded form of androgen receptor regulates its cleavage by caspase-3 and enhances cell death.
J Biol Chem. 2003 Sep 12;278(37):34918-24. Epub 2003 Jun 24.
PMID: 12824190 [PubMed - indexed for MEDLINE]

16: Hasholt L, Abell K, Norremolle A, Nellemann C, Fenger K, Sorensen SA. Related Articles, Links

Antisense downregulation of mutant huntingtin in a cell model.
J Gene Med. 2003 Jun;5(6):528-38.
PMID: 12797118 [PubMed - indexed for MEDLINE]

17: Lin CS, Lin G, Lue TF. Related Articles, Links

Isolation of two isoforms of phosphodiesterase 5 from rat penis.
Int J Impot Res. 2003 Apr;15(2):129-36.
PMID: 12789393 [PubMed - indexed for MEDLINE]

18: Bates G. Related Articles, Links

Huntingtin aggregation and toxicity in Huntington's disease.
Lancet. 2003 May 10;361(9369):1642-4. Review.
PMID: 12747895 [PubMed - indexed for MEDLINE]

19: Owecki M, Kozubski W. Related Articles, Links

[Molecular biology of polyglutamine diseases]
Postepy Hig Med Dosw. 2002;56(6):779-88. Review. Polish.
PMID: 12661407 [PubMed - indexed for MEDLINE]

20: Taylor JP, Tanaka F, Robitschek J, Sandoval CM, Taye A, Markovic-Plese S, Fischbeck KH Related Articles, Links

Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein.
Hum Mol Genet. 2003 Apr 1;12(7):749-57.
PMID: 12651870 [PubMed - indexed for MEDLINE]

21: Merienne K, Helmlinger D, Perkin GR, Devys D, Trottier Y. Related Articles, Links

Polyglutamine expansion induces a protein-damaging stress connecting heat shock protein 70 to the JNK pathway.
J Biol Chem. 2003 May 9;278(19):16957-67. Epub 2003 Feb 21.
PMID: 12598532 [PubMed - indexed for MEDLINE]

22: Sanchez I, Mahlke C, Yuan J. Related Articles, Links

Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.
Nature. 2003 Jan 23;421(6921):373-9.
PMID: 12540902 [PubMed - indexed for MEDLINE]

23: Lesort M, Lee M, Tucholski J, Johnson GV. Related Articles, Links

Cystamine inhibits caspase activity. Implications for the treatment of polyglutamine disorders.
J Biol Chem. 2003 Feb 7;278(6):3825-30. Epub 2002 Nov 27.
PMID: 12458211 [PubMed - indexed for MEDLINE]

24: Yohrling IV GJ, Jiang GC, DeJohn MM, Robertson DJ, Vrana KE, Cha JH. Related Articles, Links

Inhibition of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease.
J Neurochem. 2002 Sep;82(6):1416-23.
PMID: 12354289 [PubMed - indexed for MEDLINE]

25: Li F, Macfarlan T, Pittman RN, Chakravarti D. Related Articles, Links

Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities.
J Biol Chem. 2002 Nov 22;277(47):45004-12. Epub 2002 Sep 23.
PMID: 12297501 [PubMed - indexed for MEDLINE]

26: Carmichael J, Sugars KL, Bao YP, Rubinsztein DC. Related Articles, Links

Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation.
J Biol Chem. 2002 Sep 13;277(37):33791-8. Epub 2002 Jul 03.
PMID: 12097329 [PubMed - indexed for MEDLINE]

27: Dunah AW, Jeong H, Griffin A, Kim YM, Standaert DG, Hersch Related Articles, Links

SM, Mouradian MM, Young AB, Tanese N, Krainc D.

Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
Science. 2002 Jun 21;296(5576):2238-43. Epub 2002 May 02.
PMID: 11988536 [PubMed - indexed for MEDLINE]

28: Janknecht R. Related Articles, Links

The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease.
Histol Histopathol. 2002 Apr;17(2):657-68. Review.
PMID: 11962765 [PubMed - indexed for MEDLINE]

29: Hughes RE. Related Articles, Links

Polyglutamine disease: acetyltransferases awry.
Curr Biol. 2002 Feb 19;12(4):R141-3. Review.
PMID: 11864588 [PubMed - indexed for MEDLINE]

30: Higashiyama H, Hirose F, Yamaguchi M, Inoue YH, Fujikake N, Matsukage A, Kakizuka A. Related Articles, Links

Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration.
Cell Death Differ. 2002 Mar;9(3):264-73.
PMID: 11859409 [PubMed - indexed for MEDLINE]

31: Eder IE, Hoffmann J, Rogatsch H, Schafer G, Zopf D, Bartsch G, Klocker H. Related Articles, Links

Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor.
Cancer Gene Ther. 2002 Feb;9(2):117-25.
PMID: 11857028 [PubMed - indexed for MEDLINE]

32: Karpuj MV, Becher MW, Springer JE, Chabas D, Youssef S, Pedotti R, Mitchell D, Steinman L. Related Articles, Links

Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
Nat Med. 2002 Feb;8(2):143-9. Erratum in: Nat Med 2002 Mar;8(3):303.
PMID: 11821898 [PubMed - indexed for MEDLINE]

33: Caplen NJ, Taylor JP, Statham VS, Tanaka F, Fire A, Morgan RA. Related Articles, Links

Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference.
Hum Mol Genet. 2002 Jan 15;11(2):175-84.
PMID: 11809726 [PubMed - indexed for MEDLINE]

34: Ding Q, Lewis JJ, Strum KM, Dimayuga E, Bruce-Keller AJ, Dunn JC, Keller JN. Related Articles, Links

Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival.
J Biol Chem. 2002 Apr 19;277(16):13935-42. Epub 2002 Jan 08.
PMID: 11782460 [PubMed - indexed for MEDLINE]

35: Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP. Related Articles, Links

Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.
Neurobiol Dis. 2001 Dec;8(6):1017-26.
PMID: 11741397 [PubMed - indexed for MEDLINE]

Ren H, Nagai Y, Tucker T, Strittmatter WJ, Burke JR. Related Articles, Links

36:

Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death.
Biochem Biophys Res Commun. 2001 Nov 2;288(3):703-10.
PMID: 11676500 [PubMed - indexed for MEDLINE]

37: Zhou H, Li SH, Li XJ. Related Articles, Links

Chaperone suppression of cellular toxicity of huntingtin is independent of polyglutamine aggregation.
J Biol Chem. 2001 Dec 21;276(51):48417-24. Epub 2001 Oct 17.
PMID: 11606565 [PubMed - indexed for MEDLINE]

38: Dyer RB, McMurray CT. Related Articles, Links

Mutant protein in Huntington disease is resistant to proteolysis in affected brain.
Nat Genet. 2001 Nov;29(3):270-8.
PMID: 11600884 [PubMed - indexed for MEDLINE]

39: Bence NF, Sampat RM, Kopito RR. Related Articles, Links

Impairment of the ubiquitin-proteasome system by protein aggregation.
Science. 2001 May 25;292(5521):1552-5.
PMID: 11375494 [PubMed - indexed for MEDLINE]

40: Waelter S, Boeddrich A, Lurz R, Scherzinger E, Lueder G, Lehrach H, Wanker EE. Related Articles, Links

Accumulation of mutant huntingtin fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation.
Mol Biol Cell. 2001 May;12(5):1393-407.
PMID: 11359930 [PubMed - indexed for MEDLINE]

41: Chu BC, Orgel LE. Related Articles, Links

Inhibition of oligo(glutamine) precipitation by glutamine-containing peptides.
Biochem Biophys Res Commun. 2001 May 4;283(2):351-5.
PMID: 11327707 [PubMed - indexed for MEDLINE]

42: Rigamonti D, Sipione S, Goffredo D, Zuccato C, Fossale E, Cattaneo E. Related Articles, Links

Huntingtin's neuroprotective activity occurs via inhibition of procaspase-9 processing.
J Biol Chem. 2001 May 4;276(18):14545-8. Epub 2001 Mar 05.
PMID: 11278258 [PubMed - indexed for MEDLINE]

43: de Cristofaro T, Affaitati A, Feliciello A, Avvedimento EV, Varrone S. Related Articles, Links

Polyglutamine-mediated aggregation and cell death.
Biochem Biophys Res Commun. 2000 Jun 16;272(3):816-21.
PMID: 10860836 [PubMed - indexed for MEDLINE]

44: Heiser V, Scherzinger E, Boeddrich A, Nordhoff E, Lurz R, Schugardt N, Lehrach H, Wanker EE. Related Articles, Links

Inhibition of huntingtin fibrillogenesis by specific antibodies and small molecules: implications for Huntington's disease therapy.
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6739-44.
PMID: 10829068 [PubMed - indexed for MEDLINE]

45: Nagai Y, Tucker T, Ren H, Kenan DJ, Henderson BS, Keene JD, Strittmatter WJ, Burke JR. Related Articles, Links

Inhibition of polyglutamine protein aggregation and cell death by novel

peptides identified by phage display screening.
J Biol Chem. 2000 Apr 7;275(14):10437-42.
PMID: 10744733 [PubMed - indexed for MEDLINE]

46: Wyttenbach A, Carmichael J, Swartz J, Furlong RA, Narain Y, Rankin J, Rubinsztein DC. Related Articles, Links

Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease.
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2898-903.
PMID: 10717003 [PubMed - indexed for MEDLINE]

47: Leavitt BR, Wellington CL, Hayden MR. Related Articles, Links

Recent insights into the molecular pathogenesis of Huntington disease.
Semin Neurol. 1999;19(4):385-95. Review. Erratum in: Semin Neurol 2000;20(2):269.
PMID: 10716661 [PubMed - indexed for MEDLINE]

48: Irvine RA, Ma H, Yu MC, Ross RK, Stallcup MR, Coetzee GA. Related Articles, Links

Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length.
Hum Mol Genet. 2000 Jan 22;9(2):267-74.
PMID: 10607837 [PubMed - indexed for MEDLINE]

49: de Cristofaro T, Affaitati A, Cariello L, Avvedimento EV, Varrone S. Related Articles, Links

The length of polyglutamine tract, its level of expression, the rate of degradation, and the transglutaminase activity influence the formation of intracellular aggregates.
Biochem Biophys Res Commun. 1999 Jun 24;260(1):150-8.
PMID: 10381359 [PubMed - indexed for MEDLINE]

50: Ona VO, Li M, Vonsattel JP, Andrews LJ, Khan SQ, Chung WM, Frey AS, Menon AS, Li XJ, Stieg PE, Yuan J, Penney JB, Young AB, Cha JH, Friedlander RM. Related Articles, Links

Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease.
Nature. 1999 May 20;399(6733):263-7.
PMID: 10353249 [PubMed - indexed for MEDLINE]

51: Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. Related Articles, Links

Caspase-8 is required for cell death induced by expanded polyglutamine repeats.
Neuron. 1999 Mar;22(3):623-33.
PMID: 10197541 [PubMed - indexed for MEDLINE]

52: Kim M, Lee HS, LaForet G, McIntyre C, Martin EJ, Chang P, Kim TW, Williams M, Reddy PH, Tagle D, Boyce FM, Won L, Heller A, Aronin N, DiFiglia M. Related Articles, Links

Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition.
J Neurosci. 1999 Feb 1;19(3):964-73.
PMID: 9920660 [PubMed - indexed for MEDLINE]

53: Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH. Related Articles, Links

Biochemical abnormalities and excitotoxicity in Huntington's disease brain.
Ann Neurol. 1999 Jan;45(1):25-32.
PMID: 9894873 [PubMed - indexed for MEDLINE]

54: Related Articles, Links
Moulder KL, Onodera O, Burke JR, Strittmatter WJ, Johnson EM

Jr.

Generation of neuronal intranuclear inclusions by polyglutamine-GFP: analysis of inclusion clearance and toxicity as a function of polyglutamine length.
J Neurosci. 1999 Jan 15;19(2):705-15.
PMID: 9880591 [PubMed - indexed for MEDLINE]

55: Sheline CT, Choi DW. Related Articles, Links

Neuronal death in cultured murine cortical cells is induced by inhibition of GAPDH and triosephosphate isomerase.
Neurobiol Dis. 1998 Jul;5(1):47-54.
PMID: 9702787 [PubMed - indexed for MEDLINE]

56: Khan NA, Quemener V, Moulinoux P. Related Articles, Links

Inhibition of adenylate cyclase activity by polyamines in human erythrocyte plasma membranes.
Life Sci. 1990;46(1):43-7.
PMID: 2105420 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Items 1-56 of 56 One page.

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Mar 11 2004 06:56:25

```
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:51:05 ON 12 MAR 2004

=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 12:51:23 ON 12 MAR 2004

FILE 'ANABSTR' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'AQUASCI' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Biological Abstracts, Inc. (BIOSIS)

FILE 'BIOCOMMERCE' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOSIS' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 12:51:23 ON 12 MAR 2004

FILE 'CAPLUS' ENTERED AT 12:51:23 ON 12 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 12:51:23 ON 12 MAR 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve
```

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 12:51:23 ON 12 MAR 2004

FILE 'FOMAD' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 12:51:23 ON 12 MAR 2004

FILE 'HEALSAFE' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemi:

FILE 'LIFESCI' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 12:51:23 ON 12 MAR 2004

FILE 'NIOSHTIC' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 12:51:23 ON 12 MAR 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.

FILE 'NUTRACEUT' ENTERED AT 12:51:23 ON 12 MAR 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 12:51:23 ON 12 MAR 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 12:51:23 ON 12 MAR 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'RDISCLOSURE' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT 2004 THOMSON ISI

FILE 'SYNTHLINE' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 12:51:23 ON 12 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:51:23 ON 12 MAR 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIDS' ENTERED AT 12:51:23 ON 12 MAR 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> S intrabody
 34 FILES SEARCHED...
 63 FILES SEARCHED...
L1 1981 INTRABODY

=> S L1 AND aggregate
 46 FILES SEARCHED...
L2 241 L1 AND AGGREGATE

=> DUP REM L2
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L2

```
=> S L3 AND polyglutamine
  30 FILES SEARCHED...
  62 FILES SEARCHED...
L4            8 L3 AND POLYGLUTAMINE

=> D L4 1-8

L4   ANSWER 1 OF 8  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN   2003:294884  BIOSIS
DN   PREV200300294884
TI   SINGLE - CHAIN FV   ***INTRABODIES***   As THERAPEUTIC AGENTS FOR
     HUNTINGTON'S DISEASE.
AU   Miller, T. W. [Reprint Author]; Murphy, R. C. [Reprint Author]; Shirley,
     T. L. [Reprint Author]; Messer, A. [Reprint Author]
CS   DGD, Wadsworth Center, Albany, NY, USA
SO   Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)
     Vol. 2002, pp. Abstract No. 388.19. http://sfn.scholarone.com. cd-rom.
     Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience.
     Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT   Conference; (Meeting)
     Conference; (Meeting Poster)
     Conference; Abstract; (Meeting Abstract)
LA   English
ED   Entered STN: 25 Jun 2003
     Last Updated on STN: 25 Jun 2003

L4   ANSWER 2 OF 8  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN   2001:509397  BIOSIS
DN   PREV200100509397
TI   A single-chain Fv   ***intrabody***   reduces abnormal interactions of
     mutant huntingtin.
AU   Messer, A. [Reprint author]; Murphy, R. C.; Shirley, T. L.; Snyder-Keller,
     A. [Reprint author]
CS   NY State Dept Hlth, Wadsworth Ctr., Albany, NY, USA
SO   Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 867. print.
     Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San
     Diego, California, USA. November 10-15, 2001.
     ISSN: 0190-5295.
DT   Conference; (Meeting)
     Conference; Abstract; (Meeting Abstract)
LA   English
ED   Entered STN: 31 Oct 2001
     Last Updated on STN: 23 Feb 2002

L4   ANSWER 3 OF 8  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN   2001:269904  BIOSIS
DN   PREV200100269904
TI   Human single-chain Fv   ***intrabodies***   counteract in situ huntingtin
     aggregation in cellular models of Huntington's disease.
AU   Lecerf, Jean-Michel; Shirley, Thomas L.; Zhu, Quan; Kazantsev, Aleksey;
     Amersdorfer, Peter; Housman, David E.; Messer, Anne [Reprint author];
     Huston, James S. [Reprint author]
CS   Wadsworth Center/David Axelrod Institute, New York State Department of
     Health, Albany, NY, 12201-2002, USA
     messer@wadsworth.org; jhuston@lexigenpharm.com
SO   Proceedings of the National Academy of Sciences of the United States of
     America, (April 10, 2001) Vol. 98, No. 8, pp. 4764-4769. print.
     CODEN: PNASA6. ISSN: 0027-8424.
DT   Article
LA   English
ED   Entered STN: 6 Jun 2001
     Last Updated on STN: 19 Feb 2002

L4   ANSWER 4 OF 8  CAPLUS  COPYRIGHT 2004 ACS on STN
AN   2001:78183  CAPLUS
DN   134:136659
TI   Methods and compositions for inhibiting polypeptide accumulation
     associated with neurological disorders
IN   Huston, James S.; Messer, Anne; Lecerf, Jean-Michel
PA   USA
SO   PCT Int. Appl., 108 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
```

```
     PATENT NO.          KIND  DATE           APPLICATION NO.  DATE
     ---------------     ----  --------       ---------------  --------
PI   WO 2001006989        A2   20010201       WO 2000-US20131  20000724
     WO 2001006989        A3   20010816
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     AU 2000062347        A5   20010213       AU 2000-62347    20000724
     EP 1204674           A2   20020515       EP 2000-948919   20000724
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     JP 2003531570        T2   20031028       JP 2001-511881   20000724
PRAI US 1999-146047P      P    19990727
     US 2000-620955       A    20000721
     WO 2000-US20131      W    20000724

L4   ANSWER 5 OF 8  FEDRIP COPYRIGHT 2004 NTIS on STN
AN   2004:204473  FEDRIP
NR   CRISP 5F31NS43033-02
TI     ***Intrabody***   Therapy for Huntington's Disease
SF   Principal Investigator: MILLER, TODD W; MILLLER2@WADSWORTH.ORG, WADSWORTH
     CENTER, 120 NEW SCOTLAND AVENUE
CSP  WADSWORTH CENTER, ALBANY, NEW YORK
CSS  Supported By: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
DB   2001 (/03/02)
FYR  2003
FU   Noncompeting Continuation (Type 5)
FS   National Institutes of Health

L4   ANSWER 6 OF 8  USPATFULL on STN
AN     2003:329841  USPATFULL
TI     Antibodies that bind to an epitope on the Huntington's disease protein
IN     Khoshnan, Ali, South Pasadena, CA, UNITED STATES
       Ko, Jan, Arcadia, CA, UNITED STATES
       Patterson, Paul H., Altadena, CA, UNITED STATES
PI     US 2003232052      A1   20031218
AI     US 2003-354246     A1   20030128 (10)
PRAI   US 2002-353032P     20020128 (60)
DT     Utility
FS     APPLICATION
LN.CNT 1907
INCL   INCLM: 424/146.100
       INCLS: 530/388.260
NCL    NCLM:  424/146.100
       NCLS:  530/388.260
IC     [7]
       ICM: A61K039-395
       ICS: C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4   ANSWER 7 OF 8  USPATFULL on STN
AN     2003:207323  USPATFULL
TI     Human ataxin-1-like polypeptide IMX97018
IN     Anderson, Dirk M., Seattle, WA, UNITED STATES
PI     US 2003143681      A1   20030731
AI     US 2002-207706     A1   20020726 (10)
PRAI   US 2001-309056P     20010730 (60)
DT     Utility
FS     APPLICATION
LN.CNT 3589
INCL   INCLM: 435/069.100
       INCLS: 435/199.000; 435/320.100; 435/325.000; 435/006.000; 435/254.200;
              536/023.200
NCL    NCLM:  435/069.100
       NCLS:  435/199.000; 435/320.100; 435/325.000; 435/006.000; 435/254.200;
              536/023.200
IC     [7]
       ICM: C12Q001-68
       ICS: C12N009-22; C07H021-04; C12N001-18; C12P021-02; C12N005-06
```

```
L4   ANSWER 8 OF 8  USPATFULL on STN
AN     2003:50847  USPATFULL
TI     Methods for alleviating symptoms associated with neuropathic conditions
       comprising administration of low levels of antibodies
IN     McMichael, John, Delanson, NY, UNITED STATES
PI     US 2003035803      A1   20030220
AI     US 2002-223498     A1   20020819 (10)
RLI    Continuation-in-part of Ser. No. US 2001-918343, filed on 30 Jul 2001,
       GRANTED, Pat. No. US 6436401 Continuation-in-part of Ser. No. US
       2001-774770, filed on 31 Jan 2001, GRANTED, Pat. No. US 6294171
       Continuation-in-part of Ser. No. US 2000-514993, filed on 29 Feb 2000,
       GRANTED, Pat. No. US 6187309
PRAI   US 1999-153838P     19990914 (60)
DT     Utility
FS     APPLICATION
LN.CNT 906
INCL   INCLM: 424/146.100
NCL    NCLM:  424/146.100
IC     [7]
       ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> S huntingtin
  57 FILES SEARCHED...
L5         7454 HUNTINGTIN

=> DUP REM L5
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING IS APPROXIMATELY  18% COMPLETE FOR L5
PROCESSING IS APPROXIMATELY  45% COMPLETE FOR L5
PROCESSING IS APPROXIMATELY  74% COMPLETE FOR L5
PROCESSING IS APPROXIMATELY  96% COMPLETE FOR L5
PROCESSING COMPLETED FOR L5
L6         3176 DUP REM L5 (4278 DUPLICATES REMOVED)

=> S L6 AND inhibition
  20 FILES SEARCHED...
  38 FILES SEARCHED...
  60 FILES SEARCHED...
L7          266 L6 AND INHIBITION

=> D L7 1-266

L7   ANSWER 1 OF 266  ADISNEWS COPYRIGHT (C) 2004 Adis Data Information BV on
     STN
ACCESSION NUMBER:     2003:2086  ED: 15 May 2003  UP: 15 May 2003
DOCUMENT NUMBER:      11738324-800925885
TITLE:                Reviews: Targeting   ***huntingtin***   in Huntington's
                      disease.
SOURCE:               INPHARMA  15 May 2003  ISSN: 1173-8324
DOCUMENT TYPE:        (MIX)
WORD COUNT:           199

L7   ANSWER 2 OF 266  ADISNEWS COPYRIGHT (C) 2004 Adis Data Information BV on
     STN
ACCESSION NUMBER:     2002:1187  ED: 14 Mar 2002  UP: 14 Mar 2002
DOCUMENT NUMBER:      11738324-800899808
TITLE:                Product news: TGase inhibitors: potential treatment for
                      Huntington's disease?
SOURCE:               INPHARMA  14 Mar 2002  ISSN: 1173-8324
DOCUMENT TYPE:        (MIX)
WORD COUNT:           242

L7   ANSWER 3 OF 266  BIOSIS  COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN   2004:98798  BIOSIS
DN   PREV200400101758
TI   Cysteine string protein (CSP)   ***inhibition***   of N-type calcium
     channels is blocked by mutant   ***huntingtin***   .
AU   Miller, Linda C.; Swayne, Leigh Anne; Chen, Lina; Feng, Zhong-Ping;
     Wacker, Jennifer L.; Muchowski, Paul J.; Zamponi, Gerald W.; Braun, Janice
     E. A. [Reprint Author]
```

University of Calgary, Calgary, AB, T2N 4N1, Canada
braunj@ucalgary.ca
SO Journal of Biological Chemistry, (December 26 2003) Vol. 278, No. 52, pp. 53072-53081. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 18 Feb 2004
Last Updated on STN: 18 Feb 2004

L7 ANSWER 4 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2004:27106 BIOSIS
DN PREV200400028272
TI Role of proteolysis in polyglutamine disorders.
AU Tarlac, V.; Storey, E. [Reprint Author]
CS Department of Neuroscience, Alfred Hospital, Commercial Road, 4th Floor, Melbourne, VIC, 3004, Australia
elsdon.storey@med.monash.edu.au
SO Journal of Neuroscience Research, (November 1 2003) Vol. 74, No. 3, pp. 406-416. print.
ISSN: 0360-4012 (ISSN print).
DT Article
Editorial
LA English
ED Entered STN: 31 Dec 2003
Last Updated on STN: 31 Dec 2003

L7 ANSWER 5 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:569968 BIOSIS
DN PREV200300569923
TI Lack of ***huntingtin*** -associated protein-1 causes neuronal death resembling hypothalamic degeneration in Huntington's disease.
AU Li, Shi-Hua; Yu, Zhao-Xue; Li, Cui-Lin; Nguyen, Huu-Phuc; Zhou, Yong-Xing; Deng, Chuxia; Li, Xiao-Jiang [Reprint Author]
CS Department of Human Genetics, Emory University School of Medicine, 615 Michael Street, Atlanta, GA, 30322, USA
xiaoli@genetics.emory.edu
SO Journal of Neuroscience, (July 30 2003) Vol. 23, No. 17, pp. 6956-6964. print.
ISSN: 0270-6474 (ISSN print).
DT Article
LA English
ED Entered STN: 10 Dec 2003
Last Updated on STN: 10 Dec 2003

L7 ANSWER 6 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:536291 BIOSIS
DN PREV200300524189
TI Histone deacetylase ***inhibition*** by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.
AU Ferrante, Robert J. [Reprint Author]; Kubilus, James K.; Lee, Junghee; Ryu, Hoon; Beesen, Ayshe; Zucker, Birgit; Smith, Karen; Kowall, Neil W.; Ratan, Rajiv R.; Luthi-Carter, Ruth; Hersch, Steven M.
CS Geriatric Research Education and Clinical Center Unit 182B, Bedford Veterans Affairs Medical Center, 200 Springs Road, Bedford, MA, 01730, USA
rjferr@bu.edu
SO Journal of Neuroscience, (October 15 2003) Vol. 23, No. 28, pp. 9418-9427. print.
ISSN: 0270-6474 (ISSN print).
DT Article
LA English
ED Entered STN: 12 Nov 2003
Last Updated on STN: 12 Nov 2003

L7 ANSWER 7 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:536241 BIOSIS
DN PREV200300524139
TI ***Huntingtin*** forms toxic NH2-terminal fragment complexes that are promoted by the age-dependent decrease in proteasome activity.
AU Zhou, Hui; Cao, Fengli; Wang, Zhishan; Yu, Zhao-Xue; Nguyen, Huu-Phuc; Evans, Joy; Li, Shi-Hua; Li, Xiao-Jiang [Reprint Author]
CS Dept. of Human Genetics, Emory University School of Medicine, 615 Michael St., Atlanta, GA, 30322, USA
xiaoli@genetics.emory.edu
SO Journal of Cell Biology, (October 13 2003) Vol. 163, No. 1, pp. 109-118.

CODEN: JCLBA3. ISSN: 0021-9525.
DT Article
LA English
ED Entered STN: 12 Nov 2003
Last Updated on STN: 12 Nov 2003

L7 ANSWER 8 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:491987 BIOSIS
DN PREV200300486833
TI Geldanamycin activates a heat shock response and inhibits ***huntingtin*** aggregation in a cell culture model of Huntington's disease.
AU Sittler, A. [Reprint Author]; Lurz, R.; Lueder, G.; Priller, J.; Lehrach, H.; Hayer-Hartl, M.; Hartl, U.; Wanker, E. E.
CS IGBMC, CU Strasbourg, Illkirch, France
SO European Journal of Human Genetics, (2002) Vol. 10, No. Supplement 1, pp. 270. print.
Meeting Info.: European Human Genetics Conference 2002 in conjunction with the European Meeting on Psychosocial Aspects of Genetics 2002. Strasbourg, France. May 25-28, 2002. European Society of Human Genetics (ESHG).
ISSN: 1018-4813.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 22 Oct 2003
Last Updated on STN: 22 Oct 2003

L7 ANSWER 9 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:478915 BIOSIS
DN PREV200300478915
TI Kinetic analysis of the action of tissue transglutaminase on peptide and protein substrates.
AU Case, April; Stein, Ross L. [Reprint Author]
CS Laboratory for Drug Discovery in Neurodegeneration, Harvard Center for Neurodegeneration and Repair, 65 Landsdowne Street, Fourth Floor, Cambridge, MA, 02139, USA
rstein@rics.bwh.harvard.edu
SO Biochemistry, (August 12 2003) Vol. 42, No. 31, pp. 9466-9481. print.
ISSN: 0006-2960 (ISSN print).
DT Article
LA English
ED Entered STN: 15 Oct 2003
Last Updated on STN: 15 Oct 2003

L7 ANSWER 10 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:421888 BIOSIS
DN PREV200300421888
TI Neocortical neurons cultured from mice with expanded CAG repeats in the ***huntingtin*** gene: Unaltered vulnerability to excitotoxins and othe insults.
AU Snider, B. J. [Reprint Author]; Moss, J. L.; Revilla, F. J.; Lee, C.-S.; Wheeler, V. C.; MacDonald, M. E.; Choi, D. W.
CS Center for the Study of Nervous System Injury and Department of Neurology, Washington University School of Medicine, 660 South Euclid, Campus Box 8111, Saint Louis, MO, 63110, USA
sniderj@neuro.wustl.edu
SO Neuroscience, (1 September 2003) Vol. 120, No. 3, pp. 617-625. print.
CODEN: NRSCDN. ISSN: 0306-4522.
DT Article
LA English
ED Entered STN: 10 Sep 2003
Last Updated on STN: 10 Sep 2003

L7 ANSWER 11 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:391671 BIOSIS
DN PREV200300391671
TI Proteasome ***inhibition*** in neurodegenerative diseases.
AU Mensah, Kwame N. [Reprint Author]; Matouschek, Andreas
CS Biochemistry, Molecular Biology, and Cell Biology, Northwestern University, 2205 Tech Dr, Evanston, IL, 60208, USA
k-mensah1@northwestern.edu; matouschek@northwestern.edu
SO FASEB Journal, (March 2003) Vol. 17, No. 4-5, pp. Abstract No. 850.13.
http://www.fasebj.org/. e-file.
Meeting Info.: FASEB Meeting on Experimental Biology: Translating the

ISSN: 0892-6638 (ISSN print).
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 27 Aug 2003
Last Updated on STN: 27 Aug 2003

L7 ANSWER 12 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:334948 BIOSIS
DN PREV200300334948
TI Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: Implications for Huntington's Disease.
AU Bizat, Nicolas; Hermel, Jean-Michel; Boyer, Frederic; Jacquard, Carine; Creminon, Christophe; Ouary, Stephane; Escartin, Carole; Hantraye, Philippe; Krajewski, Stan; Brouillet, Emmanuel [Reprint Author]
CS Unite de Recherche Associee, DRM, DSV, Commissariat a l'Energie Atomique (CEA)-Centre National de la Recherche Scientifique 2210, Service Hospitalier Frederic Joliot, CEA, 4 Place du General Leclerc, 91401, Orsay Cedex, France
brouille@shfj.cea.fr
SO Journal of Neuroscience, (June 15 2003) Vol. 23, No. 12, pp. 5020-5030. print.
ISSN: 0270-6474 (ISSN print).
DT Article
LA English
ED Entered STN: 23 Jul 2003
Last Updated on STN: 23 Jul 2003

L7 ANSWER 13 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:327040 BIOSIS
DN PREV200300327040
TI PROTEASOME MODULATION BY RITONAVIR EXTENDS THE LIFE OF THE SOD1 G93A MOUSE MODEL OF AMYOTROPHIC LATERAL SCLEROSIS.
AU Kelly, N. [Reprint Author]; Sadasivan, S. [Reprint Author]; Gupta, M. [Reprint Author]; Scott, S. [Reprint Author]; Guleria, I. [Reprint Author]; Manes, L. V. [Reprint Author]; Ramasubbu, J. [Reprint Author]; Ramesh, T. M. [Reprint Author]
CS Dept. R and D, ALS Therapy Development Foundation, San Francisco, CA, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 789.2. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 16 Jul 2003
Last Updated on STN: 16 Jul 2003

L7 ANSWER 14 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:303815 BIOSIS
DN PREV200300303815
TI ANXIETY - LIKE BEHAVIOR IN AN INDUCIBLE AND A TISSUE - SPECIFIC MOUSE MODEL OF HUNTINGTON'S DISEASE.
AU Stark, K. L. [Reprint Author]; Yamamoto, A. [Reprint Author]; Holick, K. A.; Hen, R. [Reprint Author]
CS Dept Neurobiol, Columbia Univ, New York, NY, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 417.1. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 2 Jul 2003
Last Updated on STN: 2 Jul 2003

L7 ANSWER 15 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:293409 BIOSIS
DN PREV200300293409
TI ROLES OF P53 IN HUNTINGTON'S DISEASE: POSSIBLE INVOLVEMENT IN MITOCHONDRIAL FUNCTION AND CALCIUM HOMEOSTASIS.
AU Bae, B. I. [Reprint Author]; Igarashi, S. [Reprint Author]; Fujimuro, M.;

Snyder, S. H. [Reprint Author]; Sawa, A. [Reprint Author]
CS Neuroscience, Psychiatry and Behavioral Sciences, Pharmacology and Molecular Sciences, Oncology, Johns Hopkins Univ Sch Med, Baltimore, MD, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 293.19. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 25 Jun 2003
Last Updated on STN: 25 Jun 2003

L7 ANSWER 16 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:293403 BIOSIS
DN PREV200300293403
TI NON - CASPASE CLEAVAGE IS RESPONSIBLE FOR NUCLEAR AGGREGATION OF MUTANT ***HUNTINGTIN***
AU Zhou, H. [Reprint Author]; Yu, Z. X. [Reprint Author]; Nguyen, H. P. [Reprint Author]; Li, S. H. [Reprint Author]; Li, X. J. [Reprint Author]
CS Dept Human Genetics, Emory Univ Sch Med, Atlanta, GA, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 293.13. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 25 Jun 2003
Last Updated on STN: 25 Jun 2003

L7 ANSWER 17 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:282852 BIOSIS
DN PREV200300282852
TI M826, A SELECTIVE CASPASE - 3 INHIBITOR, ATTENUATES MALONATE - INDUCED NEURONAL DEATH.
AU Toulmond, S. [Reprint Author]; Ashdown, H. J. [Reprint Author]; Degen, S. [Reprint Author]; Tang, K. [Reprint Author]; Bureau, Y. [Reprint Author]; Zhu, Y. [Reprint Author]; Rozon, J. [Reprint Author]; Colucci, J. [Reprint Author]; Giroux, A. [Reprint Author]; Han, Y. [Reprint Author]; Roy, S. [Reprint Author]; Zamboni, R. [Reprint Author]; Nicholson, D. W. [Reprint Author]; Robertson, G. S. [Reprint Author]; Fluckiger, J. P. [Reprint Author]
CS Dept Pharmacology, Department of Biochemistry, Department of Chemistry, Department of Animal Resources, Merck-Frosst Canada and Co, Pointe-Claire - Dorval, Montreal, PQ, H9R 4P8, Canada
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 200.3. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 19 Jun 2003
Last Updated on STN: 19 Jun 2003

L7 ANSWER 18 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:282776 BIOSIS
DN PREV200300282776
TI TYROSINE HYDROXYLASE ACTIVITY AND mRNA CHANGES IN HUNTINGTON'S DISEASE.
AU Jiang, G. C. T. [Reprint Author]; Yohrling IV, G. J.; Miller, D. W.; DeJohn, M. M.; Vrana, K. E.; Cha, J. H. J.
CS Molecular Genetics Program, Wake Forest Univ Sch Med, Winston-Salem, NC, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 195.14. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 19 Jun 2003

L7 ANSWER 19 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:282764 BIOSIS
DN PREV200300282764
TI C - SRC ACTIVATION IS INVOLVED IN SENSITIZATION OF NMDA RECEPTORS BY POLYGLUTAMINE - EXPANDED ***HUNTINGTIN*** .
AU Liu, Y. F. [Reprint Author]; Song, C. [Reprint Author]; Liu, A. [Reprint Author]; Wang, D. [Reprint Author]
CS Dept Phamarcol, Boston Univ Sch med, Boston, MA, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 195.20. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 19 Jun 2003
Last Updated on STN: 19 Jun 2003

L7 ANSWER 20 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:269152 BIOSIS
DN PREV200300269152
TI CELL DEATH TRIGGERED BY NUCLEAR AGGREGATION OF POLYGLUTAMINE - EXPANDED ***HUNTINGTIN*** IN A NEURONAL CELL LINE IS ASSOCIATED WITH BOTH THE RECRUITMENT AND THE DEGRADATION OF CREB - BINDING PROTEIN.
AU Jiang, H. [Reprint Author]; Nucifora, F. C.; Ross, C. A.; DeFranco, D. B. [Reprint Author]
CS Pharmacology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 92.12. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 11 Jun 2003
Last Updated on STN: 11 Jun 2003

L7 ANSWER 21 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2003:269143 BIOSIS
DN PREV200300269143
TI ENHANCED TOXICITY TO CATECHOLAMINES IN POLYGLUTAMINE TRANSFECTED SH - SY5Y CELLS.
AU Smith, R. R. [Reprint Author]; Dimayuga, E. R.; Keller, J. N.; Maragos, W. F. [Reprint Author]
CS Dept Neurology, University of Kentucky, Lexington, KY, USA
SO Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 92.20. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience. Orlando, Florida, USA. November 02-07, 2002. Society for Neuroscience.
DT Conference; (Meeting)
Conference; (Meeting Poster)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 11 Jun 2003
Last Updated on STN: 11 Jun 2003

L7 ANSWER 22 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:549238 BIOSIS
DN PREV200200549238
TI ***Inhibition*** of tryptophan hydroxylase activity and decreased 5-HT1A receptor binding in a mouse model of Huntington's disease.
AU Yohrling, George J., IV [Reprint author]; Jiang, George C.-T.; DeJohn, Molly M.; Robertson, Daniel J.; Vrana, Kent E.; Cha, Jang-Ho J.
CS Neurology Research, Massachusetts General Hospital, 114 16th Street, B114-2250, Charlestown, MA, 02129-4404, USA
yohrling@helix.mgh.harvard.edu
SO Journal of Neurochemistry, (September, 2002) Vol. 82, No. 6, pp. 1416-1423. print.
CODEN: JONRA9. ISSN: 0022-3042.
DT Article
LA English

Last Updated on STN: 23 Oct 2002

L7 ANSWER 23 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:493339 BIOSIS
DN PREV200200493339
TI Impaired glutamate transport and glutamate-glutamine cycling: Downstream effects of the Huntington mutation.
AU Behrens, P. F. [Reprint author]; Franz, P.; Woodman, B.; Lindenberg, K. S.; Landwehrmeyer, G. B.
CS Department of Neurology, Universitaetsklinik, Breisacherstrasse 64, 79106, Freiburg, Germany
pfbehrens@web.de
SO Brain, (August, 2002) Vol. 125, No. 8, pp. 1908-1922. print.
CODEN: BRAIAK. ISSN: 0006-8950.
DT Article
LA English
ED Entered STN: 18 Sep 2002
Last Updated on STN: 18 Sep 2002

L7 ANSWER 24 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:385429 BIOSIS
DN PREV200200385429
TI Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.
AU Dunah, Anthone W.; Jeong, Hyunkyung; Griffin, April; Kim, Yong-Man; Standaert, David G.; Hersch, Steven M.; Mouradian, M. Maral; Young, Anne B.; Tanese, Naoko; Krainc, Dimitri [Reprint author]
CS Department of Neurology, Center for Aging, Genetics and Neurodegeneration, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
krainc@helix.mgh.harvard.edu
SO Science (Washington D C), (21 June, 2002) Vol. 296, No. 5576, pp. 2238-2243. print.
CODEN: SCIEAS. ISSN: 0036-8075.
DT Article
LA English
ED Entered STN: 17 Jul 2002
Last Updated on STN: 17 Jul 2002

L7 ANSWER 25 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:370001 BIOSIS
DN PREV200200370001
TI Bioenergetics in Huntington's disease transgenic neurons.
AU Tripathy, Richa [Reprint author]; Hoyt, Kari R. [Reprint author]
CS Division of Pharmacology, Ohio State University, 500 W 12th Ave, Columbus, OH, 43210, USA
SO FASEB Journal, (March 22, 2002) Vol. 16, No. 5, pp. A949-A950. print.
Meeting Info.: Annual Meeting of Professional Research Scientists on Experimental Biology. New Orleans, Louisiana, USA. April 20-24, 2002.
CODEN: FAJOEC. ISSN: 0892-6638.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 3 Jul 2002
Last Updated on STN: 3 Jul 2002

L7 ANSWER 26 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:164029 BIOSIS
DN PREV200200164029
TI Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
AU Karpuj, Marcela V.; Becher, Mark W.; Springer, Joe E.; Chabas, Dorothee; Youssef, Sawsan; Pedotti, Rosetta; Mitchell, Dennis; Steinman, Lawrence [Reprint author]
CS Department of Neurological Sciences, Stanford University, Stanford, CA, USA
steinman@stanford.edu
SO Nature Medicine, (February, 2002) Vol. 8, No. 2, pp. 143-149. print.
ISSN: 1078-8956.
DT Article
LA English
ED Entered STN: 5 Mar 2002
Last Updated on STN: 5 Mar 2002

AN 2002:150225 BIOSIS
DN PREV200200150225
TI Chaperone suppression of cellular toxicity of ***huntingtin*** is independent of polyglutamine aggregation.
AU Zhou, Hui; Li, Shi-Hua; Li, Xiao-Jiang [Reprint author]
CS Dept. of Genetics, Emory University School of Medicine, 1462 Clifton Rd., N.E., Atlanta, GA, 30322, USA
xiaoli@genetics.emory.edu
SO Journal of Biological Chemistry, (December 21, 2001) Vol. 276, No. 51, pp. 48417-48424. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 14 Feb 2002
Last Updated on STN: 26 Feb 2002

L7 ANSWER 28 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:148916 BIOSIS
DN PREV200200148916
TI Evidence for a role for transglutaminase in Huntington's disease and the potential therapeutic implications.
AU Karpuj, Marcela V.; Becher, Mark W.; Steinman, Lawrence [Reprint author]
CS Department of Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University, B002, Stanford, CA, 94305, USA
steinman@standford.edu
SO Neurochemistry International, (January, 2002) Vol. 40, No. 1, pp. 31-36. print.
CODEN: NEUIDS. ISSN: 0197-0186.
DT Article
LA English
ED Entered STN: 14 Feb 2002
Last Updated on STN: 26 Feb 2002

L7 ANSWER 29 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2002:22880 BIOSIS
DN PREV200200022880
TI Minocycline treatment for presymptomatic and symptomatic Huntington's disease patients.
AU Denovan-Wright, E. M. [Reprint author]; Broster, B.; Geyer, L.; Dursun, S.; Devarajan, S.; Fisk, J.; Darvesh, S.; Cook, A.; Robertson, H. A. [Reprint author]
CS Pharmacol, Dalhousie University, Halifax, NS, Canada
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 2574. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 26 Dec 2001
Last Updated on STN: 25 Feb 2002

L7 ANSWER 30 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:563189 BIOSIS
DN PREV200100563189
TI Mutant protein in Huntington disease is resistant to proteolysis in affected brain.
AU Dyer, Roy B.; McMurray, Cynthia T. [Reprint author]
CS Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic and Foundation, Rochester, MN, 55905, USA
mcmurray.cynthia@mayo.edu
SO Nature Genetics, (November, 2001) Vol. 29, No. 3, pp. 270-278. print.
ISSN: 1061-4036.
DT Article
LA English
ED Entered STN: 5 Dec 2001
Last Updated on STN: 25 Feb 2002

L7 ANSWER 31 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:562295 BIOSIS
DN PREV200100562295
TI Phosphatidic acid reduces apoptosis initiated by NGF and serum withdrawal, ceramide, rotenone and glutamate.
AU Sud, A. [Reprint author]; Chalmers-Redman, R. M. E. [Reprint author];

[Reprint author]; Tatton, N. A. [Reprint author]; Tatton, W. G. [Reprint author]
CS Neurology, Mount Sinai School of Medicine, New York, NY, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 1739. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 5 Dec 2001
Last Updated on STN: 25 Feb 2002

L7 ANSWER 32 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:547723 BIOSIS
DN PREV200100547723
TI The Huntington's disease protein inhibits acetyltransferase activity; histone deacetylase inhibitors can suppress polyglutamine pathogenesis in vivo.
AU Thompson, L. M. [Reprint author]; Steffan, J. S. [Reprint author]; Bodai, L.; Pallos, J. [Reprint author]; Apostol, B. [Reprint author]; Kazantsev, A.; Greenwald, M. [Reprint author]; Housman, D. E.; Jackson, G.; Marsh, J. L.
CS Psychiatry and Human Behavior, UC Irvine, Irvine, CA, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 1508. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 21 Nov 2001
Last Updated on STN: 25 Feb 2002

L7 ANSWER 33 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:547722 BIOSIS
DN PREV200100547722
TI p53 as a mediator of neurotoxicity in Huntington's disease.
AU Bae, B. I. [Reprint author]; Igarashi, S.; Fujimuro, M.; Luo, X. [Reprint author]; Tanaka, Y.; Taya, Y.; Ross, C. A. [Reprint author]; Snyder, S. H. [Reprint author]; Sawa, A. [Reprint author]
CS Neuroscience, Johns Hopkins Univ Sch Med, Baltimore, MD, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 1507. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 21 Nov 2001
Last Updated on STN: 25 Feb 2002

L7 ANSWER 34 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:509350 BIOSIS
DN PREV200100509350
TI Decrease of proteasome activity is age dependent and promotes nuclear accumulation of polyglutamine proteins.
AU Cao, F. [Reprint author]; Li, S. H. [Reprint author]; Li, H. [Reprint author]; Shelbourne, P.; Li, X. J. [Reprint author]
CS Dept. of Genetics, Emory University, Atlanta, GA, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 866. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 31 Oct 2001
Last Updated on STN: 23 Feb 2002

L7 ANSWER 35 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:509342 BIOSIS

TI Chaperone suppression of cellular toxicity of ***huntingtin*** is independent of polyglutamine aggregation.
AU Zhou, H. [Reprint author]; Li, S. H. [Reprint author]; Li, X. J. [Reprint author]
CS Dept Genetics, Emory Univ Sch Med, Atlanta, GA, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 865. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 31 Oct 2001
Last Updated on STN: 23 Feb 2002

L7 ANSWER 36 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:509341 BIOSIS
DN PREV200100509341
TI Heat shock protein 27 protects against cellular polyglutamine toxicity.
AU Wyttenbach, A. [Reprint author]; Sauvageot, O.; Diaz-Latoud, C.; Arrigo, A. P.; Rubinsztein, D. C. [Reprint author]
CS Medical Genetics, University of Cambridge, Cambridge, UK
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 865. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 31 Oct 2001
Last Updated on STN: 23 Feb 2002

L7 ANSWER 37 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:509339 BIOSIS
DN PREV200100509339
TI Progressive impairment of proteasome function in a transgenic mouse carrying the human Huntington's disease mutation.
AU Gong, B. [Reprint author]; Espinosa, D. Hernandez [Reprint author]; Fishman, J. M. [Reprint author]; Morton, A. J. [Reprint author]
CS Pharmacology, University of Cambridge, Cambridge, UK
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 865. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 31 Oct 2001
Last Updated on STN: 23 Feb 2002

L7 ANSWER 38 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:509332 BIOSIS
DN PREV200100509332
TI Expanded-repeat ***huntingtin*** forms intracellular aggregates that are structurally and functionally similar to aggresomes.
AU Nichols, C. J. [Reprint author]; Lawless, G. M.; Tobin, A. J. [Reprint author]; Schweitzer, E. S.
CS Physiological Science, UCLA, Los Angeles, CA, USA
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 864. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 31 Oct 2001
Last Updated on STN: 23 Feb 2002

L7 ANSWER 39 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:497437 BIOSIS
DN PREV200100497437
TI Ubiquitinated inclusion formation and cell death in cultured cortical neurons induced by proteasomal ***inhibition*** .
AU Rideout, H. J. [Reprint author]; Stefanis, L. [Reprint author]

SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 518. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 24 Oct 2001
Last Updated on STN: 23 Feb 2002

L7 ANSWER 40 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:333885 BIOSIS
DN PREV200100333885
TI ***Huntingtin*** 's neuroprotective activity occurs via ***inhibition*** of procaspase-9 processing.
AU Rigamonti, Dorotea; Sipione, Simonetta; Goffredo, Donato; Zuccato, Chiara; Fossale, Elisa; Cattaneo, Elena [Reprint author]
CS Department of Pharmacological Sciences, University of Milano, Via Balzaretti 9, 20133, Milano, Italy
elena.cattaneo@unimi.it
SO Journal of Biological Chemistry, (May 4, 2001) Vol. 276, No. 18, pp. 14545-14548. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 18 Jul 2001
Last Updated on STN: 19 Feb 2002

L7 ANSWER 41 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:307945 BIOSIS
DN PREV200100307945
TI Impairment of the ubiquitin-proteasome system by protein aggregation.
AU Bence, Neil F.; Sampat, Roopal M.; Kopito, Ron R. [Reprint author]
CS Department of Biological Sciences, Stanford University, Stanford, CA, 94305-5020, USA
kopito@stanford.edu
SO Science (Washington D C), (25 May, 2001) Vol. 292, No. 5521, pp. 1552-1555. print.
CODEN: SCIEAS. ISSN: 0036-8075.
DT Article
LA English
ED Entered STN: 27 Jun 2001
Last Updated on STN: 19 Feb 2002

L7 ANSWER 42 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:277143 BIOSIS
DN PREV200100277143
TI Accumulation of mutant ***huntingtin*** fragments in aggresome-like inclusion bodies as a result of insufficient protein degradation.
AU Waelter, Stephanie; Boeddrich, Annett; Lurz, Rudi; Scherzinger, Eberhard; Lueder, Gerhild; Lehrach, Hans; Wanker, Erich E. [Reprint author]
CS Max-Planck-Institut fuer Molekulare Genetik, D-14195, Berlin, Dahlem, Germany
wanker@molgen.mpg.de
SO Molecular Biology of the Cell, (May, 2001) Vol. 12, No. 5, pp. 1393-1407. print.
CODEN: MBCEEV. ISSN: 1059-1524.
DT Article
LA English
ED Entered STN: 13 Jun 2001
Last Updated on STN: 19 Feb 2002

L7 ANSWER 43 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:98332 BIOSIS
DN PREV200100098332
TI Modulation of apoptotic regulatory proteins and early activation of cytochrome c in rats following systemic administration of 3-nitropropionic acid.
AU Parker, C. P. [Reprint author]; Fiore, S. M.; Antonawich, F. J.
CS SUNY at Stony Brook, Stony Brook, NY, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-579.7. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.

Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 21 Feb 2001
Last Updated on STN: 15 Feb 2002

L7 ANSWER 44 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2001:88726 BIOSIS
DN PREV200100088726
TI Huntington cellular toxicity is mediated via interference with CBP regulated gene transcription.
AU Nucifora, F. C. [Reprint author]; Sasaki, M.; Huang, H.; Troncoso, J.; Dawson, V. L.; Dawson, T. M.; Ross, C. A.
CS Johns Hopkins University School of Medicine, Baltimore, MD, USA
SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract No.-382.12. print.
Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Feb 2001
Last Updated on STN: 12 Feb 2002

L7 ANSWER 45 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:541484 BIOSIS
DN PREV200000541484
TI ***Inhibition*** of Huntington synthesis by antisense oligodeoxynucleotides.
AU Nellemann, Christine; Abell, Kathrine; Norremolle, Anne; Lokkegaard, Thomas; Naver, Bjarke; Ropke, Carsten; Rygaard, Jorgen; Sorensen, Sven Asger; Hasholt, Lis [Reprint author]
CS Section of Neurogenetics, Department of Medical Biochemistry and Genetics, The Panum Institute, University of Copenhagen, Blegdamsvej 3, DK-2200, Copenhagen N: hasholt@imbg.ku.dk, Denmark
SO Molecular and Cellular Neuroscience, (October, 2000) Vol. 16, No. 4, pp. 313-323. print.
CODEN: MOCNED. ISSN: 1044-7431.
DT Article
LA English
ED Entered STN: 13 Dec 2000
Last Updated on STN: 11 Jan 2002

L7 ANSWER 46 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:424993 BIOSIS
DN PREV200000424993
TI Inhibiting caspase cleavage of ***huntingtin*** reduces toxicity and aggregate formation in neuronal and nonneuronal cells.
AU Wellington, Cheryl L.; Singaraja, Roshni; Ellerby, Lisa; Savill, Jane; Roy, Sophie; Leavitt, Blair; Cattaneo, Elena; Hackam, Abigail; Sharp, Alan; Thornberry, Nancy; Nicholson, Donald W.; Bredesen, Dale E.; Hayden, Michael R. [Reprint author]
CS Centre for Molecular Medicine and Therapeutics, 950 West 28th Ave., Vancouver, BC, V5Z 4H4, Canada
SO Journal of Biological Chemistry, (June 30, 2000) Vol. 275, No. 26, pp. 19831-19838. print.
CODEN: JBCHA3. ISSN: 0021-9258.
DT Article
LA English
ED Entered STN: 4 Oct 2000
Last Updated on STN: 8 Jan 2002

L7 ANSWER 47 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:413668 BIOSIS
DN PREV200000413668
TI Expression of ***huntingtin*** -associated protein-1 in neuronal cells implicates a role in neuritic growth.
AU Li, Shi-Hua; Li, He; Torre, Enrique R.; Li, Xiao-Jiang [Reprint author]
CS Department of Genetics, Emory University School of Medicine, Atlanta, GA, 30322, USA
SO Molecular and Cellular Neuroscience, (August, 2000) Vol. 16, No. 2, pp. 168-183. print.
CODEN: MOCNED. ISSN: 1044-7431.
DT Article
LA English

Last Updated on STN: 8 Jan 2002

L7 ANSWER 48 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:353390 BIOSIS
DN PREV200000353390
TI ***Inhibition*** of ***huntingtin*** fibrillogenesis by specific antibodies and small molecules: Implications for Huntington's disease therapy.
AU Heiser, Volker; Scherzinger, Eberhard; Boeddrich, Annett; Nordhoff, Eckhard; Lurz, Rudi; Schugardt, Nancy; Lehrach, Hans; Wanker, Erich E. [Reprint author]
CS Max-Planck-Institut fuer Molekulare Genetik, Ihnestrassee 73, D-14195, Berlin, Germany
SO Proceedings of the National Academy of Sciences of the United States of America, (June 6, 2000) Vol. 97, No. 12, pp. 6739-6744. print.
CODEN: PNASA6. ISSN: 0027-8424.
DT Article
LA English
ED Entered STN: 16 Aug 2000
Last Updated on STN: 8 Jan 2002

L7 ANSWER 49 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:178707 BIOSIS
DN PREV200000178707
TI Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome ***inhibition*** on protein aggregation in cellular models of Huntington's disease.
AU Wyttenbach, Andreas; Carmichael, Jenny; Swartz, Jina; Furlong, Robert A.; Narain, Yolanda; Rankin, Julia; Rubinsztein, David C. [Reprint author]
CS Department of Medical Genetics, Wellcome Trust Centre for the Study of Molecular Mechanisms in Disease, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Hills Road, Wellcome/Medical Research Council Building, Cambridge, CB2 2XY, UK
SO Proceedings of the National Academy of Sciences of the United States of America, (March 14, 2000) Vol. 97, No. 6, pp. 2898-2903. print.
CODEN: PNASA6. ISSN: 0027-8424.
DT Article
LA English
ED Entered STN: 11 May 2000
Last Updated on STN: 4 Jan 2002

L7 ANSWER 50 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:79825 BIOSIS
DN PREV200000079825
TI Recent insights into the molecular pathogenesis of Huntington disease.
AU Leavitt, Blair R.; Wellington, Cheryl L.; Hayden, Michael R. [Reprint author]
CS Centre for Molecular Medicine and Therapeutics, 950 West 28th Avenue, Vancouver, BC, Canada
SO Seminars in Neurology, (1999) Vol. 19, No. 4, pp. 385-396. print.
ISSN: 0271-8235.
DT Article
General Review; (Literature Review)
LA English
ED Entered STN: 23 Feb 2000
Last Updated on STN: 3 Jan 2002

L7 ANSWER 51 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 2000:73103 BIOSIS
DN PREV200000073103
TI Caspase-1 ***inhibition*** delays receptor changes and neuronal intranuclear inclusions, and corrects aberrant ***huntingtin*** cleavage in transgenic Huntington's disease mice.
AU Cha, J.-H. J. [Reprint author]; Chung, W. M. [Reprint author]; Frey, A. S. [Reprint author]; Menon, A. S. [Reprint author]; Vonsattel, J. P. G.; Li, X.-J.; Ona, V. O.; Li, M.; Andrews, L. J.; Khan, S. Q.; Stieg, P. E.; Yuan, J.; Penney, J. B. [Reprint author]; Friedlander, R. M.; Young, A. B. [Reprint author]
CS Dept. Neurology, Massachusetts General Hospital, Boston, MA, USA
SO Society for Neuroscience Abstracts, (1999) Vol. 25, No. 1-2, pp. 542. print.
Meeting Info.: 29th Annual Meeting of the Society for Neuroscience, Part 1. Miami Beach, Florida, USA. October 23-28, 1999. The Society for Neuroscience.
ISSN: 0190-5295.

Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 16 Feb 2000
Last Updated on STN: 3 Jan 2002

L7 ANSWER 52 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:497310 BIOSIS
DN PREV199900497310
TI ***Inhibition*** of caspase cleavage of ***huntingtin*** protects neurons from toxicity and aggregate formation.
AU Wellington, C. L. [Reprint author]; Singaraja, R. [Reprint author]; Ellerby, L.; Savill, J. [Reprint author]; Roy, S.; Leavitt, B. [Reprint author]; Cattaneo, E.; Hackam, A. [Reprint author]; Sharp, A.; Thornberry, N.; Bredesen, D.; Nicholson, D.; Hayden, M. R. [Reprint author]
CS CMMT, UBC, Vancouver, Canada
SO American Journal of Human Genetics, (Oct., 1999) Vol. 65, No. 4, pp. A4. print.
Meeting Info.: 49th Annual Meeting of the American Society of Human Genetics. San Francisco, California, USA. October 19-23, 1999. The American Society of Human Genetics.
CODEN: AJHGAG. ISSN: 0002-9297.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Slide)
LA English
ED Entered STN: 23 Nov 1999
Last Updated on STN: 23 Nov 1999

L7 ANSWER 53 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:288717 BIOSIS
DN PREV199900288717
TI ***Inhibition*** of caspase-1 slows disease progression in a mouse model of Huntington's disease.
AU Ona, Victor O.; Li, Mingwei; Vonsattel, Jean Paul G. [Reprint author]; Andrews, L. John; Khan, Sohail Q.; Chung, Woosik M.; Frey, Ariel S.; Menon, Anil S.; Li, Xiao-Jiang; Stieg, Philip E.; Yuan, Junying; Penney, John B.; Young, Anne B.; Cha, Jang-Ho J.; Friedlander, Robert M. [Reprint author]
CS Neurosurgical Service, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
SO Nature (London), (May 20, 1999) Vol. 399, No. 6733, pp. 263-267. print.
CODEN: NATUAS. ISSN: 0028-0836.
DT Article
LA English
ED Entered STN: 5 Aug 1999
Last Updated on STN: 5 Aug 1999

L7 ANSWER 54 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:128129 BIOSIS
DN PREV199900128129
TI Mutant ***Huntingtin*** expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase ***inhibition*** .
AU Kim, Manho; Lee, H.-S.; Laforet, Genevieve; McIntyre, Charmian; Martin, Eileen J.; Chang, Patrick; Kim, Tae Wan; Williams, M.; Reddy, P. H.; Tagle, Dan; Boyce, Frederick M.; Won, Lisa; Heller, Alfred; Aronin, Neil; Difiglia, Marian [Reprint author]
CS Lab. Cell. Neurobiol., Mass. General Hosp., MGH-East, 149 13th St., Charlestown, MA 02129, USA
SO Journal of Neuroscience, (Feb. 1, 1999) Vol. 19, No. 3, pp. 964-973. print.
CODEN: JNRSDS. ISSN: 0270-6474.
DT Article
LA English
ED Entered STN: 17 Mar 1999
Last Updated on STN: 17 Mar 1999

L7 ANSWER 55 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:105141 BIOSIS
DN PREV199900105141
TI Generation of neuronal intranuclear inclusions by polyglutamine-GFP: Analysis of inclusion clearance and toxicity as a function of polyglutamine length.
AU Moulder, Krista L.; Onodera, Osamu; Burke, James R.; Strittmatter, Warren J.; Johnson, Eugene M., Jr. [Reprint author]

Scott Ave., Box 8103, St. Louis, MO 63110, USA
SO Journal of Neuroscience, (Jan. 15, 1999) Vol. 19, No. 2, pp. 705-715. print.
CODEN: JNRSDS. ISSN: 0270-6474.
DT Article
LA English
ED Entered STN: 4 Mar 1999
Last Updated on STN: 4 Mar 1999

L7 ANSWER 56 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1999:102533 BIOSIS
DN PREV199900102533
TI Biochemical abnormalities and excitotoxicity in Huntington's disease brain.
AU Tabrizi, S. J.; Cleeter, M. W. J.; Xuereb, J.; Taanman, J.-W.; Cooper, J. M.; Schapira, A. H. V. [Reprint author]
CS Dep. Clin. Neurosci., Royal Free UCH Sch. Med., Rowland Hill St., London NW3 2PF, UK
SO Annals of Neurology, (Jan., 1999) Vol. 45, No. 1, pp. 25-32. print.
CODEN: ANNED3. ISSN: 0364-5134.
DT Article
LA English
ED Entered STN: 4 Mar 1999
Last Updated on STN: 4 Mar 1999

L7 ANSWER 57 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1998:383330 BIOSIS
DN PREV199800383330
TI ***Inhibition*** of ***Huntingtin*** by antisense oligodeoxynucleotides.
AU Nellemann, Christine; Abell, K.; Hasholt, L.; Norremolle, A.; Sorensen, S. A.
CS Dep. Med. Genetics, Panum Inst., Univ. Copenhagen, Blegdamsvej 3, DK-2200 Copenhagen, Denmark
SO European Journal of Human Genetics, (1998) Vol. 6, No. SUPPL. 1, pp. 145. print.
Meeting Info.: 30th Annual Meeting of the European Society of Human Genetics. Lisbon, Portugal. May 10-13, 1998. European Society of Human Genetics.
ISSN: 1018-4813.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LA English
ED Entered STN: 2 Sep 1998
Last Updated on STN: 2 Sep 1998

L7 ANSWER 58 OF 266 BIOSIS COPYRIGHT 2004 BIOLOGICAL ABSTRACTS INC. on STN
AN 1997:348056 BIOSIS
DN PREV199799647259
TI Iodoacetate produces striatal excitotoxic lesions.
AU Matthews, Russell T.; Ferrante, Robert J.; Jenkins, Bruce G.; Browne, Susan E.; Goetz, Katrine; Berger, Stephanie; Chen, Irin Y.-C.; Beal, M. Flint [Reprint author]
CS Neurol. Serv./WRN 408, Massachusetts Gen. Hosp., 32 Fruit St., Boston, MA 02114, USA
SO Journal of Neurochemistry, (1997) Vol. 69, No. 1, pp. 285-289.
CODEN: JONRA9. ISSN: 0022-3042.
DT Article
LA English
ED Entered STN: 11 Aug 1997
Last Updated on STN: 11 Aug 1997

L7 ANSWER 59 OF 266 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2003-28264 BIOTECHDS
TI Selecting molecules active in the prevention and/or treatment of Huntington's disease comprises evaluating the ability of the molecules to inhibit the activity of neurone-restrictive silencer element; vector-mediated reporter gene transfer and expression in host cell for drug screening and disease therapy
AU CATTANEO E; ZUCCATO C
PA UNIV MILANO
PI WO 2003087289 23 Oct 2003
AI WO 2003-IB1627 17 Apr 2003
PRAI IT 2002-809 17 Apr 2002; IT 2002-809 17 Apr 2002

LA English
OS WPI: 2003-833716 [77]

L7 ANSWER 60 OF 266 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2002-19699 BIOTECHDS
TI Targeting construct for producing a transgenic mouse useful as a disease model and for identifying modulators of gene expression, comprises sequences homologous to a ***huntingtin*** -interacting protein-1 gene and a selectable marker;
transgenic animal model construction, vector expression in host cell, and selectable marker use in disease therapy and gene therapy
AU LEVITEN M W
PA DELTAGEN INC
PI WO 2002047477 20 Jun 2002
AI WO 2000-US47740 11 Dec 2000
PRAI US 2001-12690 7 Dec 2001
DT Patent
LA English
OS WPI: 2002-537603 [57]

L7 ANSWER 61 OF 266 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2002-12186 BIOTECHDS
TI Novel agent for inhibiting protein-protein interaction useful to treat Alzheimer's disease, has two domains which bind first, second proteins with seven consecutive glutamine residues and a domain separating two domains;
vector-mediated gene transfer and expression in Drosophilia sp. for Alzheimer disease, Huntington chorea, muscular atrophy, spinocerebellar ataxia and Machado-Joseph disease gene therapy
AU KAZANTSEV A; THOMPSON L; HOUSMAN D E
PA MASSACHUSETTS INST TECHNOLOGY
PI WO 2002016644 28 Feb 2002
AI WO 2000-US26097 18 Aug 2000
PRAI US 2000-226502 18 Aug 2000
DT Patent
LA English
OS WPI: 2002-280948 [32]

L7 ANSWER 62 OF 266 BIOTECHDS COPYRIGHT 2004 THOMSON DERWENT/ISI on STN
AN 2000-03532 BIOTECHDS
TI Novel proteins useful for treating Huntington's disease by gene therapy techniques, and cancers;
recombinant ***huntingtin*** interactive protein and nucleic acid used in Huntington disease and cancer therapy
AU Kalchman M; Hayden M R; Hackam A; Chopra V; Nicholson D W; Vallaincourt J P; Rasper D M
PA Univ.British-Columbia; Merck-Frosst-Canada
LO Vancouver, British Columbia, Canada; Point Claire-Dorval, Quebec, Canada.
PI WO 9960986 2 Dec 1999
AI WO 1999-US11743 27 May 1999
PRAI US 1998-85199 27 May 1998
DT Patent
LA English
OS WPI: 2000-097055 [08]

L7 ANSWER 63 OF 266 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2003:37161457 BIOTECHNO
TI Intrabody and intrakine strategies for molecular therapy
AU Wheeler Y.Y.; Chen S.-Y.; Sane D.C.
CS D.C. Sane, Section of Cardiology, Wake Forest Univ. School of Med., Medical Center Boulevard, Winston-Salem, NC 27157-1045, United States.
E-mail: dsane@wfubmc.edu
SO Molecular Therapy, (01 SEP 2003), 8/3 (355-366), 99 reference(s)
CODEN: MTOHCK ISSN: 1525-0016
DT Journal; General Review
CY United States
LA English

L7 ANSWER 64 OF 266 BIOTECHNO COPYRIGHT 2004 Elsevier Science B.V. on STN
AN 2003:36718170 BIOTECHNO
TI Neurotrophins and neurodegeneration
AU Dawbarn D.; Allen S.J.
CS D. Dawbarn, University of Bristol, Bristol Royal Infirmary, Bristol, BS2 8HW, United Kingdom.
E-mail: dave.dawbarn@bristol.ac.uk

reference(s)
CODEN: NANEDL ISSN: 0305-1846
DT Journal; General Review
CY United Kingdom
LA English
SL English

L7 ANSWER 65 OF 266 CANCERLIT on STN
AN 2002118478 CANCERLIT
DN 21617717 PubMed ID: 11741397
TI ***Inhibition*** of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles.
AU Smith D L; Portier R; Woodman B; Hockly E; Mahal A; Klunk W E; Li X J; Wanker E; Murray K D; Bates G P
CS Division of Medical and Molecular Genetics, GKT School of Medicine, London, United Kingdom.
SO NEUROBIOLOGY OF DISEASE, (2001 Dec) 8 (6) 1017-26.
Journal code: 9500169. ISSN: 0969-9961.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 2001701230
EM 200202
ED Entered STN: 20020726
Last Updated on STN: 20021018

L7 ANSWER 66 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:116121 CAPLUS
TI Specific ***inhibition*** of Huntington's disease gene expression by siRNAs in cultured cells
AU Liu, Wanzhao; Goto, Jun; Wang, Yu-Lai; Murata, Miho; Wada, Keiji; Kanazawa, Ichiro
CS Solution Oriented Research for Science and Technology (SORST) Research Project, Japan Science and Technology Agency (JST), Saitama, 332-0012, Japan
SO Proceedings of the Japan Academy, Series B: Physical and Biological Sciences (2003), 79B(10), 293-298
CODEN: PJABDW; ISSN: 0386-2208
PB Nippon Gakushiin
DT Journal
LA English

L7 ANSWER 67 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:757393 CAPLUS
DN 139:271089
TI Phosphoinositide 3-kinase mediated ***inhibition*** of GPCRs
IN Rockman, Howard A.; Naga, Prasad Sathyamangla V.; Laporte, Stephane A.; Barak, Larry S.; Caron, Marc G.
PA USA
SO U.S. Pat. Appl. Publ., 71 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003182669	A1	20030925	US 2002-101235	20020319
WO 2003088924	A2	20031030	WO 2003-US8208	20030318

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2002-101235 A 20020319

L7 ANSWER 68 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:746151 CAPLUS
DN 140:143422

AU Luthi-Carter, Ruth; Chā, Jang-Hō J.
CS B114-2000, Genetics and Neurodegeneration, Center for Aging, Department of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129-4404, USA
SO Clinical Neuroscience Research (2003), 3(3), 165-177
CODEN: CNRLBU; ISSN: 1566-2772
PB Elsevier Science B.V.
DT Journal; General Review
LA English
RE.CNT 96 THERE ARE 96 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 69 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:573968 CAPLUS
DN 140:70812
TI Antisense downregulation of mutant ***huntingtin*** in a cell model
AU Hasholt, Lis; Abell, Kathrine; Norremolle, Anne; Nellemann, Christine; Fenger, Kirsten; Sorensen, Sven Asger
CS Section of Neurogenetics, Institute of Medical Biochemistry and Genetics, University of Copenhagen, Den.
SO Journal of Gene Medicine (2003), 5(6), 528-538
CODEN: JGMEFG; ISSN: 1099-498X
PB John Wiley & Sons Ltd.
DT Journal
LA English
RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 70 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:417568 CAPLUS
DN 139:5159
TI Overexpressed in cancer of ***huntingtin*** interacting protein, HIP1, antibodies, HIP1-encoding nucleic acids, and diagnostic and therapeutic uses
IN Ross, Theodora; Mizukami, Ikuko; Roa, Dinesh
PA The Regents of the University of Michigan, USA
SO PCT Int. Appl., 143 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003043566	A2	20030530	WO 2002-US36175	20021112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003124533	A1	20030703	US 2001-7047	20011206
PRAI US 2001-335276P	P	20011115		
US 2001-7047	A	20011206		

L7 ANSWER 71 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:405296 CAPLUS
DN 139:115771
TI Mice transgenic for exon 1 of Huntington's disease: Properties of cholinergic and dopaminergic pre-synaptic function in the striatum
AU Vetter, J. M.; Jehle, T.; Heinemeyer, J.; Franz, P.; Behrens, P. F.; Jackisch, R.; Landwehrmeyer, G. B.; Feuerstein, T. J.
CS Section of Clinical Neuropharmacology, Neurozentrum, Freiburg, Germany
SO Journal of Neurochemistry (2003), 85(4), 1054-1063
CODEN: JONRA9; ISSN: 0022-3042
PB Blackwell Publishing Ltd.
DT Journal
LA English
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 72 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN

DN 139:83149
TI Polyglutamine Expansion Induces a Protein-damaging Stress Connecting Heat Shock Protein 70 to the JNK Pathway
AU Merienne, Karine; Helmlinger, Dominique; Perkin, Gordon R.; Devys, Didier; Trottier, Yvon
CS INSERM, CNRS, Institut de Genetique et de Biologie Moleculaire et Cellulaire, Universite Louis Pasteur, Illkirch C.U. de Strasbourg, 67404, Fr.
SO Journal of Biological Chemistry (2003), 278(19), 16957-16967
CODEN: JBCHA3; ISSN: 0021-9258
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 73 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:367318 CAPLUS
DN 135:135353
TI Neurodegenerative disorders: Fatal attraction
AU Jones, Rachel
CS UK
SO Nature Reviews Neuroscience (2001), 2(5), 309
CODEN: NRNAAN; ISSN: 1471-003X
PB Nature Publishing Group
DT Journal; General Review
LA English

L7 ANSWER 74 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:742246 CAPLUS
DN 133:291954
TI An inducible expression vector for the p21 cyclin-dependent kinase inhibitor and its use in identifying genes regulated by p21
IN Chang, Bey-Dih; Roninson, Igor B.
PA Board of Trustees of the University of Illinois, USA
SO PCT Int. Appl., 119 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000061751	A1	20001019	WO 2000-US9286	20000407
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1169443	A1	20020109	EP 2000-920212	20000407
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2003521238	T2	20030715	JP 2000-611674	20000407
	WO 2001038532	A2	20010531	WO 2000-US28082	20001011
	WO 2001038532	A3	20011227		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1240323	A2	20020918	EP 2000-970780	20001011
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003525032	T2	20030826	JP 2001-539874	20001011
PRAI	US 1999-128676P	P	19990409		
	US 1999-449589	A2	19991129		
	WO 2000-US9286	W	20000407		
	WO 2000-US28082	W	20001011		

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 75 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:312117 CAPLUS
DN 133:220879
TI Role of caspases in neuronal damage
AU Taylor, Joanne; Ikeda, Masuhiro
CS University College London, Eisai London Research Laboratories Ltd., London, WC1E 6BT, UK
SO Drug News & Perspectives (2000), 13(1), 5-11
CODEN: DNPEED; ISSN: 0214-0934
PB Prous Science
DT Journal; General Review
LA English
RE.CNT 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 76 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:745832 CAPLUS
DN 132:220229
TI Mitochondrial ***inhibition*** and neuronal death in Huntington's disease
AU Behrens, Maria Isabel
CS Santiago, Chile
SO Mitochondrial Inhibitors and Neurodegenerative Disorders (2000), 167-176.
Editor(s): Sanberg, Paul R.; Nishino, Hitoo; Borlongan, Cesario V.
Publisher: Humana Press Inc., Totowa, N. J.
CODEN: 68KDAL
DT Conference; General Review
LA English
RE.CNT 78 THERE ARE 78 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 77 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:361465 CAPLUS
DN 131:181323
TI PQBP-1, a novel polyglutamine tract-binding protein, inhibits transcription activation by Brn-2 and affects cell survival
AU Waragai, Masaaki; Lammers, Claas-Hinrich; Takeuchi, Sousuke; Imafuku, Ichiro; Udagawa, Yoshiyuki; Kanazawa, Ichiro; Kawabata, Masahiro; Mouradian, M. Maral; Okazawa, Hitoshi
CS Group Molecular Neurobiology, Dep. Neurology, Graduate School Medicine, Univ. Tokyo, Hongo, Bunkyo-ku, Tokyo, 113, Japan
SO Human Molecular Genetics (1999), 8(6), 977-987
CODEN: HMGEE5; ISSN: 0964-6906
PB Oxford University Press
DT Journal
LA English
RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 78 OF 266 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:570679 CAPLUS
DN 130:2744
TI Striatal vulnerability to mitochondrial ***inhibition***
AU McLaughlin, Beth Ann Maria
CS Univ. of Pennsylvania, Philadelphia, PA, USA
SO (1998) 170 pp. Avail.: UMI, Order No. DA9829947
From: Diss. Abstr. Int., B 1998, 59(4), 1524
DT Dissertation
LA English

L7 ANSWER 79 OF 266 CIN COPYRIGHT 2004 ACS on STN
AN 31(11):11503G CIN
TI Other research news
SO BioCentury, 25 Feb 2002 (20020225), 10(9, Pt. 2), p. B12. ISSN: 1097-7201; CODEN: BICEFS.
LA English

L7 ANSWER 80 OF 266 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 2003:31901 DISSABS Order Number: AAINQ73262
TI Mutanthuntingtin enhanced sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity
AU Zeron, Melinda May [Ph.D.]; Raymond, Lynn A. [adviser]

SO Dissertation Abstracts International, (2002) Vol. 63, No. 10B, p. 4534.
Order No.: AAINQ73262. 224 pages.
ISBN: 0-612-73262-2.
DT Dissertation
FS DAI
LA English

L7 ANSWER 81 OF 266 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 2001:57245 DISSABS Order Number: AAI3006320
TI The cellular pathogenesis of Huntington's disease and related disorders
AU Nucifora, Frederick Charles, Jr. [Ph.D.]; Ross, Christopher [adviser]
CS The Johns Hopkins University (0098)
SO Dissertation Abstracts International, (2001) Vol. 62, No. 2B, p. 722.
Order No.: AAI3006320. 199 pages.
ISBN: 0-493-15635-6.
DT Dissertation
FS DAI
LA English

L7 ANSWER 82 OF 266 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2000-31894 DRUGU P B
TI Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.
AU Chen M; Ona V O; Li M; Ferrante R J; Fink K B; Zhu S; Bian J; Guo L; Farrell L A; Friedlander R M
CS Harvadr-Med.Sch.; Univ.Boston; Univ.Emory
LO Boston; Bedford, Mass.; Atlanta, Ga., USA; Bonn, Ger.
SO Nat.Med. (6, No. 7, 797-801, 2000) 5 Fig. 31 Ref.
CODEN: MAMEF ISSN: 1078-8956
AV Neuroapoptosis Laboratory, Neurosurgical Service, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, U.S.A. (R.M.F.). (e-mail: rfriedlander@rics.bwh.harvard.edu).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L7 ANSWER 83 OF 266 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2002353984 EMBASE
TI Protein conformational misfolding and amyloid formation: Characteristics of a new class of disorders that include Alzheimer's and Prion diseases.
AU Thompson A.J.; Barrow C.J.
CS C.J. Barrow, Ocean Nutrition Canada Ltd., 1721 Lower Water Street, Halifax, NS B3J 1S5, Canada. cbarrow@ocean-nutrition.com
SO Current Medicinal Chemistry, (2002) 9/19 (1751-1762).
Refs: 164
ISSN: 0929-8673 CODEN: CMCHE7
CY Netherlands
DT Journal; General Review
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
030 Pharmacology
037 Drug Literature Index
038 Adverse Reactions Titles
LA English
SL English

L7 ANSWER 84 OF 266 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2000288099 EMBASE
TI Caspases and neurodegeneration: A potential therapeutic target.
AU Schulz J.B.
CS J.B. Schulz, Neurodegeneration Laboratory, Department of Neurology, University of Tubingen, Hoppe-Seyler-Strasse 3, D-72076 Tubingen, Germany. joerg.b.schulz@uni-tuebingen.de
SO Current Opinion in Central and Peripheral Nervous System Investigational Drugs, (2000) 2/4 (417-422).
Refs: 60
ISSN: 1464-844X CODEN: COCDFA
CY United Kingdom
DT Journal; General Review
FS 008 Neurology and Neurosurgery
033 Orthopedic Surgery

048 Gastroenterology
037 Drug Literature Index
005 General Pathology and Pathological Anatomy
LA English
SL English

L7 ANSWER 85 OF 266 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 2000246077 EMBASE
TI Caspases and neurodegeneration: A potential therapeutic target.
AU Schulz J.B.
CS J.B. Schulz, Neurodegeneration Laboratory, Department of Neurology, University of Tubingen, Hoppe-Seyler-Strasse 3, D-72076 Tubingen, Germany. joerg.b.schulz@uni-tuebingen.de
SO Current Opinion in Anti-inflammatory and Immunomodulatory Investigational Drugs, (2000) 2/3 (200-205).
Refs: 60
ISSN: 1464-8474 CODEN: COAIFF
CY United Kingdom
DT Journal; General Review
FS 037 Drug Literature Index
030 Pharmacology
008 Neurology and Neurosurgery
LA English
SL English

L7 ANSWER 86 OF 266 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1999127252 EMBASE
TI Caspases as treatment targets in stroke and neurodegenerative diseases.
AU Schulz J.B.; Weller M.; Moskowitz M.A.
CS Dr. J.B. Schulz, Department of Neurology, University of Tubingen, Hoppe-Seyler-Str 3, D-72076 Tubingen, Germany
SO Annals of Neurology, (1999) 45/4 (421-429).
Refs: 80
ISSN: 0364-5134 CODEN: ANNED3
CY United States
DT Journal; Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
037 Drug Literature Index
LA English
SL English

L7 ANSWER 87 OF 266 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 1998363409 EMBASE
TI [Huntington's disease: From gene to pathomechanism].
CHOREA HUNTINGTON: VOM GEN ZUM PATHOMECHANISMUS.
AU Schweiger K.; Lehrach H.; Wanker E.E.
CS Dr. E.E. Wanker, MPI fur Molekulare Genetik, Ihnestr. 73, 14195 Berlin, Germany. wanker@mpimg-berlin-dahlem.mpg.de
SO Medizinische Genetik, (1998) 10/3 (417-422).
Refs: 46
ISSN: 0936-5931 CODEN: MGENEZ
CY Germany
DT Journal; Conference Article
FS 005 General Pathology and Pathological Anatomy
008 Neurology and Neurosurgery
022 Human Genetics
032 Psychiatry
LA German
SL English; German

L7 ANSWER 88 OF 266 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:205178 FEDRIP
NR CRISP 1R01NS45283-01
TI Protein acetylation in Huntington's disease
SF Principal Investigator: MARSH, J L; JLMARSH@UCI.EDU, UNIVERSITY OF CALIFORNIA, IRVINE, 5205 BIO SCI II (MCGAUGH HALL), IRVINE, CA 92717
CSP UNIVERSITY OF CALIFORNIA IRVINE, IRVINE, CALIFORNIA
CSS Supported By: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
DB 2012 (/01/02)
FYR 2003
DE 2011 (/30/07)

FS National Institutes of Health

L7 ANSWER 89 OF 266 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:204473 FEDRIP
NR CRISP 5F31NS43033-02
TI Intrabody Therapy for Huntington's Disease
SF Principal Investigator: MILLER, TODD W; MILLLER2@WADSWORTH.ORG, WADSWORTH CENTER, 120 NEW SCOTLAND AVENUE
CSP WADSWORTH CENTER, ALBANY, NEW YORK
CSS Supported By: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
DB 2001 (/03/02)
FYR 2003
FU Noncompeting Continuation (Type 5)
FS National Institutes of Health

L7 ANSWER 90 OF 266 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:202617 FEDRIP
NR CRISP 5R01NS35255-07
TI HUNTINGTON PROTEIN AND THE HUNTINGTON'S DISEASE MUTATION
SF Principal Investigator: HERSCH, STEVEN M; HERSCH@HELIX.MGH.HARVARD.EDU, MASSACHUSETTS GENERAL HOSPITAL, 114 16TH ST, B114/2000
CSP MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MASSACHUSETTS
CSS Supported By: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
DB 2003 (/01/97)
FYR 2003
DE 2006 (/30/04)
FU Noncompeting Continuation (Type 5)
FS National Institutes of Health

L7 ANSWER 91 OF 266 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:196769 FEDRIP
NR CRISP 1Z01MH02698-08
TI Apoptosis In Neurons
SF Principal Investigator: CHUANG, DE-MAW
CSS Supported By: NATIONAL INSTITUTE OF MENTAL HEALTH
FYR 2002
FU Not Applicable
FS National Institutes of Health

L7 ANSWER 92 OF 266 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:62514 FEDRIP
NR VA 126505
NC 0001, 632
TI The Role of Apoptosis Regulatory Proteins in Huntington's Cell Death
SF Principal Investigator: Antonawich, Francis J., Ph.D.
CSP Department of Veterans Affairs, Medical Center, Northport, NY
CSS Supported By: Department of Veterans Affairs. Research and Development (15), 810 Vermont Ave. N.W., Washington, D.C., 20420, United States of America
DB Apr 1, 1999
FS Department of Veterans Affairs

L7 ANSWER 93 OF 266 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:49031 FEDRIP
NR VA 144355
NC 0010, 518
TI Transglutaminase ***Inhibition*** Using Cystamine Therapy in Huntington's Disease Murine Models
SF Principal Investigator: Ferrante, Robert J., Ph.D.
CSP Department of Veterans Affairs, Medical Center, Bedford, MA
CSS Supported By: Department of Veterans Affairs. Research and Development (15), 810 Vermont Ave. N.W., Washington, D.C., 20420, United States of America
DB Nov 1, 2001
FS Department of Veterans Affairs

L7 ANSWER 94 OF 266 FEDRIP COPYRIGHT 2004 NTIS on STN
AN 2004:49030 FEDRIP
NR VA 144289
NC 0009, 518
TI Transglutaminase ***Inhibition*** Using Cystamine Therapy in Huntington's Disease Murine Models
SF Principal Investigator: Ferrante, Robert J., Ph.D.
CSP Department of Veterans Affairs, Medical Center, Bedford, MA
CSS Supported By: Department of Veterans Affairs. Research and Development

America
DB Nov 1, 2001
FS Department of Veterans Affairs

L7 ANSWER 95 OF 266 GENBANK.RTM. COPYRIGHT 2004 on STN

LOCUS (LOC): BX294135 GenBank (R)
GenBank ACC. NO. (GBN): BX294135 BX119912
GenBank VERSION (VER): BX294135.1 GI:32443133
CAS REGISTRY NO. (RN): 543671-98-3
SEQUENCE LENGTH (SQL): 340750
MOLECULE TYPE (CI): DNA; linear
DIVISION CODE (CI): Bacteria
DATE (DATE): 11 Jul 2003
DEFINITION (DEF): Pirellula sp. strain 1 complete genome; segment 3/24.
KEYWORDS (ST): complete genome
SOURCE: Pirellula sp.
ORGANISM (ORGN): Pirellula sp.
Bacteria; Planctomycetes; Planctomycetacia;
Planctomycetales; Planctomycetaceae; Pirellula
NUCLEIC ACID COUNT (NA): 73138 a 89540 c 100519 g 77553 t
COMMENT:
This project was carried out by
*Max Planck Institute for Molecular Genetics, Berlin, Germany; *Max
Planck Institute for Marine Microbiology, Bremen, Germany; in the
fremework of the REGX-project, http://www.regx.de ----------
Genome Center
Center: Max Planck Institute for Molecular Genetics
Center code: MPIMG
---------- Summary Statistics
Sequencing vector: pUC19; 100% of reads
Chemistry: Dye-terminator Big Dye; 100% of reads
Assembly program: Phrap; version 0.990329
Consensus quality: 7142841 bases at least Q40
Consensus quality: 7145138 bases at least Q30
Consensus quality: 7145484 bases at least Q20
Quality coverage: 8.03

This sequence was finished as follows unless otherwise noted: all
regions were double stranded, sequenced with an alternate
chemistry, or coveredby high quality data (i.e., phred quality >=
30); an attempt was made to resolve all sequencing problems, such
as compressions and repeats; allregions were covered by at least
one plasmid Sequence; assembly was additionally confirmed by long
range pcr and cosmid end sequences.

See http://www.micro-genomes.mpg.de/pirellula/ for more information
including minimal tiling path from a set of 220 cosmids out of
908. See the misc_feature tag below for the boundaries of the MTP
cosmids. ---------- Annotation
Center: Max Planck Institute for Marine Microbiology
Celsiusstrasse 1, D-28359 Bremen, Germany.
Center Code: MPIMM
Email: fog@mpi-bremen.de
Phone: +49 (0)421 2028 938 Fax: +49 (0)421 2028 580

Three different programs (Glimmer, Critica and Orpheus) were used
for ORF-prediction. A nonredundant list of ORFs was generated by
suitable parsing of the results.
Automated annotation was done with the software package Pedant Pro
(http://www.biomax.de). All ORF predictions and annotations were
manually corrected by considering all results of the different
tools applied. See http://www.regx.de for more information and
access to supplementary information.
----------.
REFERENCE: 1 (bases 1 to 340750)
AUTHOR (AU): Gloeckner,F.O.; Kube,M.; Bauer,M.; Teeling,H.;
Lombardot,T.; Ludwig,W.; Gade,D.; Beck,A.; Borzym,K.;
Heitmann,K.; Rabus,R.; Schlesner,H.; Amann,R.;
Reinhardt,R.
TITLE (TI): Complete genome sequence of the marine planctomycete
Pirellula sp. strain 1
JOURNAL (SO): Proc. Natl. Acad. Sci. U.S.A., 100 (14), 8298-8303
(2003)
OTHER SOURCE (OS): CA 139:96134

AUTHOR (AU): Kube,M.; Borzym,K.; Heitmann,K.; Klages,S.; Marquardt,I.; Lehrack,S.; Beck,A.; Pawlik,R.; Reinhardt,R.; Gloeckner,F.O.; Bauer,M.; Teeling,H.; Lombardot,T.; Ludwig,W.; Gade,D.; Rabus,R.; Schlesner,H.; Amann,R.

TITLE (TI): Direct Submission

JOURNAL (SO): Submitted (21-JAN-2003) Max Planck Institute for Molecular Genetics, proScience Ihnestrasse 73, D-14195 Berlin, Germany Max Planck Institute for Marine

L7 ANSWER 97 OF 266 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10277840 IFIPAT;IFIUDB;IFICDB
TI PROTEIN AGGREGATION ASSAYS AND USES THEREOF; DETECTION OF MODULATOR OF PREFERENTIAL ENZYME ACTIVITY FOR USE IN THE TREATMENT OF NERVOUS SYSTEM AND RESPIRATORY DISORDERS; OBTAIN PROTEIN SAMPLE, INCUBATE WITH MODULATOR, MONITOR PROTEIN AGGREGATION IN SAMPLE
IN Cashman Neil (CA); Chakrabartty Avijit (CA); Kondejewski Les (CA); Qi Xiao-Fei (CA)
PA Unassigned Or Assigned To Individual (68000)
PI US 2003022243 A1 20030130
AI US 2002-176809 20020620
PRAI US 2001-299849P 20010620 (Provisional)
FI US 2003022243 20030130
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 115
GI 20 Figure(s).

FIG. 1 shows the structure of human SOD-1. Molecular modeling of human SOD-1 was carried out using the program InsightII (Accelrys, Burlington, Mass.) using protein data bank (pdb) coordinates from 1SPD. FIG. 1A shows that SOD-1 is a homodimeric enzyme responsible for the redox-catalyzed detoxification of superoxide. SOD-1 exists primarily in a betabarrel conformation with each subunit containing one Cu and one Zn atom. FIG. 1B illustrates a 90 degrees rotation of the view shown in FIG. 1A showing the detail of the active site Cu and Zn atoms in one SOD-1 monomer. The Cu is coordinated by 4 histidine residues and is necessary for the redox activity of SOD-1. The Zn atom is coordinated by 3 histidine residues and one aspartic acid residue and is required for maintaining the shape of the active site of SOD-1 but not required for SOD-1 activity.

FIG. 2 shows a schematic representation of two different methods that can be used to screen for agents capable of modulating or stabilizing SOD-1 protein conformation in vitro. FIG. 2A shows that upon application of stress (e.g., thermal or oxidative stress) a slightly unfolded aggregation-prone intermediate becomes populated. In the absence of any stabilizing factors, the intermediate goes on to form aggregates. FIG. 2B shows that one method to prevent aggregation of SOD-1 is to identify agents which bind to the aggregation-prone intermediate or to the aggregate and result in blocking sites that may be responsible for association of these species. FIG. 2C shows a second method of screening for inhibitors that relies on identifying agents that bind to SOD-1.

FIG. 3 shows the metal catalyzed oxidation (MCO)-induced aggregation of SOD-1. FIG. 3A shows the detection of MCOinduced SOD-1 aggregation by right angle light scattering (RALS) measurements. FIG. 3B shows the detection of MCO-induced SOD-1 aggregation before and after a 37 degrees C. incubation period by RALS. RALS of SOD-1 aggregates was measured using a DynaPro99-MSXTC/12 instrument. FIG. 3C shows the detection of MCO-induced SOD-1 aggregation by dynamic light scattering (DLS).

FIG. 4 shows the detection of SOD-1 aggregates using different biophysical methods. FIG. 4A shows detection of SOD-1 aggregates by UV absorption. (Sample pH was as follows: A, 4. 97; B, 5.37; C, 5.83; D, 6.05; E, 6.17; F, 6.44; G, 6.64; H, 6. 75; I, 7.01; and J, 7.19.) FIG. 4B shows detection of SOD-1 aggregates by RALS. FIG. 4C shows detection of SOD-1 aggregates using tryptophan (Trp) fluorescence.

FIG. 5 shows the detection of SOD-1 aggregates using electron microscopy and atomic force microscopy. FIGS. 5A and 5B show detection of SOD-1 aggregates by negative stain electron microscopy. The magnification is 25,000 and 57,000 in FIGS. 5A and 5B, respectively. FIG. 5C shows the detection of SOD-1 aggregates by atomic force measurement microscopy.

FIG. 6 shows MCO-induced aggregation of zinc-deficient and mutant SOD-1 as detected by RALS. FIG. 6A shows wild-type holoenzyme, zinc-deficient SOD-1, or mutant holoenzyme SOD-1 at a concentration of 10 mu M SOD-1 incubated in the presence of 4 mM ascorbic acid and 0.2 mM CuCl2 in 10 mM Tris, 10 mM acetate buffer, pH 7.0 (black bars) whereas control reactions

degrees C. for 48 hours. FIG. 6B shows MCO-induced SOD-1 aggregation is pH dependent.

FIG. 7 shows MCO-induced modifications of SOD-1. Human wt SOD-1 at a concentration of 30 mu M in 10 mM sodium acetate buffer, pH 5.0 was incubated in the presence of 2 mM ascorbate and 25 mu M copper at 60 degrees C. and aliquots of supernatants analyzed at the times indicated by SDS PAGE (FIG. 7A) or native PAGE (FIG. 7B). Pellets were also analyzed by native PAGE (FIG. 7B) after a 24 hour incubation by centrifuging incubated samples and suspending pellets in sample buffer. Lanes labeled "C" represent control samples incubated under the same conditions in the absence of copper and ascorbate. The bracket indicates the bands on the gel that are indicative of conformational heterogeneity.

FIG. 8 shows the detection of SOD-1 aggregation using biochemical methods. FIG. 8A shows an analysis of MCO-induced SOD-1 aggregation by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE). FIG. 8Bshows an analysis of MCOinduced SOD-1 aggregation by native PAGE. FIG. 8C shows an analysis of MCO-induced SOD-1 aggregation by filter retardation assay. FIG. 8D shows an analysis of MCO-induced SOD-1 aggregation by size exclusion chromatography (SEC). FIG. 8E shows an analysis of MCO-induced SOD-1 aggregation by filter retardation assay after dissolution of the insoluble aggregates in a 1% SDS solution.

FIG. 9 shows an analysis of MCO-induced SOD-1 aggregation by SEC. FIG. 9A shows a time course for SOD-1 aggregation as measured by monitoring the amount of soluble SOD-1 remaining in solution following treatment of human wt SOD-1 at a concentration of 30 mu M in 10 mM sodium acetate buffer, pH 5.0 with 2 mM ascorbate and 25 mu M copper at 37 degrees C. Aliquots of supernatant were analyzed by SEC at the times indicated. FIG. 9B shows the temperature dependence of SOD-1 aggregation. SOD-1 aggregation was determined as in FIG. 9A by incubating SOD-1 treated with Cu and ascorbate at different temperatures and comparing peak areas to those of controls to determine the amount of soluble SOD-1 remaining. FIG. 9C shows the pH dependence of aggregation. SOD-1 aggregation was determined as in FIG. 9A with the exception that Cu and ascorbate treatment were carried out at 60 degrees C. in 10 mM Tris-acetate buffer at the pH values indicated after 24 hours.

FIG. 10 shows a competitive ELISA assay used to detect SOD-1 aggregation. FIG. 10A shows a schematic of the methodology used to carry out a competitive ELISA assay to measure the amount of aggregated SOD-1 following treatment using a MCO system. FIG. 10B shows an example of a competitive ELISA.

FIG. 11 shows two independent examples of a competitive ELISA using SOD-1 or MCO-treated SOD-1.

FIG. 12 shows the results from an amino acid analysis of untreated and MCO-treated SOD-1.

FIG. 13 shows the results from mass spectrometric analysis of tryptic peptides derived from untreated and MCO-treated SOD-1.

FIG. 14 shows molecular modeling of MCO-treated human SOD-1. Molecular modeling was carried out using the program InsightII (Accelrys, Burlington, Mass.) using pdb coordinates from 1SPD. The oxidized sites present in SOD-1 treated with Cu and ascorbate as determined by mass spectroscopic analysis are mapped onto the structure of a monomer of SOD-1 and shown as either a side view (FIG. 14A) or top view (FIG. 14B). Shown also are copper and zinc atoms in the active site.

FIG. 15 shows the ***inhibition*** of MCO-induced SOD-1 aggregation using EDTA and anaerobic conditions.

FIG. 16 shows an ANS dye binding assay to characterize the folded state of SOD-1 under various conditions. FIG. 16A shows the results from ANS dye binding assays. Human wt SOD-1 at a concentration of 3 mu M incubated in the presence of 4 mM ascorbate and 200 mu M copper in 10 mM sodium acetate buffer, pH 5.0, at 60 degrees C. for 29 hours. Control preparations were incubated in the absence of copper and ascorbate under the same conditions. Following incubation, samples were vortexed thoroughly and ANS dye contained in DMSO added to a final concentration of 20 mu M ANS. Samples were incubated at room temperature for 20 minutes and fluorescence measured on a CaryVarian Eclipse Spectrofluorimeter using an excitation of 372 nm and emission recorded between 400-600 nm. FIG. 16B shows results from ANS dye binding assays. Apo-SOD-1 at a concentration of 30 mu M in 10 mM sodium acetate buffer, pH 5.0 was incubated at either 60 degrees C. or 4 degrees C. ANS dye binding was carried out as described in FIG. 16A.

FIG. 17 shows a native state stabilization assay using apo-SOD-1. FIG. 17A shows results where aliquots of supernatants were analyzed by reversed-phase high performance liquid chromatography (RP HPLC) and quantitation of amounts of soluble SOD-1 remaining following incubation. FIG. 17B shows detection of SOD-1 aggregates by protein staining

sodium acetate buffer, pH 5.0, and washes discarded. To the tubes was added 100 mu l of micro BCA protein determination reagent (Pierce), the tubes sealed and incubated at 60 degrees C. for up to 1 hour to allow for color development. The amount of protein present was quantitated by measuring absorbance at 562 nm.

FIG. 18 shows a native state stabilization assay used to test various agents for ***inhibition*** of aggregation of apo-SOD-1. FIG. 18A shows analysis of SOD-1 aggregation by RP-HPLC. FIG. 18B shows a graph depicting peak areas from chromatograms derived in FIG. 18A that were derived and plotted to show amount of soluble SOD-1 remaining after each treatment.

FIG. 19 shows immunocytochemical staining of HEK293A cells transfected with SOD-1. HEK293A cells were transfected with HAtagged human wt SOD-1 (FIG. 19A), HA-tagged human mutant G85R SOD-1 (FIG. 19B), or HA-tagged human mutant G41S SOD-1 (FIG. 19C).

FIG. 20 shows biochemical assays for cell based aggregation. HEK293A cells were transfected with human wt SOD-1 or human mutant SOD-1 cDNA contained in the pFLUC plasmid (Valentis) and analyzed by SDS PAGE/Western blot analysis under reducing conditions (FIGS. 20A and 20B) or native PAGE/Western blot analysis (FIGS. 20C and 20D).

L7 ANSWER 98 OF 266 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10244224 IFIPAT;IFIUDB;IFICDB
TI MODULATING CELL SURVIVAL BY MODULATING ***HUNTINGTIN*** FUNCTION
IN Hackam Abigail S; Hayden Michael (CA); Leavitt Blair R (CA)
PA Unassigned Or Assigned To Individual (68000)
PI US 2002187931 A1 20021212
AI US 2002-9478 20020531
WO 2001-CA495 20010412
PRAI CA 2000-2305088 20000413
CA 2000-2326543 20001212
FI US 2002187931 20021212
DT Utility; Patent Application - First Publication **
00001000
FS CHEMICAL
APPLICATION
CLMN 36
GI 17 Figure(s).

FIG. 1 presents a schematic representation of the balance between normal cell proliferation and cell death. An imbalance will result in abnormal proliferation or abnormal cell death as is observed in various diseases and disorders.

FIG. 2 depicts the testicular morphology of yeast artificial chromosome (YAC) rescued ***huntingtin*** knockout mice. The YACs used to rescue mice contain the ***huntingtin*** gene with 18, 46 or 72 CAG repeats. The normal number of CAG repeats found in humans without HD is 18. Greater numbers of CAG repeats are associated with HD development, with 46 being an intermediate number and 72 being a high number of repeats. Semi-thin sections of testes stained with toluidine blue from 8 month old mice reveal the gross testicular morphology of mice with varying amounts of endogenous ***huntingtin*** rescued with YAC18 (a, b, c), YAC46 (d, e, f), and YAC72 (g, h, i) transgenes. Massive degeneration of spermatocytes is shown, and this novel cell death phenotype is CAG repeat size-dependent and is modulated by the level of endogenous ***huntingtin*** . The cell death is most pronounced in YAC72 rescued knockout mice, intermediate in YAC46 knockout mice and not present in YAC18 rescued mice.

FIG. 3 depicts protein aggregates in YAC72 rescued ***huntingtin*** knockout mice. Ultrastructural analysis of the testes of YAC72 mice lacking endogenous ***huntingtin*** revealed the presence of abnormal aggregates of intracellular protein (arrows) within spermatids, sertoli cells and sperm tails. The composition of these protein aggregates is currently unknown, but they resemble the ultrastructural appearance of ***huntingtin*** aggregates found in human HD brain tissue. Ectopic microtubule bundles and manchettes were also identified (arrows).

FIG. 4 depicts electron microscopic (EM) analysis of degenerating testicular cells from YAC72 rescued ***huntingtin*** knockout mice. Ultrastructural analysis of testes from YAC72 mice nullizygous for endogenous ***huntingtin*** reveals massive cell death of spermatids, phagocytosis of degenerating cells and formation of multinucleated giant cells.

FIG. 5 demonstrates that the C-terminus of ***huntingtin*** protein is anti-apoptotic. Using the methylthiazol tetrazolium (MTT) assay to measure cell viability, it is shown that expression of the Cterminus (C-ter) of ***huntingtin*** protects HEK 293T cells from tamoxifen

(LacZ) as a control.

FIG. 6 demonstrates that the C-terminus of ***huntingtin*** protein confers protection against ***huntingtin*** toxicity in NT2 cells. Mutant ***huntingtin*** protein (HD138) was co-transfected with control protein, pyruvate kinase (PK), or with ***huntingtin*** Cterminus (C-ter) and cell death in response to tamoxifen stimulus was measured. Expression of the C-terminus reduced HD138-dependent cell death (p=0.002).

FIG. 7 demonstrates that the C-terminus of ***huntingtin*** protein rescues HIP-1 toxicity in NT2 cells. Expression of the Cterminus in NT2 cells reduces HIP-1 mediated cell death, compared with expression of control protein (PK) (p less-than 0. 01).

FIG. 8 demonstrates that the C-terminus of ***huntingtin*** protein reduces mutant ***huntingtin*** protein aggregate formation. Expression of the C-terminus (C-ter) reduces the number of aggregates formed by a truncated version of mutant ***huntingtin*** protein (1955-128), compared with coexpression of ***huntingtin*** and the LacZ control. Aggregates were induced by tamoxifen stimulus (A) or by HIP-1 expression (B).

FIG. 9 shows results of studies with YAC transgenic mice expressing increased levels of wild-type human ***huntingtin*** are resistant to neurodegeneration following kainic acid-induced seizures. a, Quantification of degenerating hippocampal neurons following kainic acid-induced seizures in mice expressing 2-3 times the endogenous levels of wild-type ***huntingtin*** (212 line) and littermate controls (FVB/NJ). Average numbers of degenerating neurons per animal identified by Fluoro-Jade labeling are expressed for the CA1, CA3 and total hippocampal regions. Data is expressed as mean +/-SEM with significance determined using a two-tailed students t-test. Images of degenerating neurons (arrows) using Fluoro-Jade labeling (b. line 212 20x, c. FVB/NJ 20x, d. FVB/NJ 100x), silver staining (e. line 212 20x, f. FVB/NJ 20x, g. FVB/NJ 100x), and TUNEL staining (h. line 212 20x, i. FVB/NJ 20x,j. FVB/NJ 100x) within the hippocampus following KA-induced seizures.

FIG. 10 shows YAC transgenic mice expressing increased levels of wild-type human ***huntingtin*** have decreased caspase-3 activation following kainic acid-induced seizures. Quantification of hippocampal and cerebellar DEVD-ase activity following kainic acid-induced seizures in mice expressing 2-3 times the endogenous levels of wild-type ***huntingtin*** (212 line) and littermate controls (FVB/NJ). Data is expressed as mean +/-SEM with significance determined using a two-tailed students t-test.

FIG. 11 shows rescue of the Hdh nullizygous lethal phenotype by YAC transgenes expressing mutant ***huntingtin*** . Resultant genotypes for the F2 offspring of a cross between a YAC72 transgene positive, Hdh gene heterozygous mouse (+,+/-genotype) and a transgene negative, Hdh heterozygous mouse (-,+/genotype). (a). The upper PCR bands represent the presence or absence of the YAC transgene and the lower bands represent the state of the endogenous Hdh gene. The mouse represented in lane two has the YAC72 transgene, but lacks the endogenous Hdh gene (+,-/-genotype). This mouse demonstrates that mutant human ***huntingtin*** expression form our YAC transgene rescued the Hdh nullizygous state. Mice with targeted disruption of the Hdh gene were rescued from the embryonic lethal phenotype equally by all three of the YAC transgenes described in this paper. The F2 offspring of our experimental breedings had the expected 1:2:1 ratio of genotypes for all of the YAC transgenes examined (B). Western blot analysis of ***huntingtin*** protein expression (C) confirmed the absence of endogenous htt protein in Hdh nullizygous mice (-/-) compared to wild-type (+/+) and demonstrated similar levels of human transgenic ***huntingtin*** expression in YAC18, YAC46, and YAC72 rescued Hdh nullizygous mice (+,-/-). Average testicular weight and epididymal sperm counts for YAC72+/+, YAC72+/-, and YAC72-/-mice at four months of age are shown in (D) and (E) respectively. YAC72-/-mice had significant testicular atrophy (p less-than 10-5) and decreased sperm counts (p less-than 10-5) compared to YAC72+/+ and YAC72+/ -mice.

FIG. 12 shows testicular morphology of YAC transgene rescued Hdh nullizygous mice. Semi-thin sections of testes stained with toluidine blue from 8-month-old mice reveal the gross testicular morphology of mice with the YAC18 (a,b,c), YAC46 (d, e,f), and YAC72 (g,h,i) htt transgenes and either 100% of endogenous htt levels (+/+), 50% of endogenous htt levels (+/-) or absence of endogenous htt (-/-). Massive degeneration of spermatogenic cells occurs in the seminiferous tubules of mice expressing mutant htt with 46 or 72 polyglutamine repeats (panels i and f). The cell death is most pronounced in YAC72 (i) , intermediate in YAC46 (f), and not present in YAC18 (c) rescued Hdh nullizygous mice. The human HD

length of the CAG repeat, and these results suggest that this novel cell death phenotype is CAG repeat length-dependent. Increasing levels of endogenous htt markedly reduced the amount of spermatogenic cell degeneration (panels d,e and g,h) observed in YAC46 and YAC72 mice. (Bar=100 mu m.)

FIG. 13 shows morphologic, biochemical, and ultrastructural evidence for apoptotic cell death in the testes of YAC72 mice lacking endogenous htt. Massive death of spermatogenic cells was observed in YAC72 mice lacking endogenous htt by toluidine blue staining (A) which revealed decreased numbers of spermatogenic cells, and a disordered epiythelium filled with vacuoles compared to the well large numbers of spermatocytes in well ordered stratified epithelium of YAC72+/+ mice (C). Increased apoptosis was evident in the testes of YAC72-/-mice by increased TUNEL labelling of spermatogenic cells (arrows in panel B) compared to YAC72 mice with normal levels of endogenous ***huntingtin*** (D). EM analysis of degenerating testicular cells from YAC72 (-/-) mice also provided evidence of apoptosis. Ultrastructural analysis of testes from YAC72 mice nullizygous for Hdh reveals massive cell death of spermatids, phagocytosis of degenerating cells, and formation of multinucleated giant cells. The epithelium of YAC72 mice tacking endogenous htt was characterized by degenerating spermatids filled with cytoplasmic vacuoles (E), phagosomes containing shrunken electron-dense spermatids engulfed within Sertoli cells (F), and spermatogenic giant cells (G). Bars (A-D) =100 mu m, (E)=10 mu m, (F)=5 mu m, (G) 10 mu m.

FIG. 14 shows protein aggregates in YAC72 (-/-) mice. Ultrastructural analysis of the testes of YAC72 mice lacking endogenous htt revealed the occasional presence of abnormal aggregates of intracellular protein (arrows) within elongate spermatids (A), sertoli cells (B), and sperm tails (C). The composition of these protein aggregates is not entirely clear, but they resemble the ultrastructural appearance of ***huntingtin*** aggregates found in human HD brain tissue. Ectopic microtubule bundles (D) and manchettes (E) were also identified (asterisks). The bundle in E is in a spermatogonium. N=nucleus. Bars (A, B) =5 mu m, (C,D)=1 mu m, (E)=5 mu m.

FIG. 15 presents immunocytochemical analysis of protein aggregates and actin distribution in sections from the testes of YAC72-/-mice. Abnormal protein aggregates within degenerating spermatogenic cells in the testes of YAC72-/-mice contain ***huntingtin*** (Figures A, phase, and B, immunofluorescence) . In normal epithelium (Figures E, phase, and F, fluorescence), actin filaments in Sertoli cells are concentrated in unique adhesion plaques (ectoplasmic specializations) that occur at apical sites of attachment to spermatids (Apical) and at basal sites of attachment to neighbouring Sertoli cells (Basal). In YAC72-/-mice (FIGS. G-J), filament bundles (asterisks) in apical regions occur in areas not associated with spermatid heads, although filament bundles at basal sites occur in their normal position. Bars (A-D)=10 mu m, (E-J)=50 mu m.

FIG. 16 shows the effect of htt over-expression on body weight. Transgenic mice aged 5-8 months old that over-express wild-type htt (n=11) had a significantly increased total body mass compared to sex and age matched control mice (n=12). The average body weight was approximately 25% greater for the transgenic mice compared to wild-type. The increased body weight of the transgenic mice suggests that the wild-type htt is causing increased cellular survival or proliferation in general in these mice.

FIG. 17 shows the effect of transfecting NIH3T3 cells with a wild-type ***huntingtin*** gene or a known oncogene (ras). Cellular proliferatic was assessed following transient transfections of NIH3T3 cells using a standardised colorometric assay of cell number. Transfection of a full-length htt construct or the oncogene ras each lead to a significant increase in cellular proliferation of approximately 3-fold compared to empty vector alone. !

L7 ANSWER 99 OF 266 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10217245 IFIPAT;IFIUDB;IFICDB
TI ***INHIBITION*** OF PROTEIN-PROTEIN INTERACTION
IN Housman David E; Kazantsev Aleksey G; Marsh J Lawrence; Thompson Leslie M
PA Unassigned Or Assigned To Individual (68000)
PI US 2002160952 A1 20021031
AI US 2001-933638 20010820
PRAI WO 2001-US26097 20010820
US 2000-226502P 20000818 (Provisional)
FI US 2002160952 20021031
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 17

FIG. 1 is a representation of the Tata-binding protein (SEQ ID NO: 12; TBP; encoded by Genbank Accession No. M55654). The alpha-helical regions H1 (LKTIALRAR; SEQ ID NO:2), H2 (EEQSRLAARKYAR; SEQ ID NO:3), H3 (LEGLVLTHQQF; SEQ ID NO:4), and H4 (AEIYEAFENIYPILKGFRK; SEQ ID NO:5) are indicated.

FIG. 2 is a representation of portions of therapeutic agents. The portions can serve as, or as part of, the third domain. The portions shown here are referred to in the text below as H1/H2, H2/H3, and H3/H4 (SEQ ID Nos:6-8, respectively).

FIG. 3 is a summary of aggregation observed following cotransfection of cells with the HD-104Q-EGFP construct (under the control of the EF-1 alpha promoter) and therapeutic agents in which the third domain contained the H1/H2, H2/H3, or H3/H4 sequences (upper Table). The results were collected following two independent transfections, and cells were counted in 6-8 separate fields. Almost identical results were obtained when the promoters driving each expressed polypeptide were switched and the therapeutic agent was tagged with DS Red (lower Table).

L7 ANSWER 100 OF 266 IFIPAT COPYRIGHT 2004 IFI on STN
AN 10066215 IFIPAT;IFIUDB;IFICDB
TI COMPOUNDS THAT SELECTIVELY BIND TO EXPANDED POLYGLUTAMINE REPEAT DOMAINS AND METHODS OF USE THEREOF; A PEPTIDE OR POLYPEPTIDE CONTAINING TRYPTOPHAN AND A CHARGED AMINO ACID SELECTED FROM LYSINE, ARGANINE AND HISTIDINE AND THE COMPOUND IS CONJUGATED TO A DETACTABLE GROUP, USEFUL TO DETECT AN EXPANDED POLYGLUTAMINE DOAMINE IN A SAMPLE
IN Burke James R; Nagai Yoshitaka (JP); Strittmatter Warren J
PA Unassigned Or Assigned To Individual (68000)
PI US 2002009752 A1 20020124
AI US 2001-780070 20010209
PRAI US 2000-189781P 20000316 (Provisional)
FI US 2002009752 20020124
DT Utility; Patent Application - First Publication
FS CHEMICAL
APPLICATION
CLMN 39
GI 12 Figure(s).

FIG. 1A. Schematic representation of thioredoxin-polyglutamine fusion protein. HP-Thioredoxin=His-Patch thioredoxin. Qn=polyglutamine domain containing n sequential glutamines.

FIG. 1B. Concentration curve of thioredoxin-Qn protein aggregation. Thio-Qn proteins containing pathologic-length glutamine repeats aggregate in vitro. Thio-Q81 (*) aggregates at lower concentration than thio-Q62 (*), while thio-Q35 (*) does not aggregate.

FIG. 1C. Time-course of thioredoxin-Q62 protein aggregation. Thio-Q62 (*) aggregation consists of a lag phase followed by rapid polymerization. Thio-Q62 concentration 17 mu M. In Figures B and C, plateau is reached by 72 hours incubation. Turbidity measured at 405 nm following a 72 hour incubation (13) . Results shown are from representative experiments (n=4). Variation between duplicate wells was less than 10%.

FIG. 2. Polyglutamine binding peptide ***inhibition*** of thioredoxinQ62 aggregation. QBP 1 inhibits thio-Q62 aggregation in a concentration-dependent pattern (Filled bars). A random peptide (RAN; Open bar) and a scrambled version of QBP1 (SCR; Hatched bar), at 25 mu M, inhibited thio-Q62 aggregation less than 10%. Aggregation was assayed by turbidity at 405 nm (Hackam, A. S. et al. (1998) J Cell Biol 141, 1097-1105). Results shown are from representative experiments (n=4). Variation between duplicate wells was less than 10%.

FIG. 3. Intracellular distribution of Qn-YFP and QBP1-CFP in COS 7 cells.

FIG. 3A: Schematic representations of Qn-YFP (upper) and QBP1, RAN or SCR-CFP fusion proteins (lower).

FIG. 3B: Fluorescent micrographs demonstrating co-localization of QBP1-CFP with Q81-YFP aggregates in COS 7 cells 48 hours after transfection. a and b; Co-expression of Q19-YFP and QBP1CFP, c and d; Q81-YFP and QBP1-CFP, e and f; Q81-YFP and RANCFP, g and h; Q81-YFP and SCR-CFP. a, c, e, g; images obtained by YFP filter set (Omega Optical Inc., Brattlesboro, Vt.). b, d, f, h; by CFP filter set (Omega Optical Inc.). No YFP signal could be seen using the CFP filter and no CFP fluorescence was detected using the YFP filter. Magnification x 320

FIG. 4. QBP1 expression decreases the number of cells containing polyglutamine aggregates. Open bar=cells co-transfected with QnYFP and RAN-CFP. Hatched bar=cells co-transfected with Qn-YFP and SCR-CFP. Filled bar=cells co-transfected with Qn-YFP and QBP1-CFP. Dotted bar=cells co-transfected with Qn-YFP and (QBP1) 2-CFP.

COS-7 cells examined 48 hours after transfection using a Zeiss fluorescence microscope with the CFP/YFP filter set from Omega Optical

the number of transfected cells containing aggregate and dividing by the total number of transfected cells multiplied times 100. In each experiment at least 200 transfected cells were counted. Experiments were repeated at least four times. Error bars represent standard errors. *=p less-than 0.05;**=p less-than 0.01 (Student's ttest)

FIG. 5. QBP1 expression inhibits polyglutamine-mediated cell death. Open bar=cells co-transfected with Q57-YFP and RAN-CFP. Hatched bar=cells co-transfected with Q57-YFP and SCR-CFP. Filled bar=cells co-transfected with Q57-YFP and QBP1-CFP. Dotted bar=cells co-transfected with Q57-YFP and (QBPI)2-CFP. COS-7 cells examined 48 hours after transfection using a Zeiss fluorescence microscope with rhodamine filter set. The percentage of dead cells was calculated by counting the number of transfected cells stained with ethidium homodimer and dividing by the total number of transfected cells multiplied times 100. In each experiment at least 200 transfected cells were counted. Experiments were repeated at least three times. Error bars represent standard errors. *=p less-than 0.05; **=p less-than 0.01 (Student's t-test).

FIG. 6. In vitro aggregation of thio-Q62 plus QBP1s at 1 microMolar.

FIG. 7. In vitro aggregation of thio-Q62 plus QBP1s at ten microMolar.

L7 ANSWER 101 OF 266 IFIPAT COPYRIGHT 2004 IFI on STN
AN 03953226 IFIPAT;IFIUDB;IFICDB
TI COMPOUNDS THAT SELECTIVELY BIND TO EXPANDED POLYGLUTAMINE REPEAT DOMAINS AND METHODS OF USE THEREOF
IN Burke James R; Nagai Yoshitaka (JP); Strittmatter Warren J
PA Duke University (25202)
PI US 6632616 B2 20031014
US 2002009752 A1 20020124
AI US 2001-780070 20010209
PRAI US 2000-189781P 20000316 (Provisional)
FI US 6632616 20031014
DT Utility
FS CHEMICAL
GRANTED
CLMN 6
GI 8 Drawing Sheet(s), 10 Figure(s).

FIG. 1A. Schematic representation of thioredoxin-polyglutamine fusion protein. HP-Thioredoxin=His-Patch thioredoxin. Qn=polyglutamine domain containing n sequential glutamines.

FIG. 1B. Concentration curve of thioredoxin-Qn protein aggregation. Thio-Qn proteins containing pathologic-length glutamine repeats aggregate in vitro. Thio-Q81 (*) aggregates at lower concentration than thio-Q62 (*), while thio-Q35 (*) does not aggregate.

FIG. 1C. Time-course of thioredoxin-Q62 protein aggregation. Thio-Q62 (*) aggregation consists of a lag phase followed by rapid polymerization. Thio-Q62 concentration 17 mu M. In FIGS. B and C, plateau is reached by 72 hours incubation. Turbidity measured at 405 nm following a 72 hour incubation (13). Results shown are from representative experiments (n=4). Variation between duplicate wells was less than 10%.

FIG. 2. Polyglutamine binding peptide ***inhibition*** of thioredoxinQ62 aggregation. QBP 1 inhibits thio-Q62 aggregation in a concentration-dependent pattern (Filled bars). A random peptide (RAN; Open bar) and a scrambled version of QBP1 (SCR; Hatched bar), at 25 mu M, inhibited thio-Q62 aggregation less than 10%. Aggregation was assayed by turbidity at 405 nm (Hackam, A. S. et al. (1998) J Cell Biol 141, 1097-1105). Results shown are from representative experiments (n=4). Variation between duplicate wells was less than 10%.

FIG. 3. Intracellular distribution of Qn-YFP and QBP1-CFP in COS 7 cells.

FIG. 3A: Schematic representations of Qn-YFP (upper) and QBP1, RAN or SCR-CFP fusion proteins (lower).

FIG. 3B: Fluorescent micrographs demonstrating co-localization of QBP1-CFP with Q81-YFP aggregates in COS 7 cells 48 hours after transfection. a and b; Co-expression of Q19-YFP and QBP1CFP, c and d; Q81-YFP and QBP1-CFP, e and f; Q81-YFP and RANCFP, g and h; Q81-YFP and SCR-CFP. a, c, e, g; images obtained by YFP filter set (Omega Optical Inc., Brattlesboro, Vt.). b, d, f, h; by CFP filter set (Omega Optical Inc.). No YFP signal could be seen using the CFP filter and no CFP fluorescence was detected using the YFP filter. Magnification x 320

FIG. 4. QBP1 expression decreases the number of cells containing polyglutamine aggregates. Open bar=cells co-transfected with QnYFP and RAN-CFP. Hatched bar=cells co-transfected with Qn-YFP and SCR-CFP. Filled bar=cells co-transfected with Qn-YFP and QBP1-CFP. Dotted bar=cells co-transfected with Qn-YFP and (QBP1) 2-CFP.

FIG. 5. QBP1 expression inhibits polyglutamine-mediated cell death. Open bar=cells co-transfected with Q57-YFP and RAN-CFP. Hatched bar=cells

with Q57-YFP and QBP1-CFP. Dotted bar=cells co-transfected with Q57-YFP and (QBPI)2-CFP. COS-7 cells examined 48 hours after transfection using a Zeiss fluorescence microscope with rhodamine filter set. The percentage of dead cells was calculated by counting the number of transfected cells stained with ethidium homodimer and dividing by the total number of transfected cells multiplied times 100. In each experiment at least 200 transfected cells were counted. Experiments were repeated at least three times. Error bars represent standard errors. *=p less-than 0.05; **=p less-than 0.01 (Student's t-test).

FIG. 6. In vitro aggregation of thio-Q62 plus QBP1s at 1 microMolar.

FIG. 7. In vitro aggregation of thio-Q62 plus QBP1s at ten microMolar.

L7 ANSWER 102 OF 266 MEDLINE on STN
AN 2004119643 IN-PROCESS
DN PubMed ID: 14962977
TI Striatal cells from mutant ***huntingtin*** knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway.
AU Ruan Qingmin; Lesort Mathieu; MacDonald Marcy E; Johnson Gail V W
SO Human molecular genetics, (2004 Apr 1) 13 (7) 669-81.
Journal code: 9208958. ISSN: 0964-6906.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS IN-DATA-REVIEW; IN-PROCESS; NONINDEXED; Priority Journals
ED Entered STN: 20040311
Last Updated on STN: 20040311

L7 ANSWER 103 OF 266 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 2001:165878 PROMT
TITLE: EUROPEAN PATENT DISCLOSURES.(Brief Article)
SOURCE: BIOWORLD Today, (27 Feb 2001) Vol. 12, No. 39.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 2102
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 104 OF 266 PROMT COPYRIGHT 2004 Gale Group on STN

ACCESSION NUMBER: 1999:329612 PROMT
TITLE: INTRACTABLE BRAIN DISORDER YIELDS ONE SECRET HARVARD NEUROSURGEON DISSECTS ROLE OF APOPTOSIS IN HUNTINGTON'S DISEASE; FORESEES DRUG THERAPIES.
AUTHOR(S): Leff, David N.
SOURCE: BIOWORLD Today, (20 May 1999) Vol. 10, No. 97.
PUBLISHER: American Health Consultants, Inc.
DOCUMENT TYPE: Newsletter
LANGUAGE: English
WORD COUNT: 1039
FULL TEXT IS AVAILABLE IN THE ALL FORMAT

L7 ANSWER 105 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2003:943685 SCISEARCH
GA The Genuine Article (R) Number: 734KQ
TI Aggregation of expanded polyglutamine domain in yeast leads to defects in endocytosis
AU Meriin A B; Zhang X Q; Miliaras N B; Kazantsev A; Chernoff Y O; McCaffery J M; Wendland B; Sherman M Y (Reprint)
CS Boston Univ, Sch Med, Dept Biochem, K323, 715 Albany St, Boston, MA 02118 USA (Reprint); Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, Integrated Imaging Ctr, Baltimore, MD 21218 USA; Georgia Inst Technol, Sch Biol, Atlanta, GA 30332 USA; Georgia Inst Technol, Inst Bioengn & Biosci, Atlanta, GA 30332 USA
CYA USA
SO MOLECULAR AND CELLULAR BIOLOGY, (NOV 2003) Vol. 23, No. 21, pp. 7554-7565. Publisher: AMER SOC MICROBIOLOGY, 1752 N ST NW, WASHINGTON, DC 20036-2904 USA.
ISSN: 0270-7306.
DT Article; Journal
LA English
REC Reference Count: 63

L7 ANSWER 106 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2003:670798 SCISEARCH
GA The Genuine Article (R) Number: 705YA
TI Proteasome ***inhibition*** induces inclusion bodies associated with intermediate filaments and fragmentation of the Golgi apparatus
AU Harada M (Reprint); Kumemura H; Omary M B; Kawaguchi T; Maeyama N; Hanada S; Taniguchi E; Koga H; Suganuma T; Ueno T; Sata M
CS Kurume Univ, Sch Med, Dept Med 2, 67 Asahi Machi, Kurume, Fukuoka 830, Japan (Reprint); Kurume Univ, Sch Med, Dept Med 2, Kurume, Fukuoka 830, Japan; Kurume Univ, Sch Med, Res Ctr Innovat Canc Therapy, Kurume, Fukuoka 830, Japan; Stanford Univ, Sch Med, Ctr Digest Dis, Palo Alto, CA 94304 USA; Miyazaki Med Coll, Dept Anat, Miyazaki 88916, Japan
CYA Japan; USA
SO EXPERIMENTAL CELL RESEARCH, (1 AUG 2003) Vol. 288, No. 1, pp. 60-69.
Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA.
ISSN: 0014-4827.
DT Article; Journal
LA English
REC Reference Count: 43
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 107 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2003:380364 SCISEARCH
GA The Genuine Article (R) Number: 676HY
TI ***Huntingtin*** aggregation and toxicity in Huntington's disease
AU Bates G (Reprint)
CS Univ London Kings Coll, Guys Hosp, GKT Sch Med, London SE1 9RT, England (Reprint)
CYA England
SO LANCET, (10 MAY 2003) Vol. 361, No. 9369, pp. 1642-1644.
Publisher: LANCET LTD, 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND.
ISSN: 0140-6736.
DT General Review; Journal
LA English
REC Reference Count: 24
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 108 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2003:82642 SCISEARCH
GA The Genuine Article (R) Number: 637UW
TI Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders
AU Sanchez I (Reprint); Mahlke C; Yuan J Y
CS Boston Univ, Sch Med, Dept Anat & Neurobiol, 715 Albany St, Boston, MA 02118 USA (Reprint); Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA
CYA USA
SO NATURE, (23 JAN 2003) Vol. 421, No. 6921, pp. 373-379.
Publisher: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND.
ISSN: 0028-0836.
DT Article; Journal
LA English
REC Reference Count: 30
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 109 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2002:360613 SCISEARCH
GA The Genuine Article (R) Number: 543HR
TI Polyglutamine expansion, protein aggregation, proteasome activity, and neural survival
AU Ding Q X; Lewis J J; Strum K M; Dimayuga E; Bruce-Keller A J; Dunn J C; Keller J N (Reprint)
CS Univ Kentucky, Dept Anat & Neurobiol, 101 Sanders Brown Bldg, Lexington, KY 40536 USA (Reprint); Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Dept Sci Biol, Lexington, KY 40536 USA; Univ Kentucky, Dept Gerontol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA
CYA USA
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (19 APR 2002) Vol. 277, No. 16, pp. 13935-13942.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA.

DT Article; Journal
LA English
REC Reference Count: 47
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 110 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2002:198030 SCISEARCH
GA The Genuine Article (R) Number: 524VB
TI Identification of ter94, Drosophila VCP, as a modulator of polyglutamine-induced neurodegeneration
AU Higashiyama H; Hirose F; Yamaguchi M; Inoue Y H; Fujikake N; Matsukage A; Kakizuka A (Reprint)
CS Kyoto Univ, Grad Sch Biostudies, Lab Functional Biol, Kyoto 6068501, Japan (Reprint); Osaka Biosci Inst, Dept 4, Osaka 5650874, Japan; Aichi Canc Ctr Res Inst, Cell Biol Sect, Div Biochem, Aichi 4648581, Japan; Cold Spring Harbor Lab, New York, NY USA
CYA Japan; USA
SO CELL DEATH AND DIFFERENTIATION, (MAR 2002) Vol. 9, No. 3, pp. 264-273.
Publisher: NATURE PUBLISHING GROUP, HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND.
ISSN: 1350-9047.
DT Article; Journal
LA English
REC Reference Count: 42
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 111 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2000:478043 SCISEARCH
GA The Genuine Article (R) Number: 327HD
TI Polyglutamine-mediated aggregation and cell death
AU deCristofaro T; Affaitati A; Feliciello A; Avvedimento E V; Varrone S (Reprint)
CS UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOL & PATOL CELLULARE & MOL, CNR, I-80131 NAPLES, ITALY (Reprint); UNIV NAPLES FEDERICO II, DIPARTIMENTO BIOL & PATOL CELLULARE & MOL, CNR, I-80131 NAPLES, ITALY; UNIV CATANZARO MAGNA GRECIA, DIPARTIMENTO MED SPERIMENTALE & CLIN, CATANZARO, ITALY
CYA ITALY
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (16 JUN 2000) Vol. 272, No. 3, pp. 816-821.
Publisher: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495.
ISSN: 0006-291X.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 42
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 112 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 2000:286351 SCISEARCH
GA The Genuine Article (R) Number: 302BT
TI ***Inhibition*** of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening
AU Nagai Y; Tucker T; Ren H Z; Kenan D J; Henderson B S; Keene J D; Strittmatter W J; Burke J R (Reprint)
CS DUKE UNIV, MED CTR, DEPT MED NEUROL, BOX 2900, DURHAM, NC 27710 (Reprint); DUKE UNIV, MED CTR, DEANE LAB, DURHAM, NC 27710; DUKE UNIV, MED CTR, DIV NEUROL, DEPT MED, DURHAM, NC 27710; DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710; DUKE UNIV, MED CTR, DEPT MICROBIOL, DURHAM, NC 27710; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710
CYA USA
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (7 APR 2000) Vol. 275, No. 14, pp. 10437-10442.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.
ISSN: 0021-9258.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 39

L7 ANSWER 113 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 1999:901345 SCISEARCH
GA The Genuine Article (R) Number: 241JQ
TI ***Inhibition*** of caspase cleavage of ***huntingtin*** protects

AU Wellington C L (Reprint); Singaraja R; Ellerby L; Savill J; Roy S; Leavitt B; Cattaneo E; Hackam A; Sharp A; Thornberry N; Bredesen D; Nicholson D; Hayden M R
CS UBC, CMMT, VANCOUVER, BC, CANADA; BURNHAM INST, LA JOLLA, CA 92037; MERCK FROSST CANADA INC, MONTREAL, PQ, CANADA; UNIV MILAN, INST PHARMACOL SCI, MILAN, ITALY; JOHNS HOPKINS UNIV, DEPT PYSCH BEH SCI, BALTIMORE, MD
CYA CANADA; USA; ITALY
SO AMERICAN JOURNAL OF HUMAN GENETICS, (OCT 1999) Vol. 65, No. 4, Supp. [S], pp. 11-11.
Publisher: UNIV CHICAGO PRESS, 5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603.
ISSN: 0002-9297.
DT Conference; Journal
FS LIFE; CLIN
LA English
REC Reference Count: 0

L7 ANSWER 114 OF 266 SCISEARCH COPYRIGHT 2004 THOMSON ISI on STN
AN 1998:520276 SCISEARCH
GA The Genuine Article (R) Number: ZX500
TI ***Inhibition*** of ***Huntingtin*** by Antisense Oligodeoxynucleotides
AU Nellemann C (Reprint); Abell K; Hasholt L; Norremolle A; Sorensen S A
CS UNIV COPENHAGEN, PANUM INST, DEPT MED GENET, DK-2200 COPENHAGEN N, DENMARK
CYA DENMARK
SO EUROPEAN JOURNAL OF HUMAN GENETICS, (30 MAY 1998) Vol. 6, Supp. [1], pp. P4160-P4160.
Publisher: STOCKTON PRESS, HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND.
ISSN: 1018-4813.
DT Conference; Journal
FS LIFE
LA English
REC Reference Count: 0

L7 ANSWER 115 OF 266 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2003:298711 TOXCENTER
DN PubMed ID: 14561870
TI Histone deacetylase ***inhibition*** by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice
AU Ferrante Robert J; Kubilus James K; Lee Junghee; Ryu Hoon; Beesen Ayshe; Zucker Birgit; Smith Karen; Kowall Neil W; Ratan Rajiv R; Luthi-Carter Ruth; Hersch Steven M
CS Geriatric Research Education and Clinical Center, Bedford Veterans Affairs Medical Center, Bedford, Massachusetts 01730, USA. rjferr@bu.edu
NC AG12992 (NIA)
AG13846 (NIA)
AT00613 (NCCAM)
NS35255 (NINDS)
SO Journal of neuroscience : official journal of the Society for Neuroscience, (2003 Oct 15) 23 (28) 9418-27.
Journal Code: 8102140. ISSN: 1529-2401.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDLINE
OS MEDLINE 2003483579
LA English
ED Entered STN: 20031223
Last Updated on STN: 20031223

L7 ANSWER 116 OF 266 TOXCENTER COPYRIGHT 2004 ACS on STN
AN 2002:164901 TOXCENTER
DN PubMed ID: 11988536
TI Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease
CM Comment in: Science. 2002 Jun 21;296(5576):2149-50. PubMed ID: 12077389
AU Dunah Anthone W; Jeong Hyunkyung; Griffin April; Kim Yong-Man; Standaert David G; Hersch Steven M; Mouradian M Maral; Young Anne B; Tanese Naoko; Krainc Dimitri
CS Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Center for Aging, Genetics and Neurodegeneration, Charlestown, MA 02129, USA
NC 5R37AG13617 (NIA)
AT00613 (NCCAM)
NS02174 (NINDS)

NS35255 (NINDS)
SO Science, (2002 Jun 21) 296 (5576) 2238-43.
Journal Code: 0404511. ISSN: 1095-9203.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
FS MEDLINE
OS MEDLINE 2002334508
LA English
ED Entered STN: 20020730
Last Updated on STN: 20030106

L7 ANSWER 117 OF 266 USPATFULL on STN
AN 2004:63809 USPATFULL
TI Aza-peptide epoxides
IN Powers, James C., Atlanta, GA, UNITED STATES
Asgian, Juliana L., Fullerton, CA, UNITED STATES
James, Karen E., Cumming, GA, UNITED STATES
Li, Zhao-Zhao, Norcross, GA, UNITED STATES
PI US 2004048327 A1 20040311
AI US 2003-603054 A1 20030624 (10)
PRAI US 2002-394221P 20020705 (60)
US 2002-394023P 20020705 (60)
US 2002-394024P 20020705 (60)
DT Utility
FS APPLICATION
LN.CNT 4866
INCL INCLM: 435/023.000
INCLS: 530/330.000; 530/331.000; 549/551.000; 544/147.000
NCL NCLM: 435/023.000
NCLS: 530/330.000; 530/331.000; 549/551.000; 544/147.000
IC [7]
ICM: C12Q001-37
ICS: C07K007-06; C07K005-06; C07K005-04

L7 ANSWER 118 OF 266 USPATFULL on STN
AN 2004:58177 USPATFULL
TI Cytoskeleton-associated proteins
IN Baughn, Mariah R, San Leandro, CA, UNITED STATES
Yao, Monique G, Carmel, IN, UNITED STATES
Chawla, Narinder K, Union City, CA, UNITED STATES
Gietzen, Kimberly J, San Jose, CA, UNITED STATES
Thangavelu, Kavitha, Sunnyvale, CA, UNITED STATES
Lu, Yan, Mountain View, CA, UNITED STATES
Ding, Li, Creve Coeur, MI, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
Tang, Y Tom, San Jose, CA, UNITED STATES
Lal, Preeti G, Santa Clara, CA, UNITED STATES
Batra, Sajeev, Oakland, CA, UNITED STATES
Lu, Dyung Aina M, San Jose, CA, UNITED STATES
M Sanjanwala, Madhusudan, Los Altos, CA, UNITED STATES
Arvizu, Chandra S, San Jose, CA, UNITED STATES
Ramkumar, Jayalaxmi, Fremont, CA, UNITED STATES
Griffin, Jennifer A, Fremont, CA, UNITED STATES
Gururajan, Rajagopal, San Jose, CA, UNITED STATES
Azimzai, Yalda, Oakland, CA, UNITED STATES
Xu, Yuming, Mountain View, CA, UNITED STATES
Burford, Neil, Durham, CT, UNITED STATES
PI US 2004044184 A1 20040304
AI US 2003-415187 A1 20030423 (10)
WO 2001-US50983 20011026
DT Utility
FS APPLICATION
LN.CNT 7917
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000
IC [7]
ICM: C07K014-47
ICS: C07H021-04; C12P021-02; C12N005-06

L7 ANSWER 119 OF 266 USPATFULL on STN
AN 2004:57384 USPATFULL
TI Methods and compositions for functional ubiquitin assays
IN Pray, Todd, San Francisco, CA, UNITED STATES

Benñett, Mark, Moraga, CA, UNITED STATES
Parlati, Frank, San Francisco, CA, UNITED STATES
PI US 2004043386 A1 20040304
AI US 2002-232951 A1 20020830 (10)
DT Utility
FS APPLICATION
LN.CNT 3105
INCL INCLM: 435/006.000
INCLS: 435/007.200; 435/456.000
NCL NCLM: 435/006.000
NCLS: 435/007.200; 435/456.000
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; C12N015-867

L7 ANSWER 120 OF 266 USPATFULL on STN
AN 2004:57380 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Padigaru, Muralidhara, Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Pena, Carol E. A., New Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Vernet, Corine A.M., Branford, CT, UNITED STATES
Guo, Xiaojia Sasha, Branford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Fernandes, Elma R., Branford, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Liu, Yi, San Diego, CA, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Catterton, Elina, Madison, CT, UNITED STATES
Leite, Mario W., Milford, CT, UNITED STATES
Zhong, Haihong, Guilford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
PI US 2004043382 A1 20040304
AI US 2002-92900 A1 20020307 (10)
PRAI US 2001-274322P 20010308 (60)
US 2001-283675P 20010413 (60)
US 2001-338092P 20011203 (60)
US 2001-274281P 20010308 (60)
US 2001-274191P 20010308 (60)
US 2001-325681P 20010927 (60)
US 2001-304354P 20010710 (60)
US 2001-279995P 20010330 (60)
US 2001-294899P 20010531 (60)
US 2001-287424P 20010430 (60)
US 2001-299027P 20010618 (60)
US 2001-309198P 20010731 (60)
US 2001-281444P 20010404 (60)
US 2001-274194P 20010308 (60)
US 2001-274849P 20010309 (60)
US 2001-330380P 20011018 (60)
US 2001-275235P 20010312 (60)
US 2001-288342P 20010503 (60)
US 2001-275578P 20010313 (60)
US 2001-291240P 20010516 (60)
US 2001-294485P 20010530 (60)
US 2001-299310P 20010619 (60)
US 2001-275579P 20010313 (60)
US 2001-275601P 20010313 (60)

US 2001-280900P 20010402 (60)
US 2001-276776P 20010316 (60)
US 2001-294889P 20010531 (60)
US 2001-318770P 20010912 (60)
US 2001-276994P 20010319 (60)
US 2001-277338P 20010320 (60)
US 2001-325430P 20010927 (60)
US 2001-332094P 20011121 (60)
US 2001-299303P 20010619 (60)
US 2001-288066P 20010502 (60)
US 2001-277321P 20010320 (60)
US 2001-280822P 20010402 (60)
US 2001-277239P 20010320 (60)
US 2001-277327P 20010320 (60)
US 2001-277791P 20010321 (60)
US 2001-333184P 20011114 (60)
US 2001-277833P 20010322 (60)
US 2001-318462P 20010910 (60)
US 2001-288528P 20010503 (60)
US 2001-278152P 20010323 (60)
US 2001-332272P 20011114 (60)
US 2001-278894P 20010326 (60)
US 2001-312903P 20010816 (60)
US 2001-333272P 20011114 (60)
US 2001-279036P 20010327 (60)
US 2001-332172P 20011114 (60)
US 2001-337426P 20011203 (60)
US 2001-278999P 20010327 (60)
US 2001-279344P 20010328 (60)
US 2001-332271P 20011114 (60)
US 2001-291099P 20010516 (60)
US 2001-291190P 20010515 (60)
US 2001-280233P 20010330 (60)
US 2001-280802P 20010402 (60)
US 2001-335301P 20011031 (60)
US 2001-337185P 20011204 (60)
US 2002-345705P 20020103 (60)
DT Utility
FS APPLICATION
LN.CNT 51622
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 121 OF 266 USPATFULL on STN
AN 2004:50903 USPATFULL
TI Methods for protein refolding
IN Randolph, Theodore W., Niwot, CO, UNITED STATES
Carpenter, John F., Littleton, CO, UNITED STATES
St.John, Richard J., San Francisco, CA, UNITED STATES
Webb, Jonathan N., Zionsville, IN, UNITED STATES
PI US 2004038333 A1 20040226
AI US 2003-425371 A1 20030426 (10)
RLI Continuation of Ser. No. WO 2001-US45728, filed on 31 Oct 2001, PENDING
DT Utility
FS APPLICATION
LN.CNT 2671
INCL INCLM: 435/068.100
INCLS: 530/412.000
NCL NCLM: 435/068.100
NCLS: 530/412.000
IC [7]
ICM: C12P021-06

L7 ANSWER 122 OF 266 USPATFULL on STN
AN 2004:50862 USPATFULL
TI Wound healing biomarkers
IN Burslem, Martyn Frank, Sandwich, UNITED KINGDOM

Cooper, Lisa, London, UNITED KINGDOM
Martin, Paul, London, UNITED KINGDOM
PI US 2004038292 A1 20040226
AI US 2002-175184 A1 20020618 (10)
PRAI GB 2001-14869 20010618
US 2001-305346P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 67123
INCL INCLM: 435/007.100
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/007.100
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: G01N033-53
ICS: C07H021-04; C12P021-02; C12N005-06; C12N009-64

L7 ANSWER 123 OF 266 USPATFULL on STN
AN 2004:44503 USPATFULL
TI Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
IN Murray, Richard, Cupertino, CA, UNITED STATES
Glynne, Richard, Palo Alto, CA, UNITED STATES
Watson, Susan R., El Cerrito, CA, UNITED STATES
Aziz, Natasha, Palo Alto, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA, UNITED STATES, 94080 (U.S. corporation)
PI US 2004033495 A1 20040219
AI US 2002-211462 A1 20020801 (10)
PRAI US 2001-310025P 20010803 (60)
US 2001-334244P 20011129 (60)
DT Utility
FS APPLICATION
LN.CNT 24599
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 124 OF 266 USPATFULL on STN
AN 2004:44501 USPATFULL
TI Proteins and nucleic acids encoding same
IN Tchernev, Velizar T., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Miller, Charles E., Hill Drive, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Gusev, Vladimir Y., UNITED STATES
Colman, Steven D., Guilford, CT, UNITED STATES
Wolenc, Adam Ryan, New Haven, CT, UNITED STATES
Pena, Carol E. A., Guilford, CT, UNITED STATES
Furtak, Katarzyna, Anosia, CT, UNITED STATES
Grosse, William M., Bransford, CT, UNITED STATES
Alsobrook, John P., II, Madison, CT, UNITED STATES
Lepley, Denise M., Branford, CT, UNITED STATES
Rieger, Daniel K., Branford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
PI US 2004033493 A1 20040219
AI US 2002-72012 A1 20020131 (10)
PRAI US 2001-267459P 20010208 (60)
US 2001-266975P 20010207 (60)
US 2001-267057P 20010207 (60)
US 2001-266767P 20010205 (60)

US 2001-265395P 20010131 (60)
US 2001-265412P 20010131 (60)
US 2001-265517P 20010131 (60)
US 2001-265514P 20010131 (60)
US 2001-267823P 20010209 (60)
US 2001-268974P 20010215 (60)
US 2001-271855P 20010227 (60)
US 2001-271839P 20010227 (60)
US 2001-273046P 20010302 (60)
US 2001-272788P 20010302 (60)
US 2001-275989P 20010314 (60)
US 2001-275925P 20010314 (60)
US 2001-275947P 20010314 (60)
US 2001-275950P 20010314 (60)
US 2001-276450P 20010315 (60)
US 2001-276448P 20010315 (60)
US 2001-276397P 20010316 (60)
US 2001-276768P 20010316 (60)
US 2001-278652P 20010320 (60)
US 2001-278775P 20010326 (60)
US 2001-278778P 20010326 (60)
US 2001-279882P 20010329 (60)
US 2001-279884P 20010329 (60)
US 2001-280147P 20010330 (60)
US 2001-283083P 20010411 (60)
US 2001-282992P 20010411 (60)
US 2001-285133P 20010420 (60)
US 2001-285749P 20010423 (60)
US 2001-288327P 20010503 (60)
US 2001-288504P 20010503 (60)
US 2001-294047P 20010529 (60)
US 2001-294473P 20010530 (60)
US 2001-296964P 20010608 (60)
US 2001-298959P 20010618 (60)
US 2001-299324P 20010619 (60)
US 2001-312020P 20010813 (60)
US 2001-312908P 20010816 (60)
US 2001-312889P 20010816 (60)
US 2001-313930P 20010821 (60)
US 2001-315470P 20010828 (60)
US 2001-316447P 20010831 (60)
US 2001-318115P 20010907 (60)
US 2001-318118P 20010907 (60)
US 2001-318740P 20010912 (60)
US 2001-323379P 20010919 (60)
US 2001-330308P 20011018 (60)
US 2001-330245P 20011018 (60)
US 2001-332701P 20011114 (60)
US 2001-271664P 20010226 (60)
DT Utility
FS APPLICATION
LN.CNT 59681
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/183.000; 424/155.100
NCL NCLM: 435/006.000
NCLS: 435/007.230; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 435/183.000; 424/155.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; A61K039-395; C12N009-00; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 125 OF 266 USPATFULL on STN
AN 2004:39568 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Kekuda, Ramesh, Danbury, CT, UNITED STATES
Miller, Charles E., Guilford, CT, UNITED STATES
Malyankar, Uriel M., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Liu, Xiaohong, Branford, CT, UNITED STATES
Gusev, Vladimir Y., Madison, CT, UNITED STATES

Vernet, Corine A.M., Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Pena, Carol E. A., New Haven, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Burgess, Catherine E., Wethersfield, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Shimkets, Richard A., Guilford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Casman, Stacie J., North Haven, CT, UNITED STATES
Ji, Weizhen, Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Leite, Mario W., Milford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Rothenberg, Mark E., Clinton, CT, UNITED STATES
Mazur, Ann, Bloomfield, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES

PI	US 2004030110	A1	20040212
AI	US 2002-114270	A1	20020402 (10)
PRAI	US 2001-281086P		20010403 (60)
	US 2001-281136P		20010403 (60)
	US 2001-281863P		20010405 (60)
	US 2001-281906P		20010405 (60)
	US 2001-282020P		20010406 (60)
	US 2001-282930P		20010410 (60)
	US 2001-282934P		20010410 (60)
	US 2001-283512P		20010412 (60)
	US 2001-283710P		20010413 (60)
	US 2001-284234P		20010417 (60)
	US 2001-285325P		20010419 (60)
	US 2001-285381P		20010420 (60)
	US 2001-285609P		20010420 (60)
	US 2001-285748P		20010423 (60)
	US 2001-285890P		20010423 (60)
	US 2001-286068P		20010424 (60)
	US 2001-286292P		20010425 (60)
	US 2001-287213P		20010427 (60)
	US 2001-288257P		20010502 (60)
	US 2001-294164P		20010529 (60)
	US 2001-294484P		20010530 (60)
	US 2001-298952P		20010618 (60)
	US 2001-299237P		20010619 (60)
	US 2001-299276P		20010619 (60)
	US 2001-318750P		20010912 (60)
	US 2001-324800P		20010925 (60)
	US 2001-324802P		20010925 (60)
	US 2001-325684P		20010927 (60)
	US 2001-330143P		20011017 (60)
	US 2001-332115P		20011121 (60)
	US 2001-332131P		20011114 (60)
	US 2001-332240P		20011114 (60)
	US 2001-332779P		20011114 (60)
	US 2001-337621P		20011204 (60)
	US 2002-345783P		20020103 (60)
	US 2002-350251P		20020116 (60)
DT	Utility		
FS	APPLICATION		
LN.CNT	35659		
INCL	INCLM: 536/023.100		
NCL	NCLM: 536/023.100		
IC	[7]		
	ICM: C07H021-02		
	ICS: C07H021-04		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 126 OF 266 USPATFULL on STN
AN 2004:38576 USPATFULL

screening for modulators of breast cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Gish, Kurt C., San Francisco, CA, UNITED STATES
Afar, Daniel, Brisbane, CA, UNITED STATES
PA Eos Technology, Inc., South San Francisco, CA, UNITED STATES, 94080-7019 (U.S. corporation)
PI US 2004029114 A1 20040212
AI US 2002-58270 A1 20020124 (10)
PRAI US 2001-263965P 20010124 (60)
US 2001-265928P 20010202 (60)
US 2001-282698P 20010409 (60)
US 2001-288590P 20010504 (60)
US 2001-294443P 20010529 (60)
DT Utility
FS APPLICATION
LN.CNT 42494
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C07K014-72; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 127 OF 266 USPATFULL on STN
AN 2004:32039 USPATFULL
TI Novel human proteins, polynucleotides encoding them and methods of using the same
IN Gangolli, Esha A., Madison, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Gilbert, Jennifer, Madison, CT, UNITED STATES
Casman, Stacie, North Haven, CT, UNITED STATES
Blalock, Angela, Branford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Vernet, Corine, Branford, CT, UNITED STATES
Shenoy, Suresh, Branford, CT, UNITED STATES
Mishra, Vishnu S., Gainesville, FL, UNITED STATES
Furtak, Katarzyna, Ansonia, CT, UNITED STATES
Gerlach, Valerie L., Branford, CT, UNITED STATES
Edinger, Shlomit, New Haven, CT, UNITED STATES
Malyanker, Uriel, Branford, CT, UNITED STATES
Stone, David, Guilford, CT, UNITED STATES
Millet, Isabelle, Milford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
Gunther, Erik, Branford, CT, UNITED STATES
Ellerman, Karen, Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
PI US 2004024181 A1 20040205
AI US 2001-55569 A1 20011026 (10)
PRAI US 2000-243642P 20001026 (60)
US 2000-243320P 20001026 (60)
US 2000-243592P 20001026 (60)
US 2000-243681P 20001027 (60)
US 2000-243863P 20001027 (60)
US 2000-244443P 20001031 (60)
US 2000-245029P 20001101 (60)
US 2000-244995P 20001101 (60)
US 2000-245293P 20001102 (60)
US 2000-245315P 20001102 (60)
US 2000-245316P 20001102 (60)
US 2001-262994P 20010119 (60)
US 2001-269056P 20010215 (60)
US 2001-272923P 20010302 (60)
US 2001-276565P 20010315 (60)
US 2001-318119P 20010907 (60)
DT Utility
FS APPLICATION
LN.CNT 10785
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000

ICM: C07K014-705
ICS: C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 128 OF 266 USPATFULL on STN
AN 2004:31251 USPATFULL
TI SiRNA-mediated gene silencing with viral vectors
IN Davidson, Beverly L., North Liberty, IA, UNITED STATES
Xia, Haibin, Iowa City, IA, UNITED STATES
Mao, Qinwen, Iowa City, IA, UNITED STATES
PI US 2004023390 A1 20040205
AI US 2003-430351 A1 20030505 (10)
RLI Continuation of Ser. No. US 2002-322086, filed on 17 Dec 2002, ABANDONED
Continuation-in-part of Ser. No. US 2002-212322, filed on 5 Aug 2002, PENDING
DT Utility
FS APPLICATION
LN.CNT 2503
INCL INCLM: 435/456.000
INCLS: 435/320.100; 435/235.100
NCL NCLM: 435/456.000
NCLS: 435/320.100; 435/235.100
IC [7]
ICM: C12N015-86
ICS: C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 129 OF 266 USPATFULL on STN
AN 2004:18798 USPATFULL
TI In vivo production of cyclic peptides for inhibiting protein-protein interaction
IN Lorenz, James B., Bones, NORWAY
Kinsella, Todd M., Redwood City, CA, UNITED STATES
Pray, Todd, San Francisco, CA, UNITED STATES
Bennett, Mark K., Moraga, CA, UNITED STATES
PI US 2004014100 A1 20040122
AI US 2003-422536 A1 20030423 (10)
RLI Continuation of Ser. No. US 2002-232758, filed on 30 Aug 2002, PENDING
Continuation-in-part of Ser. No. US 2001-800770, filed on 6 Mar 2001, PENDING
PRAI US 2000-187130P 20000306 (60)
DT Utility
FS APPLICATION
LN.CNT 4089
INCL INCLM: 435/006.000
INCLS: 435/007.200
NCL NCLM: 435/006.000
NCLS: 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 130 OF 266 USPATFULL on STN
AN 2004:13377 USPATFULL
TI Treating dominant disorders
IN McMurray, Cynthia T., Oronoco, MN, UNITED STATES
Richelson, Elliott, Ponte Vedra Beach, FL, UNITED STATES
McMahon, Beth M., Alameda, CA, UNITED STATES
PI US 2004009899 A1 20040115
AI US 2002-195722 A1 20020715 (10)
DT Utility
FS APPLICATION
LN.CNT 1702
INCL INCLM: 514/008.000
INCLS: 514/044.000; 536/023.100
NCL NCLM: 514/008.000
NCLS: 514/044.000; 536/023.100
IC [7]
ICM: A61K048-00
ICS: C07H021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 131 OF 266 USPATFULL on STN
AN 2004:12959 USPATFULL

chronic inflammatory diseases
IN Wohlgemuth, Jay, Palo Alto, CA, UNITED STATES
Fry, Kirk, Palo Alto, CA, UNITED STATES
Woodward, Robert, Pleasanton, CA, UNITED STATES
Ly, Ngoc, San Bruno, CA, UNITED STATES
PI US 2004009479 A1 20040115
AI US 2002-131827 A1 20020424 (10)
RLI Continuation-in-part of Ser. No. US 2001-6290, filed on 22 Oct 2001, PENDING
PRAI US 2001-296764P 20010608 (60)
DT Utility
FS APPLICATION
LN.CNT 19677
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 132 OF 266 USPATFULL on STN
AN 2004:7410 USPATFULL
TI Method and composition for detection and treatment of breast cancer
IN Su, Yan A., Bethesda, MD, UNITED STATES
Yang, Jun, Hinsdale, IL, UNITED STATES
PI US 2004005644 A1 20040108
AI US 2003-373801 A1 20030227 (10)
PRAI US 2002-359999P 20020228 (60)
DT Utility
FS APPLICATION
LN.CNT 6110
INCL INCLM: 435/007.230
NCL NCLM: 435/007.230
IC [7]
ICM: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 133 OF 266 USPATFULL on STN
AN 2004:7405 USPATFULL
TI Glycerylaldehyde-3-phosphate dehyrogenase promoter inducing cell death
IN Ishitani, Ryoichi, Shiki-shi, JAPAN
PI US 2004005639 A1 20040108
AI US 2003-343921 A1 20030521 (10)
WO 2001-JP6858 20010809
PRAI JP 2000-242014 20000810
DT Utility
FS APPLICATION
LN.CNT 585
INCL INCLM: 435/007.200
INCLS: 435/189.000; 435/353.000; 435/320.100
NCL NCLM: 435/007.200
NCLS: 435/189.000; 435/353.000; 435/320.100
IC [7]
ICM: G01N033-53
ICS: G01N033-567; C12N009-02; C12N015-09; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 134 OF 266 USPATFULL on STN
AN 2004:7329 USPATFULL
TI Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Gish, Kurt C., San Francisco, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)
PI US 2004005563 A1 20040108
AI US 2002-173999 A1 20020617 (10)
PRAI US 2002-372246P 20020412 (60)
US 2001-350666P 20011113 (60)
US 2001-315287P 20010827 (60)
US 2001-299234P 20010618 (60)
DT Utility
FS APPLICATION
LN.CNT 32540
INCL INCLM: 435/006.000
INCLS: 435/007.230; 435/366.000; 435/183.000; 435/320.100; 435/069.100; 536/023.200

NCLS: 435/007.230; 435/366.000; 435/183.000; 435/320.100; 435/069.100; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 135 OF 266 USPATFULL on STN
AN 2004:7327 USPATFULL
TI Novel full-length cDNA
IN Isogai, Takao, Ibaraki, JAPAN
Sugiyama, Tomoyasu, Tokyo, JAPAN
Otsuki, Tetsuji, Chiba, JAPAN
Wakamatsu, Ai, Chiba, JAPAN
Sato, Hiroyuki, Osaka, JAPAN
Ishii, Shizuko, Chiba, JAPAN
Yamamoto, Jun-Ichi, Chiba, JAPAN
Isono, Yuuko, Chiba, JAPAN
Hio, Yuri, Chiba, JAPAN
Otsuka, Kaoru, Saitama, JAPAN
Nagai, Keiichi, Tokyo, JAPAN
Irie, Ryotaro, Chiba, JAPAN
Tamechika, Ichiro, Osaka, JAPAN
Seki, Naohiko, Chiba, JAPAN
Yoshikawa, Tsutomu, Chiba, JAPAN
Otsuka, Motoyuki, Tokyo, JAPAN
Nagahari, Kenji, Tokyo, JAPAN
Masuho, Yasuhiko, Tokyo, JAPAN
PA Helix Research Institute (non-U.S. corporation)
PI US 2004005560 A1 20040108
AI US 2002-108260 A1 20020328 (10)
PRAI JP 2002-137785 20020322
DT Utility
FS APPLICATION
LN.CNT 16587
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/388.100; 530/350.000; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/388.100; 530/350.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G06F019-00; G01N033-48; G01N033-50; C12P021-02; C12N005-06; C07K014-47; C07K016-18; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 136 OF 266 USPATFULL on STN
AN 2004:7326 USPATFULL
TI Markers of neuronal differentiation and morphogenesis
IN Loring, Jeanne F., Foster City, CA, UNITED STATES
Kaser, Matthew R., Castro Valley, CA, UNITED STATES
PI US 2004005559 A1 20040108
AI US 2002-62674 A1 20020130 (10)
RLI Continuation-in-part of Ser. No. US 2000-625102, filed on 24 Jul 2000, ABANDONED
DT Utility
FS APPLICATION
LN.CNT 5725
INCL INCLM: 435/006.000
INCLS: 536/024.300
NCL NCLM: 435/006.000
NCLS: 536/024.300
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 137 OF 266 USPATFULL on STN
AN 2004:4510 USPATFULL
TI Human tumor-associated gene
IN Hoon, David S. B., Los Angeles, CA, United States
PA John Wayne Cancer Institute, Santa Monica, CA, United States (U.S. corporation)
PI US 6673914 B1 20040106

PRAI US 1998-72126P 19980122 (60)
DT Utility
FS GRANTED
LN.CNT 5257
INCL INCLM: 536/023.500
INCLS: 536/023.100; 435/320.100; 435/243.000; 435/358.000; 530/350.000
NCL NCLM: 536/023.500
NCLS: 536/023.100; 435/320.100; 435/243.000; 435/358.000; 530/350.000
IC [7]
ICM: C07H021-04
EXF 536/23.1; 536/23.5; 536/24.5; 536/24.1; 536/24.37; 530/350; 435/320.1; 435/325; 435/243; 435/252.3; 435/252.33; 435/254.1; 435/358
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 138 OF 266 USPATFULL on STN
AN 2003:335310 USPATFULL
TI Novel human proteins, polynucleotides encoding them and methods of using the same
IN Spytek, Kimberly A., New Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Edinger, Shlomit R., New Haven, CT, UNITED STATES
Stone, David J., Guilford, CT, UNITED STATES
Guo, Xiaojia Sasha, Branford, CT, UNITED STATES
Anderson, David W., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Gerlach, Valerie, Branford, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Pena, Carol E. A., New Haven, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
Kekuda, Ramesh, Norwalk, CT, UNITED STATES
Gorman, Linda, Branford, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Smithson, Glennda, Guilford, CT, UNITED STATES
MacDougall, John R., Hamden, CT, UNITED STATES
Mezes, Peter S., Old Lyme, CT, UNITED STATES
Peyman, John A., New Haven, CT, UNITED STATES
Zhong, Mei, Branford, CT, UNITED STATES
PI US 2003236188 A1 20031225
AI US 2002-136728 A1 20020501 (10)
PRAI US 2001-288395P 20010503 (60)
US 2001-289087P 20010507 (60)
US 2001-289619P 20010508 (60)
US 2001-289818P 20010509 (60)
US 2001-289817P 20010509 (60)
US 2001-290194P 20010511 (60)
US 2001-290753P 20010514 (60)
US 2001-291189P 20010515 (60)
US 2001-292374P 20010521 (60)
US 2001-293107P 20010523 (60)
US 2001-294110P 20010529 (60)
US 2001-293747P 20010525 (60)
US 2001-294434P 20010530 (60)
US 2001-318346P 20010910 (60)
US 2001-322646P 20010917 (60)
DT Utility
FS APPLICATION
LN.CNT 12466
INCL INCLM: 514/012.000
INCLS: 435/006.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000
NCL NCLM: 514/012.000
NCLS: 435/006.000; 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000
IC [7]
ICM: A61K038-17
ICS: C12Q001-68; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 139 OF 266 USPATFULL on STN
AN 2003:334944 USPATFULL
TI Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Markowitz, Sanford David, Pepper Pike, OH, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)

AI US 2002-87080 A1 20020227 (10)
PRAI US 2001-284555P 20010417 (60)
US 2001-281149P 20010402 (60)
US 2001-272206P 20010227 (60)
DT Utility
FS APPLICATION
LN.CNT 22670
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/388.260; 536/023.200; 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/388.260; 536/023.200; 435/007.230
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 140 OF 266 USPATFULL on STN
AN 2003:330210 USPATFULL
TI Protein-protein interactions in adipocyte cells (3)
IN Legrain, Pierre, Paris, FRANCE
Whiteside, Simon, Cambridge, UNITED KINGDOM
Mao, Jen-I, Palo Alto, CA, UNITED STATES
Khrebtukova, Irina, San Francisco, CA, UNITED STATES
Luo, Shujun, Berkeley, CA, UNITED STATES
PA Hybrigenics, Paris, FRANCE (non-U.S. corporation)
PI US 2003232421 A1 20031218
AI US 2002-139794 A1 20020506 (10)
PRAI US 2001-288885P 20010504 (60)
DT Utility
FS APPLICATION
LN.CNT 13515
INCL INCLM: 435/226.000
INCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 536/023.200; 514/001.000
NCL NCLM: 435/226.000
NCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 536/023.200; 514/001.000
IC [7]
ICM: A61K031-00
ICS: G01N033-53; C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 141 OF 266 USPATFULL on STN
AN 2003:324595 USPATFULL
TI Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
IN Yat Wah Tom, Edward, Sacramento, CA, UNITED STATES
Zlotnik, Albert, Palo Alto, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)
PI US 2003228570 A1 20031211
AI US 2003-366435 A1 20030212 (10)
RLI Continuation of Ser. No. US 2002-206473, filed on 24 Jul 2002, ABANDONED
PRAI US 2002-366782P 20020321 (60)
US 2001-308188P 20010726 (60)
DT Utility
FS APPLICATION
LN.CNT 22742
INCL INCLM: 435/005.000
INCLS: 435/006.000; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 530/388.300; 536/023.720
NCL NCLM: 435/005.000
NCLS: 435/006.000; 435/069.300; 435/320.100; 435/325.000; 530/350.000; 530/388.300; 536/023.720
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; C07H021-04; C07K014-02; C07K016-08; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 142 OF 266 USPATFULL on STN
AN 2003:320403 USPATFULL
TI Neurodegeneration mutants, method for identifying same, and method for

IN Ganetzky, Barry S., Madison, WI, UNITED STATES
Palladino, Michael J., Madison, WI, UNITED STATES
PI US 2003226156 A1 20031204
AI US 2002-154086 A1 20020522 (10)
DT Utility
FS APPLICATION
LN.CNT 2693
INCL INCLM: 800/008.000
INCLS: 530/350.000; 435/069.100; 435/320.100; 435/348.000; 536/023.500
NCL NCLM: 800/008.000
NCLS: 530/350.000; 435/069.100; 435/320.100; 435/348.000; 536/023.500
IC [7]
ICM: A01K067-033
ICS: C07H021-04; C12N005-06; C07K014-705; C12P021-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 143 OF 266 USPATFULL on STN
AN 2003:318636 USPATFULL
TI Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
IN Becker, Kenneth David, San Diego, CA, UNITED STATES
Velicelebi, Gonul, San Diego, CA, UNITED STATES
Ellliott, Kathryn J., San Diego, CA, UNITED STATES
Wang, Xin, San Diego, CA, UNITED STATES
Tanzi, Rudolph E., Hull, MA, UNITED STATES
Bertram, Lars, Brighton, MA, UNITED STATES
Saunders, Aleister J., Philadelphia, PA, UNITED STATES
Mullin, Kristina M., south Boston, MA, UNITED STATES
Sampson, Andrew Joseph, Dayton, OH, UNITED STATES
PA The General Hospital Corporation (U.S. corporation)
PI US 2003224380 A1 20031204
AI US 2002-282174 A1 20021025 (10)
PRAI US 2001-339525P 20011025 (60)
US 2001-338010P 20011108 (60)
US 2001-336929P 20011108 (60)
US 2001-338363P 20011109 (60)
US 2001-337052P 20011204 (60)
US 2002-368919P 20020328 (60)
US 2001-348065P 20011025 (60)
US 2001-336983P 20011102 (60)
DT Utility
FS APPLICATION
LN.CNT 13662
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 144 OF 266 USPATFULL on STN
AN 2003:312170 USPATFULL
TI Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
IN Ayers, Mark D., Ayer, MA, UNITED STATES
Stec, Jim, Plymouth, MA, UNITED STATES
Damokosh, Andrew, West Hartford, CT, UNITED STATES
Clark, Edwin, Ashland, MA, UNITED STATES
Hess, Kenneth R., Houston, TX, UNITED STATES
Hortobagyi, Gabriel N., Bellaire, TX, UNITED STATES
Pusztai, Lajos, Pearland, TX, UNITED STATES
Symmans, W. Fraser, Houston, TX, UNITED STATES
PA MILLENNIUM PHARMACEUTICALS, INC., Cambridge, MA, 02139 (U.S. corporation)
M.D. Anderson Cancer Center, Houston, TX, 77030 (U.S. corporation)
PI US 2003219767 A1 20031127
AI US 2002-285393 A1 20021031 (10)
PRAI US 2001-334994P 20011031 (60)
US 2001-335981P 20011102 (60)
DT Utility
FS APPLICATION
LN.CNT 8308
INCL INCLM: 435/006.000
INCLS: 435/007.230
NCL NCLM: 435/006.000
NCLS: 435/007.230

ICM: C12Q001-68
ICS: G01N033-574
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 145 OF 266 USPATFULL on STN
AN 2003:312147 USPATFULL
TI Novel nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Asundi, Vinod, Foster City, CA, UNITED STATES
Zhang, Jie, Campbell, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
PI US 2003219744 A1 20031127
AI US 2002-117722 A1 20020404 (10)
RLI Continuation-in-part of Ser. No. US 2000-620312, filed on 19 Jul 2000, GRANTED, Pat. No. US 6569662 Continuation-in-part of Ser. No. US 2000-552317, filed on 25 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING
DT Utility
FS APPLICATION
LN.CNT 9575
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 146 OF 266 USPATFULL on STN
AN 2003:312144 USPATFULL
TI Novel full-length cDNA
IN Isogai, Takao, Ibaraki, JAPAN
Sugiyama, Tomoyasu, Tokyo, JAPAN
Otsuki, Tetsuji, Chiba, JAPAN
Wakamatsu, Ai, Chiba, JAPAN
Sato, Hiroyuki, Osaka, JAPAN
Ishii, Shizuko, Chiba, JAPAN
Yamamoto, Jun-Ichi, Chiba, JAPAN
Isono, Yuuko, Chiba, JAPAN
Hio, Yuri, Chiba, JAPAN
Otsuka, Kaoru, Saitama, JAPAN
Nagai, Keiichi, Tokyo, JAPAN
Irie, Ryotaro, Chiba, JAPAN
Tamechika, Ichiro, Osaka, JAPAN
Seki, Naohiko, Chiba, JAPAN
Yoshikawa, Tsutomu, Chiba, JAPAN
Otsuka, Motoyuki, Tokyo, JAPAN
Nagahari, Kenji, Tokyo, JAPAN
Masuho, Yasuhiko, Tokyo, JAPAN
PA Helix Research Institute (non-U.S. corporation)
PI US 2003219741 A1 20031127
AI US 2002-94749 A1 20020312 (10)
PRAI JP 2001-328381 20010914
US 2002-350435P 20020124 (60)
DT Utility
FS APPLICATION
LN.CNT 13491
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/388.260; 530/350.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/388.260; 530/350.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-47; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 147 OF 266 USPATFULL on STN
AN 2003:295019 USPATFULL

fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
IN Zhang, Han-Zhong, San Diego, CA, UNITED STATES
Cai, Sui Xiong, San Diego, CA, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Yang, Wu, Irvine, CA, UNITED STATES
PA Cytovia, Inc. (U.S. corporation)
PI US 2003208037 A1 20031106
AI US 2002-138375 A1 20020506 (10)
RLI Continuation of Ser. No. US 2000-583225, filed on 30 May 2000, ABANDONED Division of Ser. No. US 1999-357952, filed on 21 Jul 1999, GRANTED, Pat. No. US 6248904
PRAI US 1998-93642P 19980721 (60)
DT Utility
FS APPLICATION
LN.CNT 3991
INCL INCLM: 530/330.000
INCLS: 549/223.000
NCL NCLM: 530/330.000
NCLS: 549/223.000
IC [7]
ICM: C07K005-10
ICS: C07D311-82
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 148 OF 266 USPATFULL on STN
AN 2003:294783 USPATFULL
TI Proteins, polynucleotides encoding them and methods of using the same
IN Malyankar, Uriel M., Branford, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Spytek, Kimberly A., New Haven, CT, UNITED STATES
Zerhusen, Bryan D., Branford, CT, UNITED STATES
Patturajan, Meera, Branford, CT, UNITED STATES
Guo, Xiaojia (Sasha), Branford, CT, UNITED STATES
Kekuda, Ramesh, Stamford, CT, UNITED STATES
Gangolli, Esha A., Madison, CT, UNITED STATES
Shimkets, Richard A., West Haven, CT, UNITED STATES
Taupier, Raymond J., JR., East Haven, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Padigaru, Muralidhara, Branford, CT, UNITED STATES
PI US 2003207800 A1 20031106
AI US 2001-15115 A1 20011113 (10)
PRAI US 2000-248153P 20001113 (60)
US 2000-249598P 20001117 (60)
US 1999-164240P 19991108 (60)
US 2001-266127P 20010202 (60)
US 2001-269562P 20010216 (60)
US 2001-304348P 20010710 (60)
US 2001-309261P 20010731 (60)
US 2001-313283P 20010817 (60)
DT Utility
FS APPLICATION
LN.CNT 13855
INCL INCLM: 514/012.000
INCLS: 435/069.100; 530/350.000; 536/023.500; 435/320.100; 435/325.000
NCL NCLM: 514/012.000
NCLS: 435/069.100; 530/350.000; 536/023.500; 435/320.100; 435/325.000
IC [7]
ICM: A61K038-17
ICS: C12P021-02; C12N005-06; C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 149 OF 266 USPATFULL on STN
AN 2003:290096 USPATFULL
TI Animal model of polyglutamine toxicity, methods of use, and modulators of polyglutamine toxicity
IN Kazemi-Esfarfani, Parsa, Williamsville, NY, UNITED STATES
Benzer, Seymour, San Marino, CA, UNITED STATES
PA California Institute of Technology, a California corporation (U.S. corporation)
PI US 2003204859 A1 20031030
AI US 2003-465217 A1 20030618 (10)
RLI Continuation of Ser. No. US 2000-639207, filed on 14 Aug 2000, PENDING
PRAI US 1999-148934P 19990812 (60)
US 1999-148933P 19990812 (60)

US 2000-205720P 20000519 (60)
DT Utility
FS APPLICATION
LN.CNT 5751
INCL INCLM: 800/003.000
INCLS: 800/008.000
NCL NCLM: 800/003.000
NCLS: 800/008.000
IC [7]
ICM: A01K067-033
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 150 OF 266 USPATFULL on STN
AN 2003:288725 USPATFULL
TI Human mesenchymal progenitor cell
IN Seshi, Beerelli, Tampa, FL, UNITED STATES
PI US 2003203483 A1 20031030
AI US 2002-263419 A1 20021003 (10)
RLI Continuation-in-part of Ser. No. US 2001-914508, filed on 7 Nov 2001, PENDING A 371 of International Ser. No. WO 2001-US16408, filed on 21 May 2001, PENDING
PRAI US 2001-327140P 20011003 (60)
US 2001-334277P 20011128 (60)
US 2002-352636P 20020128 (60)
US 2002-412450P 20020920 (60)
US 2001-277700P 20010321 (60)
US 2000-209245P 20000605 (60)
DT Utility
FS APPLICATION
LN.CNT 4739
INCL INCLM: 435/366.000
INCLS: 424/093.700
NCL NCLM: 435/366.000
NCLS: 424/093.700
IC [7]
ICM: C12N005-08
ICS: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 151 OF 266 USPATFULL on STN
AN 2003:282627 USPATFULL
TI Genostics
IN Roberts, Gareth Wyn, Cambs, UNITED KINGDOM
PA GENOSTIC PHARMA LIMITED (non-U.S. corporation)
PI US 2003198970 A1 20031023
AI US 2002-206568 A1 20020729 (10)
RLI Continuation of Ser. No. US 1999-325123, filed on 3 Jun 1999, ABANDONED
PRAI GB 1998-12098 19980606
GB 1998-28289 19981223
DT Utility
FS APPLICATION
LN.CNT 4299
INCL INCLM: 435/006.000
INCLS: 536/024.300
NCL NCLM: 435/006.000
NCLS: 536/024.300
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 152 OF 266 USPATFULL on STN
AN 2003:282611 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003198954 A1 20031023
AI US 2001-1142 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)

FS APPLICATION
LN.CNT 25681
INCL INCLM: 435/006.000
INCLS: 536/023.200
NCL NCLM: 435/006.000
NCLS: 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 153 OF 266 USPATFULL on STN
AN 2003:282610 USPATFULL
TI Novel proteins and nucleic acids encoding same
IN Spytek, Kimberly A., New Haven, CT, UNITED STATES
Majumder, Kumud, Stamford, CT, UNITED STATES
Tchernev, Velizar T., Branford, CT, UNITED STATES
Mishra, Vishnu, Gainesville, FL, UNITED STATES
Padigaru, Muralidhara, Bronx, NY, UNITED STATES
Spaderna, Steven K., Berlin, CT, UNITED STATES
Shenoy, Suresh G., Branford, CT, UNITED STATES
Rastelli, Luca, Guilford, CT, UNITED STATES
Li, Li, Branford, CT, UNITED STATES
Taupier, Raymond J., East Haven, CT, UNITED STATES
Gangolli, Esha, Madison, CT, UNITED STATES
PI US 2003198953 A1 20031023
AI US 2001-863776 A1 20010523 (9)
RLI Continuation-in-part of Ser. No. US 2000-540763, filed on 30 Mar 2000, PENDING
PRAI US 2000-206679P 20000524 (60)
US 2000-206688P 20000524 (60)
US 2000-206829P 20000524 (60)
US 2000-207748P 20000530 (60)
US 2000-207798P 20000530 (60)
US 2000-208263P 20000531 (60)
US 2000-208831P 20000602 (60)
US 2000-209451P 20000605 (60)
US 2000-210060P 20000607 (60)
US 2000-219507P 20000720 (60)
US 2000-221337P 20000726 (60)
US 2000-221927P 20000731 (60)
US 2001-263135P 20010119 (60)
US 2001-263688P 20010124 (60)
US 2001-263694P 20010124 (60)
DT Utility
FS APPLICATION
LN.CNT 10235
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 154 OF 266 USPATFULL on STN
AN 2003:271014 USPATFULL
TI Optineurin nucleic acid molecules and uses thereof
IN Raymond, Vincent, Sainte-Foy, CANADA
Morissette, Jean, Sainte-Foy, CANADA
Si, Erwin, Alameda, CA, UNITED STATES
PA Erwin Si, Vincent Raymond and Jean Morissette (non-U.S. corporation)
PI US 2003190617 A1 20031009
AI US 2002-91281 A1 20020306 (10)
DT Utility
FS APPLICATION
LN.CNT 7510
INCL INCLM: 435/006.000
INCLS: 435/325.000; 435/368.000; 435/252.300; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/325.000; 435/368.000; 435/252.300; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C12N005-08; C07H021-04; C12N001-21

L7 ANSWER 155 OF 266 USPATFULL on STN
AN 2003:265302 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2003186317 A1 20031002
AI US 2001-971782 A1 20011009 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3143
INCL INCLM: 435/007.100
INCLS: 435/007.900
NCL NCLM: 435/007.100
NCLS: 435/007.900
IC [7]
ICM: G01N033-53
ICS: G01N033-542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 156 OF 266 USPATFULL on STN
AN 2003:258338 USPATFULL
TI Dipeptide apoptosis inhibitors and the use thereof
IN Keana, John F.W., Eugene, OR, UNITED STATES
Cai, Sui Xiong, San Diego, CA, UNITED STATES
Guastella, John, Irvine, CA, UNITED STATES
Yang, Wu, Irvine, CA, UNITED STATES
Drewe, John A., Costa Mesa, CA, UNITED STATES
Weber, Eckard, San Diego, CA, UNITED STATES
PA Cytovia, Inc. (U.S. corporation)
PI US 2003181391 A1 20030925
AI US 2003-429095 A1 20030505 (10)
RLI Division of Ser. No. US 2000-653279, filed on 31 Aug 2000, GRANTED, Pat. No. US 6596693 Division of Ser. No. US 1999-270736, filed on 16 Mar 1999, GRANTED, Pat. No. US 6184210 Continuation-in-part of Ser. No. US 1998-168945, filed on 9 Oct 1998, ABANDONED
PRAI US 1997-61676P 19971010 (60)
DT Utility
FS APPLICATION
LN.CNT 1484
INCL INCLM: 514/019.000
INCLS: 560/171.000; 560/169.000
NCL NCLM: 514/019.000
NCLS: 560/171.000; 560/169.000
IC [7]
ICM: A61K038-04
ICS: C07K005-04; C07C233-45
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 157 OF 266 USPATFULL on STN
AN 2003:258335 USPATFULL
TI Substituted 2-aminobenzamide caspase inhibitors and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Wang, Yan, Austin, TX, UNITED STATES
Weber, Eckard, San Diego, CA, UNITED STATES
Mills, Gordon B., Houston, TX, UNITED STATES
Green, Douglas R., San Diego, CA, UNITED STATES
PA Cytovia, Inc. (U.S. corporation)
PI US 2003181388 A1 20030925
AI US 2003-434335 A1 20030509 (10)
RLI Division of Ser. No. US 2000-527225, filed on 16 Mar 2000, PENDING
PRAI US 1999-158386P 19991012 (60)
US 1999-124675P 19990316 (60)
DT Utility
FS APPLICATION
LN.CNT 1599
INCL INCLM: 514/017.000
INCLS: 514/019.000; 514/018.000; 530/330.000; 530/331.000
NCL NCLM: 514/017.000
NCLS: 514/019.000; 514/018.000; 530/330.000; 530/331.000
IC [7]
ICM: A61K038-08

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 158 OF 266 USPATFULL on STN
AN 2003:252719 USPATFULL
TI Model for neurodegenerative disease
IN Hernandez Perez, Felix, Madrid, SPAIN
De Grado, Jesus Avila, Madrid, SPAIN
Lozano, Jose Javier Lucas, Madrid, SPAIN
PI US 2003177510 A1 20030918
AI US 2003-276460 A1 20030519 (10)
WO 2001-GB2218 20010518
PRAI GB 2000-12056 20000518
DT Utility
FS APPLICATION
LN.CNT 1173
INCL INCLM: 800/012.000
INCLS: 800/014.000; 800/018.000
NCL NCLM: 800/012.000
NCLS: 800/014.000; 800/018.000
IC [7]
ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 159 OF 266 USPATFULL on STN
AN 2003:250493 USPATFULL
TI Ubiquilin, a presenilin interactor and methods of using same
IN Monteiro, Mervyn J., Columbia, MD, UNITED STATES
Mah, Alex L., Baltimore, MD, UNITED STATES
Perry, George, University Heights, OH, UNITED STATES
Smith, Mark A., Cleveland, OH, UNITED STATES
PI US 2003175278 A1 20030918
AI US 2002-293000 A1 20021113 (10)
PRAI US 2001-338549P 20011113 (60)
DT Utility
FS APPLICATION
LN.CNT 2516
INCL INCLM: 424/146.100
INCLS: 435/007.200; 435/069.100; 435/320.100; 435/325.000; 435/226.000; 536/023.200; 530/388.260
NCL NCLM: 424/146.100
NCLS: 435/007.200; 435/069.100; 435/320.100; 435/325.000; 435/226.000; 536/023.200; 530/388.260
IC [7]
ICM: A61K039-395
ICS: G01N033-53; G01N033-567; C07H021-04; C12N009-64; C12P021-02; C12N005-06; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 160 OF 266 USPATFULL on STN
AN 2003:246893 USPATFULL
TI Substituted 2-aminobenzamide caspase inhibitors and the use thereof
IN Cai, Sui Xiong, San Diego, CA, United States
Wang, Yan, San Diego, CA, United States
PA Cytovia, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6620782 B1 20030916
AI US 2000-527225 20000316 (9)
PRAI US 1999-158386P 19991012 (60)
US 1999-124675P 19990316 (60)
DT Utility
FS GRANTED
LN.CNT 1666
INCL INCLM: 514/010.000
INCLS: 514/002.000; 514/009.000; 514/011.000; 514/538.000; 514/561.000; 514/560.000; 514/038.000; 514/041.000; 514/435.000; 514/254.100; 514/325.000; 514/410.000
NCL NCLM: 514/010.000
NCLS: 514/002.000; 514/009.000; 514/011.000; 514/038.000; 514/041.000; 514/254.100; 514/325.000; 514/410.000; 514/435.000; 514/538.000; 514/560.000; 514/561.000
IC [7]
ICM: A61K038-05
ICS: A01N037-12; C07C229-00; C12N005-00
EXF 514/10; 514/2; 514/9; 514/11; 514/538; 514/501; 514/561; 514/811; 514/824; 514/863; 514/866; 514/886; 514/894; 514/917; 560/38; 560/41; 435/41; 435/325; 435/254.1; 435/410

L7 ANSWER 161 OF 266 USPATFULL on STN
AN 2003:244219 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003170628 A1 20030911
AI US 2001-999570 A1 20011114 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25549
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/007.100; 435/320.100; 435/325.000; 530/350.000; 530/388.100; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; C07H021-04; C12P021-02; C12N005-06; C07K014-47
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 162 OF 266 USPATFULL on STN
AN 2003:238400 USPATFULL
TI Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid beta, prion protein, amylin, alpha-synuclein, or polyglutamine repeats for induction of an immune response thereto
IN Frangione, Blas, New York, NY, UNITED STATES
Wisniewski, Thomas, Statent Island, NY, UNITED STATES
Sigurdsson, Einar M., New York, NY, UNITED STATES
PA NEW YORK UNIVERSITY (U.S. corporation)
PI US 2003166558 A1 20030904
AI US 2002-301488 A1 20021121 (10)
PRAI US 2001-331801P 20011121 (60)
DT Utility
FS APPLICATION
LN.CNT 4966
INCL INCLM: 514/012.000
INCLS: 514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000; 530/327.000; 530/328.000; 530/326.000
NCL NCLM: 514/012.000
NCLS: 514/013.000; 514/014.000; 514/015.000; 530/324.000; 530/325.000; 530/327.000; 530/328.000; 530/326.000
IC [7]
ICM: A61K038-16
ICS: A61K038-10; A61K038-08; C07K014-00; C07K007-08; C07K007-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 163 OF 266 USPATFULL on STN
AN 2003:237706 USPATFULL
TI NARC10 and NARC16, programmed cell death-associated molecules and uses thereof
IN Chiang, Lillian Wei-Ming, Edison, NJ, UNITED STATES
PA Millennium Pharmaceuticals, Inc. (U.S. corporation)
PI US 2003165863 A1 20030904
AI US 2002-47855 A1 20020115 (10)
PRAI US 2001-262306P 20010116 (60)
DT Utility
FS APPLICATION
LN.CNT 4471
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/226.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 164 OF 266 USPATFULL on STN
AN 2003:232020 USPATFULL
TI Wt1-interacting protein wtip
IN Sugiyama, Haruo, Osaka, JAPAN
Kim, Eui Ho, Osaka, JAPAN
PI US 2003162220 A1 20030828
AI US 2002-181804 A1 20020723 (10)
WO 2001-JP461 20010124
PRAI JP 2000-14949 20000124
DT Utility
FS APPLICATION
LN.CNT 2071
INCL INCLM: 435/007.100
INCLS: 435/320.100
NCL NCLM: 435/007.100
NCLS: 435/320.100
IC [7]
ICM: C12N015-00
ICS: G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 165 OF 266 USPATFULL on STN
AN 2003:231986 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003162186 A1 20030828
AI US 2002-154678 A1 20020522 (10)
PRAI US 2001-293574P 20010525 (60)
US 2001-298698P 20010615 (60)
US 2001-302277P 20010629 (60)
US 2001-305456P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 25533
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 166 OF 266 USPATFULL on STN
AN 2003:226449 USPATFULL
TI Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
IN Ramesh, Tennore, Westwood, MA, UNITED STATES
Scott, Sean, San Francisco, CA, UNITED STATES
PI US 2003158262 A1 20030821
AI US 2002-286631 A1 20021101 (10)
PRAI US 2001-333263P 20011116 (60)
DT Utility
FS APPLICATION
LN.CNT 2300
INCL INCLM: 514/646.000
INCLS: 514/674.000
NCL NCLM: 514/646.000
NCLS: 514/674.000
IC [7]
ICM: A61K031-135
ICS: A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 167 OF 266 USPATFULL on STN
AN 2003:225892 USPATFULL
TI Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
IN Roninson, Igor B., Wilmette, IL, UNITED STATES
Poole, Jason C., Chicago, IL, UNITED STATES
PI US 2003157704 A1 20030821
AI US 2002-233032 A1 20020829 (10)
PRAI US 2001-315791P 20010829 (60)

FS APPLICATION
LN.CNT 3944
INCL INCLM: 435/320.100
INCLS: 435/006.000; 435/325.000; 435/235.100; 435/239.000; 435/005.000
NCL NCLM: 435/320.100
NCLS: 435/006.000; 435/325.000; 435/235.100; 435/239.000; 435/005.000
IC [7]
ICM: C12Q001-70
ICS: C12Q001-68; C12N007-00; C12N007-01; C12N007-02; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74; C12N005-00; C12N005-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 168 OF 266 USPATFULL on STN
AN 2003:225714 USPATFULL
TI Identification of genetic markers of biological age and metabolism
IN Weindruch, Richard H., Madison, WI, UNITED STATES
Prolla, Tomas A., Madison, WI, UNITED STATES
Lee, Cheol-Koo, Madison, WI, UNITED STATES
PI US 2003157526 A1 20030821
AI US 2002-307706 A1 20021202 (10)
RLI Division of Ser. No. US 2000-630567, filed on 8 Aug 2000, PENDING
PRAI US 1999-148540P 19990812 (60)
US 2000-178232P 20000126 (60)
US 2000-211923P 20000616 (60)
DT Utility
FS APPLICATION
LN.CNT 2652
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 169 OF 266 USPATFULL on STN
AN 2003:225673 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE (non-U.S. corporation)
PI US 2003157485 A1 20030821
AI US 2001-992095 A1 20011113 (9)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25484
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000; 536/023.200; 530/388.260; 435/007.200
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/320.100; 435/325.000; 435/226.000; 800/008.000; 536/023.200; 530/388.260; 435/007.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-567; A01K067-00; C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 170 OF 266 USPATFULL on STN
AN 2003:221208 USPATFULL
TI Compound screening method
IN Verwaerde, Philippe, Neuville en Ferrain, FRANCE
Bogaert, Thierry, Kortrijk, BELGIUM
Platteeuw, Christ, Gent, BELGIUM
Cuvillier, Gwladys, Gentbrugge, BELGIUM
Behgyn, Myriam, Gent, BELGIUM
Feichtinger, Richard, Gent, BELGIUM
PA Devgen, N.V., Zwijnaarde, BELGIUM (non-U.S. corporation)
PI US 2003154501 A1 20030814
AI US 2002-214445 A1 20020807 (10)
RLI Continuation-in-part of Ser. No. US 2000-550107, filed on 14 Apr 2000,

2000, PENDING
PRAI GB 1999-8670 19990415
GB 1999-8677 19990415
US 1999-129596P 19990415 (60)
DT Utility
FS APPLICATION
LN.CNT 3149
INCL INCLM: 800/008.000
INCLS: 435/040.500
NCL NCLM: 800/008.000
NCLS: 435/040.500
IC [7]
ICM: A01K067-033
ICS: G01N001-30; G01N033-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 171 OF 266 USPATFULL on STN
AN 2003:220740 USPATFULL
TI Methods and compositions for diagnosing and treating rheumatoid arthritis
IN Pittman, Debra D., Windham, NH, UNITED STATES
Feldman, Jeffrey L., Arlington, MA, UNITED STATES
Shields, Kathleen M., Harvard, MA, UNITED STATES
Trepicchio, William L., Andover, MA, UNITED STATES
PI US 2003154032 A1 20030814
AI US 2001-23451 A1 20011217 (10)
PRAI US 2000-255861P 20001215 (60)
DT Utility
FS APPLICATION
LN.CNT 25385
INCL INCLM: 702/020.000
NCL NCLM: 702/020.000
IC [7]
ICM: G06F019-00
ICS: G01N033-48
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 172 OF 266 USPATFULL on STN
AN 2003:214340 USPATFULL
TI Polynucleotide therapy
IN Fontoura, Paulo, Mountain View, CA, UNITED STATES
Garren, Hideki, Palo Alto, CA, UNITED STATES
Robinson, William H., Menlo Park, CA, UNITED STATES
Steinman, Lawrence, Stanford, CA, UNITED STATES
Ruiz, Pedro Jose, Redwood City, CA, UNITED STATES
Utz, Paul J., Portola Valley, CA, UNITED STATES
PI US 2003148983 A1 20030807
AI US 2002-302098 A1 20021121 (10)
PRAI US 2001-332070P 20011121 (60)
DT Utility
FS APPLICATION
LN.CNT 3759
INCL INCLM: 514/044.000
NCL NCLM: 514/044.000
IC [7]
ICM: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 173 OF 266 USPATFULL on STN
AN 2003:213688 USPATFULL
TI Diagnosis of diseases associated with dna transcription
IN Olek, Alexander, Berlin, GERMANY, FEDERAL REPUBLIC OF
Piepenbrock, Christian, Berlin, GERMANY, FEDERAL REPUBLIC OF
Berlin, Kurt, Stahnsdorf, GERMANY, FEDERAL REPUBLIC OF
PI US 2003148326 A1 20030807
AI US 2003-240453 A1 20030121 (10)
WO 2001-EP3973 20010406
PRAI DE 2000-10019058 20000406
DE 2000-10019173 20000407
DE 2000-10032529 20000630
DE 2000-10043826 20000901
DT Utility
FS APPLICATION
LN.CNT 1052
INCL INCLM: 435/006.000

NCL NCLM: 435/006.000
NCLS: 435/287.200; 530/350.000; 536/024.300
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12M001-34; C07K014-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 174 OF 266 USPATFULL on STN
AN 2003:197129 USPATFULL
TI Dipeptide apoptosis inhibitors and the thereof
IN Keana, John F. W., Eugene, OR, United States
Cai, Sui Xiong, San Diego, CA, United States
Guastella, John, Irvine, CA, United States
Yang, Wu, Irvine, CA, United States
Drewe, John A., Costa Mesa, CA, United States
Weber, Eckard, San Diego, CA, United States
PA Cytovia, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6596693 B1 20030722
AI US 2000-653279 20000831 (9)
RLI Division of Ser. No. US 1999-270736, filed on 16 Mar 1999, now patented, Pat. No. US 6184210 Continuation-in-part of Ser. No. US 1998-168945, filed on 9 Oct 1998, now abandoned
PRAI US 1997-61676P 19971010 (60)
DT Utility
FS GRANTED
LN.CNT 1579
INCL INCLM: 514/019.000
INCLS: 514/002.000; 514/237.500; 514/357.000; 514/456.000; 514/478.000; 514/557.000; 514/567.000; 514/866.000
NCL NCLM: 514/019.000
NCLS: 514/002.000; 514/237.500; 514/357.000; 514/456.000; 514/478.000; 514/557.000; 514/567.000
IC [7]
ICM: A61K038-05
ICS: C07D213-04
EXF 514/2; 514/19; 514/237.5; 514/357; 514/456; 514/478; 514/557; 514/567; 514/866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 175 OF 266 USPATFULL on STN
AN 2003:188691 USPATFULL
TI Inhibitors and disassemblers of fibrillogenesis
IN Gordon, David J., Chicago, IL, UNITED STATES
Meredith, Stephen C., Chicago, IL, UNITED STATES
PI US 2003130484 A1 20030710
AI US 2002-103658 A1 20020320 (10)
PRAI US 2001-277477P 20010320 (60)
DT Utility
FS APPLICATION
LN.CNT 4503
INCL INCLM: 530/350.000
INCLS: 514/012.000; 435/007.100
NCL NCLM: 530/350.000
NCLS: 514/012.000; 435/007.100
IC [7]
ICM: A61K038-17
ICS: C07K014-435; G01N033-53
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 176 OF 266 USPATFULL on STN
AN 2003:188564 USPATFULL
TI Use of polyamine analogs for amyotrophic lateral sclerosis
IN Ramesh, Tennore, Westwood, MA, UNITED STATES
Scott, Sean, San Francisco, CA, UNITED STATES
PI US 2003130357 A1 20030710
AI US 2002-286042 A1 20021101 (10)
PRAI US 2001-333263P 20011116 (60)
DT Utility
FS APPLICATION
LN.CNT 2107
INCL INCLM: 514/674.000
NCL NCLM: 514/674.000
IC [7]
ICM: A61K031-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 177 OF 266 USPATFULL on STN
AN 2003:188557 USPATFULL
TI Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
IN Ramesh, Tennore, Westwood, MA, UNITED STATES
Scott, Sean, San Francisco, CA, UNITED STATES
PI US 2003130350 A1 20030710
AI US 2002-286604 A1 20021101 (10)
PRAI US 2001-333263P 20011116 (60)
DT Utility
FS APPLICATION
LN.CNT 2115
INCL INCLM: 514/564.000
INCLS: 424/130.100
NCL NCLM: 514/564.000
NCLS: 424/130.100
IC [7]
ICM: A61K031-198
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 178 OF 266 USPATFULL on STN
AN 2003:180749 USPATFULL
TI Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
IN Mack, David H., Menlo Park, CA, UNITED STATES
Gish, Kurt C., San Francisco, CA, UNITED STATES
PA Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)
PI US 2003124579 A1 20030703
AI US 2002-235399 A1 20020904 (10)
PRAI US 2002-372246P 20020412 (60)
US 2001-350666P 20011113 (60)
US 2001-317544P 20010905 (60)
DT Utility
FS APPLICATION
LN.CNT 7005
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.100
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 536/023.100
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 179 OF 266 USPATFULL on STN
AN 2003:180704 USPATFULL
TI HIP1 cancer markers
IN Ross, Theodora, Ann Arbor, MI, UNITED STATES
Mizukami, Ikuko, Ann Arbor, MI, UNITED STATES
Rao, Dinesh, Ypsilanti, MI, UNITED STATES
PI US 2003124533 A1 20030703
AI US 2001-7047 A1 20011206 (10)
PRAI US 2001-335276P 20011115 (60)
DT Utility
FS APPLICATION
LN.CNT 3615
INCL INCLM: 435/006.000
INCLS: 435/007.230; 530/388.800; 536/023.500
NCL NCLM: 435/006.000
NCLS: 435/007.230; 530/388.800; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C07K016-30
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 180 OF 266 USPATFULL on STN
AN 2003:180313 USPATFULL
TI Compositions and methods for the therapy and diagnosis of ovarian cancer
IN Bangur, Chaitanya S., Seattle, WA, UNITED STATES
Retter, Marc W., Carnation, WA, UNITED STATES
Fanger, Gary R., Mill Creek, WA, UNITED STATES
Hill, Paul, Duvall, WA, UNITED STATES
PA Corixa Corporation, Seattle, WA (U.S. corporation)
PI US 2003124140 A1 20030703
AI US 2002-198053 A1 20020717 (10)

PENDING Continuation-in-part of Ser. No. US 2001-884441, filed on 18 Jun 2001, PENDING Continuation-in-part of Ser. No. US 2001-827271, filed on 4 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2000-667857, filed on 20 Sep 2000, PENDING Continuation-in-part of Ser. No. US 2000-636801, filed on 10 Aug 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-617747, filed on 17 Jul 2000, PENDING Continuation-in-part of Ser. No. US 1999-404879, filed on 24 Sep 1999, GRANTED, Pat. No. US 6468546 Continuation-in-part of Ser. No. US 1999-338933, filed on 23 Jun 1999, GRANTED, Pat. No. US 6488931 Continuation-in-part of Ser. No. US 1998-216003, filed on 17 Dec 1998, PENDING Continuation-in-part of Ser. No. US 1998-215681, filed on 17 Dec 1998, PENDING
DT Utility
FS APPLICATION
LN.CNT 14715
INCL INCLM: 424/185.100
INCLS: 435/006.000; 435/007.230; 435/069.300; 435/183.000; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 424/185.100
NCLS: 435/006.000; 435/007.230; 435/069.300; 435/183.000; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: A61K039-00
ICS: C12Q001-68; G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 181 OF 266 USPATFULL on STN
AN 2003:152863 USPATFULL
TI Novel nucleic acids and polypeptides
IN Zhou, Ping, Cupertino, CA, UNITED STATES
Tang, Y. Tom, San Jose, CA, UNITED STATES
Liu, Chenghua, San Jose, CA, UNITED STATES
Asundi, Vinod, Foster City, CA, UNITED STATES
Drmanac, Radoje T., Palo Alto, CA, UNITED STATES
PI US 2003104529 A1 20030605
AI US 2002-37270 A1 20020104 (10)
RLI Division of Ser. No. US 2000-620312, filed on 19 Jul 2000, PENDING Continuation-in-part of Ser. No. US 2000-552317, filed on 25 Apr 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000, PENDING
DT Utility
FS APPLICATION
LN.CNT 9348
INCL INCLM: 435/069.100
INCLS: 435/320.100; 435/183.000; 435/325.000; 530/350.000; 536/023.200
NCL NCLM: 435/069.100
NCLS: 435/320.100; 435/183.000; 435/325.000; 530/350.000; 536/023.200
IC [7]
ICM: C12P021-02
ICS: C12N005-06; C07K014-435; C12N009-00; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 182 OF 266 USPATFULL on STN
AN 2003:142952 USPATFULL
TI Nucleic acids and polypeptides
IN Tang, Y. Tom, San Jose, CA, United States
Zhou, Ping, San Jose, CA, United States
Drmanac, Radoje T., Palo Alto, CA, United States
PA Hyseq, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6569662 B1 20030527
AI US 2000-620312 20000719 (9)
RLI Continuation-in-part of Ser. No. US 2000-552317, filed on 25 Apr 2000, now abandoned Continuation-in-part of Ser. No. US 2000-488725, filed on 21 Jan 2000
DT Utility
FS GRANTED
LN.CNT 6101
INCL INCLM: 435/212.000
INCLS: 435/183.000; 435/195.000; 435/213.000; 435/214.000; 435/218.000; 435/219.000; 435/226.000; 435/227.000
NCL NCLM: 435/212.000
NCLS: 435/183.000; 435/195.000; 435/213.000; 435/214.000; 435/218.000; 435/219.000; 435/226.000; 435/227.000
IC [7]

ICS: C12N009-14; C12N009-48; C12N009-76; C12N009-74; C12N009-64; C12N009-28
EXF 435/69.1; 435/252.3; 435/320.1; 435/183; 435/212; 435/219; 435/226; 435/213; 435/214; 435/218; 435/227; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 183 OF 266 USPATFULL on STN
AN 2003:142927 USPATFULL
TI Identification of genetic markers of biological age and metabolism
IN Weindruch, Richard H., Madison, WI, United States
Prolla, Tomas A., Madison, WI, United States
Lee, Cheol-Koo, Madison, WI, United States
PA Wisconsin Alumni Research Foundation, Madison, WI, United States (U.S. corporation)
PI US 6569624 B1 20030527
AI US 2000-630567 20000808 (9)
PRAI US 1999-148540P 19990812 (60)
US 2000-178232P 20000126 (60)
US 2000-211923P 20000616 (60)
DT Utility
FS GRANTED
LN.CNT 1733
INCL INCLM: 435/006.000
INCLS: 536/024.300
NCL NCLM: 435/006.000
NCLS: 536/024.300
IC [7]
ICM: C12Q001-68
ICS: C07H021-04
EXF 435/6; 536/24.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 184 OF 266 USPATFULL on STN
AN 2003:140406 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003096247 A1 20030522
AI US 2001-986 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility
FS APPLICATION
LN.CNT 25656
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200; 800/008.000
IC [7]
ICM: C12Q001-68
ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 185 OF 266 USPATFULL on STN
AN 2003:133926 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003092011 A1 20030515
AI US 2001-489 A1 20011114 (10)
RLI Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI WO 2001-IB1715 20010806
US 2001-305456P 20010713 (60)
US 2001-302277P 20010629 (60)
US 2001-298698P 20010615 (60)
US 2001-293574P 20010525 (60)
DT Utility

LN.CNT 25607
INCL INCLM: 435/006.000
INCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL NCLM: 435/006.000
NCLS: 800/003.000; 435/007.900; 435/183.000; 435/069.100; 435/320.100; 435/325.000; 536/023.200
IC [7]
ICM: C12Q001-68
ICS: G01N033-53; G01N033-542; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 186 OF 266 USPATFULL on STN
AN 2003:120811 USPATFULL
TI Antisense modulation of caspase 3 expression
IN Zhang, Hong, Carlsbad, CA, UNITED STATES
Cowsert, Lex M., San Mateo, CA, UNITED STATES
PI US 2003083295 A1 20030501
AI US 2002-181107 A1 20020711 (10)
WO 2001-US888 20010111
DT Utility
FS APPLICATION
LN.CNT 3640
INCL INCLM: 514/044.000
INCLS: 536/023.200
NCL NCLM: 514/044.000
NCLS: 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 187 OF 266 USPATFULL on STN
AN 2003:120026 USPATFULL
TI Identification of modulatory molecules using inducible promoters
IN Brown, Steven J., San Diego, CA, UNITED STATES
Dunnington, Damien J., San Diego, CA, UNITED STATES
Clark, Imran, San Diego, CA, UNITED STATES
PI US 2003082511 A1 20030501
AI US 2001-965201 A1 20010925 (9)
DT Utility
FS APPLICATION
LN.CNT 5526
INCL INCLM: 435/004.000
INCLS: 435/006.000
NCL NCLM: 435/004.000
NCLS: 435/006.000
IC [7]
ICM: C12Q001-00
ICS: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 188 OF 266 USPATFULL on STN
AN 2003:102229 USPATFULL
TI (CAG)/Q expansion disorders
IN Cooper, Arthur J. L., Croton on Hudson, NY, United States
Blass, John P., Bronxville, NY, United States
PA Cornell Research Foundation, Inc., Ithaca, NY, United States (U.S. corporation)
PI US 6548243 B1 20030415
WO 2000003739 20000127
AI US 2001-743590 20010313 (9)
WO 1999-US15899 19990714
PRAI US 1998-92845P 19980714 (60)
DT Utility
FS GRANTED
LN.CNT 793
INCL INCLM: 435/004.000
INCLS: 435/006.000; 435/015.000
NCL NCLM: 435/004.000
NCLS: 435/006.000; 435/015.000
IC [7]
ICM: C12Q001-00
EXF 435/4; 435/6; 435/15; 536/23.2

L7 ANSWER 189 OF 266 USPATFULL on STN
AN 2003:99696 USPATFULL
TI Purification of functional ribonucleoprotein complexes
IN Reed, Robin, Belmont, MA, UNITED STATES
Zhou, Zhaolan, Malden, MA, UNITED STATES
PI US 2003068803 A1 20030410
AI US 2002-47991 A1 20020114 (10)
PRAI US 2001-261521P 20010112 (60)
DT Utility
FS APPLICATION
LN.CNT 2882
INCL INCLM: 435/199.000
INCLS: 435/226.000
NCL NCLM: 435/199.000
NCLS: 435/226.000
IC [7]
ICM: C12N009-22
ICS: C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 190 OF 266 USPATFULL on STN
AN 2003:93067 USPATFULL
TI Reagents and methods for identifying and modulating expression of genes regulated by CDK inhibitors
IN Poole, Jason, Chicago, IL, UNITED STATES
Chang, Bey-Dih, Lombard, IL, UNITED STATES
Roninson, Igor B., Wilmette, IL, UNITED STATES
PI US 2003064426 A1 20030403
AI US 2001-861925 A1 20010521 (9)
PRAI US 2001-265840P 20010201 (60)
DT Utility
FS APPLICATION
LN.CNT 3443
INCL INCLM: 435/008.000
INCLS: 435/184.000; 435/320.100; 435/325.000; 435/069.100
NCL NCLM: 435/008.000
NCLS: 435/184.000; 435/320.100; 435/325.000; 435/069.100
IC [7]
ICM: C12Q001-66
ICS: C12N009-99; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 191 OF 266 USPATFULL on STN
AN 2003:65342 USPATFULL
TI Calcium binding protein
IN Tang, Y. Tom, San Jose, CA, UNITED STATES
Guegler, Karl J., Menlo Park, CA, UNITED STATES
Corley, Neil C., Castro Valley, CA, UNITED STATES
Gorgone, Gina A., Boulder Creek, CA, UNITED STATES
Yue, Henry, Sunnyvale, CA, UNITED STATES
PI US 2003045466 A1 20030306
AI US 2001-25730 A1 20011218 (10)
RLI Division of Ser. No. US 1999-470253, filed on 22 Dec 1999, GRANTED, Pat. No. US 6365371 Division of Ser. No. US 1998-190965, filed on 13 Nov 1998, GRANTED, Pat. No. US 6071721
DT Utility
FS APPLICATION
LN.CNT 2724
INCL INCLM: 514/012.000
INCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000; 435/252.300; 800/008.000
NCL NCLM: 514/012.000
NCLS: 530/350.000; 536/023.500; 435/069.100; 435/320.100; 435/325.000; 435/252.300; 800/008.000
IC [7]
ICM: A61K038-17
ICS: A01K067-00; C12P021-02; C12N005-06; C07K014-435; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 192 OF 266 USPATFULL on STN
AN 2003:57525 USPATFULL
TI Protein-protein interactions in adipocyte cells
IN Legrain, Pierre, Paris, FRANCE
Marullo, Stefano, Paris, FRANCE

PI US 2003040089 A1 20030227
AI US 2002-38010 A1 20020102 (10)
PRAI US 2001-259377P 20010102 (60)
DT Utility
FS APPLICATION
LN.CNT 7738
INCL INCLM: 435/183.000
INCLS: 435/069.100; 435/007.100; 435/325.000; 435/320.100; 536/023.200; 702/019.000
NCL NCLM: 435/183.000
NCLS: 435/069.100; 435/007.100; 435/325.000; 435/320.100; 536/023.200; 702/019.000
IC [7]
ICM: G01N033-53
ICS: G06F019-00; G01N033-48; G01N033-50; C07H021-04; C12N009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 193 OF 266 USPATFULL on STN
AN 2003:45267 USPATFULL
TI Therapeutic use of selective PDE10 inhibitors
IN Lebel, Lorraine A., North Stonington, CT, UNITED STATES
Menniti, Frank S., Mystic, CT, UNITED STATES
Schmidt, Christopher J., Old Lyme, CT, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2003032579 A1 20030213
AI US 2002-177018 A1 20020620 (10)
RLI Continuation-in-part of Ser. No. US 2002-139183, filed on 3 May 2002, PENDING Continuation-in-part of Ser. No. US 2002-126113, filed on 19 Apr 2002, PENDING
PRAI US 2001-285148P 20010420 (60)
DT Utility
FS APPLICATION
LN.CNT 1270
INCL INCLM: 514/001.000
NCL NCLM: 514/001.000
IC [7]
ICM: A61K031-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 194 OF 266 USPATFULL on STN
AN 2003:37677 USPATFULL
TI Helper virus-free herpesvirus amplicon particles and uses thereof
IN Federoff, Howard J., Rochester, NY, UNITED STATES
Bowers, William J., Webster, NY, UNITED STATES
Frelinger, John G., Pittsford, NY, UNITED STATES
Willis, Richard A., Denver, CO, UNITED STATES
Evans, Thomas D., Davis, CA, UNITED STATES
Dewhurst, Stephen, Rochester, NY, UNITED STATES
Tolba, Khaled A., Rochester, NY, UNITED STATES
Rosenblatt, Joseph D., Ft. Lauderdale, FL, UNITED STATES
PI US 2003027322 A1 20030206
AI US 2001-997848 A1 20011129 (9)
PRAI US 2000-253858P 20001129 (60)
US 2000-250079P 20001130 (60)
DT Utility
FS APPLICATION
LN.CNT 2012
INCL INCLM: 435/235.100
INCLS: 435/456.000; 435/325.000
NCL NCLM: 435/235.100
NCLS: 435/456.000; 435/325.000
IC [7]
ICM: C12N007-00
ICS: C12N015-86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 195 OF 266 USPATFULL on STN
AN 2003:37603 USPATFULL
TI Human cDNAs and proteins and uses thereof
IN Bejanin, Stephane, Paris, FRANCE
Tanaka, Hiroaki, Antony, FRANCE
PA GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI US 2003027248 A1 20030206
AI US 2001-924340 A1 20010806 (9)
PRAI US 2001-305456P 20010713 (60)

```
       US 2001-298698P     20010615 (60)
       US 2001-293574P     20010525 (60)
DT     Utility
FS     APPLICATION
LN.CNT 25650
INCL   INCLM: 435/069.100
       INCLS: 435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;
              435/006.000
NCL    NCLM:  435/069.100
       NCLS:  435/183.000; 435/320.100; 435/325.000; 530/350.000; 536/023.200;
              435/006.000
IC     [7]
       ICM: C12P021-02
       ICS: C12Q001-68; C07H021-04; C12N009-00; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7   ANSWER 196 OF 266  USPATFULL on STN
AN     2003:37516  USPATFULL
TI     Human cDNAs and proteins and uses thereof
IN     Bejanin, Stephane, Paris, FRANCE
       Tanaka, Hiroaki, Antony, FRANCE
PA     GENSET, S.A., Paris, FRANCE, 75008 (non-U.S. corporation)
PI     US 2003027161      A1   20030206
AI     US 2001-992600     A1   20011113 (9)
RLI    Division of Ser. No. US 2001-924340, filed on 6 Aug 2001, PENDING
PRAI   WO 2001-IB1715       20010806
       US 2001-305456P     20010713 (60)
       US 2001-302277P     20010629 (60)
       US 2001-298698P     20010615 (60)
       US 2001-293574P     20010525 (60)
DT     Utility
FS     APPLICATION
LN.CNT 25529
INCL   INCLM: 435/006.000
       INCLS: 435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
              536/023.200; 800/008.000
NCL    NCLM:  435/006.000
       NCLS:  435/069.100; 435/183.000; 435/320.100; 435/325.000; 530/350.000;
              536/023.200; 800/008.000
IC     [7]
       ICM: C12Q001-68
       ICS: A01K067-00; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7   ANSWER 197 OF 266  USPATFULL on STN
AN     2003:33554  USPATFULL
TI     DNA fragmentation factor
IN     Wang, Xiaodong, Dallas, TX, United States
       Liu, Xuesong, Dallas, TX, United States
PA     Board of Regents, The University of Texas System, Austin, TX, United
       States (U.S. corporation)
PI     US 6515118         B1   20030204
AI     US 1997-842760          19970417 (8)
DT     Utility
FS     GRANTED
LN.CNT 953
INCL   INCLM: 536/023.100
       INCLS: 435/069.000T; 435/520.100; 435/325.000
NCL    NCLM:  536/023.100
       NCLS:  435/069.100; 435/320.100; 435/325.000
IC     [7]
       ICM: C07H021-02
       ICS: C12N001-20; C12N015-00; C12N005-02
EXF    536/23.1; 435/325; 435/320.1; 435/69T
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7   ANSWER 198 OF 266  USPATFULL on STN
AN     2003:24204  USPATFULL
TI     Therapeutic use of selective PDE10 inhibitors
IN     Lebel, Lorraine A., North Stonington, CT, UNITED STATES
       Menniti, Frank S., Mystic, CT, UNITED STATES
       Schmidt, Christopher J., Old Lyme, CT, UNITED STATES
PA     Pfizer Inc. (U.S. corporation)
PI     US 2003018047      A1   20030123
AI     US 2002-139183     A1   20020503 (10)
```

PENDING
PRAI US 2001-285148P 20010420 (60)
DT Utility
FS APPLICATION
LN.CNT 1221
INCL INCLM: 514/317.000
INCLS: 514/308.000
NCL NCLM: 514/317.000
NCLS: 514/308.000
IC [7]
ICM: A61K031-47
ICS: A61K031-445
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 199 OF 266 USPATFULL on STN
AN 2003:4268 USPATFULL
TI Sodium dodecyl sulfate compositions for inactivating prions
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Supattapone, Surachai, Hanover, NH, UNITED STATES
PI US 2003004312 A1 20030102
AI US 2002-56222 A1 20020122 (10)
RLI Continuation-in-part of Ser. No. US 2001-904178, filed on 11 Jul 2001, PENDING Continuation-in-part of Ser. No. US 2000-699284, filed on 26 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-494814, filed on 31 Jan 2000, GRANTED, Pat. No. US 6322802 Continuation-in-part of Ser. No. US 1999-447456, filed on 22 Nov 1999, GRANTED, Pat. No. US 6331296 Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, GRANTED, Pat. No. US 6214366 Continuation-in-part of Ser. No. US 1999-235372, filed on 20 Jan 1999, GRANTED, Pat. No. US 6221614 Continuation-in-part of Ser. No. US 1998-151057, filed on 10 Sep 1998, ABANDONED Continuation-in-part of Ser. No. US 1998-26957, filed on 20 Feb 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-804536, filed on 21 Feb 1997, GRANTED, Pat. No. US 5891641
DT Utility
FS APPLICATION
LN.CNT 3471
INCL INCLM: 530/350.000
NCL NCLM: 530/350.000
IC [7]
ICM: C07K014-435
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 200 OF 266 USPATFULL on STN
AN 2002:343879 USPATFULL
TI Novel Polynucleotides
IN Nakagawa, Satoshi, Tokyo, JAPAN
Mizoguchi, Hiroshi, Tokyo, JAPAN
Ando, Seiko, Tokyo, JAPAN
Hayashi, Mikiro, Tokyo, JAPAN
Ochiai, Keiko, Tokyo, JAPAN
Yokoi, Haruhiko, Tokyo, JAPAN
Tateishi, Naoko, Tokyo, JAPAN
Senoh, Akihiro, Tokyo, JAPAN
Ikeda, Masato, Tokyo, JAPAN
Ozaki, Akio, Hofu-shi, JAPAN
PI US 2002197605 A1 20021226
AI US 2000-738626 A1 20001218 (9)
PRAI JP 1999-377484 19991216
JP 2000-159162 20000407
JP 2000-280988 20000803
DT Utility
FS APPLICATION
LN.CNT 13673
INCL INCLM: 435/006.000
INCLS: 435/091.200; 435/287.200
NCL NCLM: 435/006.000
NCLS: 435/091.200; 435/287.200
IC [7]
ICM: C12Q001-68
ICS: C12P019-34; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 201 OF 266 USPATFULL on STN
AN 2002:338194 USPATFULL
TI Oligomeric chaperone proteins

Chatellier, Jean, Les Martres de Veyre, FRANCE
Fersht, Alan Roy, Cambridge, UNITED KINGDOM
PI US 2002193564 A1 20021219
AI US 2001-7314 A1 20011108 (10)
RLI Continuation-in-part of Ser. No. WO 2000-GB1822, filed on 12 May 2000, UNKNOWN
PRAI GB 1999-11298 19990514
GB 1999-30530 19991223
DT Utility
FS APPLICATION
LN.CNT 2196
INCL INCLM: 530/350.000
INCLS: 435/235.100
NCL NCLM: 530/350.000
NCLS: 435/235.100
IC [7]
ICM: C07K014-005
ICS: C12N007-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 202 OF 266 USPATFULL on STN
AN 2002:338071 USPATFULL
TI Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
IN Peet, Malcolm, Sheffield, UNITED KINGDOM
Vaddadi, Krishna S., Melbourne, AUSTRALIA
PA Laxdale Limited (non-U.S. corporation)
PI US 2002193439 A1 20021219
AI US 2002-191430 A1 20020710 (10)
RLI Continuation of Ser. No. US 2001-14603, filed on 14 Dec 2001, PENDING
Division of Ser. No. US 2000-492741, filed on 27 Jan 2000, GRANTED, Pat. No. US 6384077
PRAI GB 1999-1809 19990127
DT Utility
FS APPLICATION
LN.CNT 1151
INCL INCLM: 514/560.000
NCL NCLM: 514/560.000
IC [7]
ICM: A61K031-202
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 203 OF 266 USPATFULL on STN
AN 2002:332717 USPATFULL
TI Substituted alpha-hydroxy acid caspase inhibitors and the use thereof
IN Wang, Yan, San Diego, CA, United States
Cai, Sui Xiong, San Diego, CA, United States
Weber, Eckard, San Diego, CA, United States
Mills, Gordon B., Houston, TX, United States
Green, Douglas R., San Diego, CA, United States
Guan, Lufeng, San Diego, CA, United States
PA Cytovia, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6495522 B1 20021217
AI US 2000-649810 20000828 (9)
PRAI US 1999-151077P 19990827 (60)
US 1999-158373P 19991012 (60)
DT Utility
FS GRANTED
LN.CNT 2503
INCL INCLM: 514/019.000
INCLS: 435/001.100; 435/002.000; 435/260.000; 435/405.000; 504/115.000; 514/183.000; 514/399.000; 514/478.000; 514/534.000; 514/538.000; 514/563.000; 558/275.000; 558/276.000; 560/037.000; 560/051.000; 560/129.000; 560/169.000; 560/170.000; 562/442.000; 562/553.000; 562/561.000; 562/569.000; 548/334.100
NCL NCLM: 514/019.000
NCLS: 435/001.100; 435/002.000; 435/260.000; 435/405.000; 504/115.000; 514/183.000; 514/399.000; 514/478.000; 514/534.000; 514/538.000; 514/563.000; 548/334.100; 558/275.000; 558/276.000; 560/037.000; 560/051.000; 560/129.000; 560/169.000; 560/170.000; 562/442.000; 562/553.000; 562/561.000; 562/569.000
IC [7]
ICM: A61K031-195
ICS: C07C271-12; C07C271-22; C07C271-28
EXF 427/4; 435/1.1; 435/1.2; 435/1.3; 435/2; 435/260; 435/405; 504/115;

514/183; 514/399; 514/478; 514/534; 514/538; 514/563; 548/334.1; 558/275; 558/276; 560/37; 560/51; 560/129; 560/169; 560/170; 562/442; 562/553; 562/561; 562/567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 204 OF 266 USPATFULL on STN
AN 2002:323220 USPATFULL
TI Highly purified EPA and other EPA derivatives for psychiatric and neurological disorders
IN Peet, Malcolm, Sheffield, UNITED KINGDOM
Vaddadi, Krishna S., Melbourne, AUSTRALIA
PA Laxdale Limited (non-U.S. corporation)
PI US 2002183389 A1 20021205
AI US 2002-173622 A1 20020619 (10)
RLI Continuation of Ser. No. US 2001-14603, filed on 14 Dec 2001, PENDING
Division of Ser. No. US 2000-492741, filed on 27 Jan 2000, GRANTED, Pat. No. US 6384077
PRAI GB 1999-1809 19990127
DT Utility
FS APPLICATION
LN.CNT 1151
INCL INCLM: 514/560.000
NCL NCLM: 514/560.000
IC [7]
ICM: A61K031-202
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 205 OF 266 USPATFULL on STN
AN 2002:314644 USPATFULL
TI ASSAYS FOR APOTOSIS MODULATORS
IN ELLIOTT, KATHRYN J., SAN DIEGO, CA, UNITED STATES
KOUNNAS, MARIA Z., SAN DIEGO, CA, UNITED STATES
DYER, REBECCA J., SAN DIEGO, CA, UNITED STATES
MUNOZ, BENITO, SAN DIEGO, CA, UNITED STATES
WAGNER, STEVEN L., SAN DIEGO, CA, UNITED STATES
PI US 2002177120 A1 20021128
AI US 1999-326472 A1 19990604 (9)
DT Utility
FS APPLICATION
LN.CNT 2250
INCL INCLM: 435/004.000
INCLS: 530/300.000; 530/350.000
NCL NCLM: 435/004.000
NCLS: 530/300.000; 530/350.000
IC [7]
ICM: C12Q001-00
ICS: C07K002-00; C07K004-00; C07K005-00; C07K007-00; C07K014-00; C07K016-00; C07K017-00; A61K038-00; C07K001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 206 OF 266 USPATFULL on STN
AN 2002:309311 USPATFULL
TI Identification of genes involved in alzheimer's disease using drosophila melanogaster
IN Cohen, Dalia, Livingston, NJ, UNITED STATES
Dengler, Uwe Jochen, Loerrach, GERMANY, FEDERAL REPUBLIC OF
Finelli, Alyce Lynn, Parsippany, NJ, UNITED STATES
Freuler, Felix, Riehen, SWITZERLAND
Konsolaki, Mary, Westfield, NJ, UNITED STATES
Reinhardt, Mischa Werner Henri Marie, Bantzenheim, FRANCE
Zusman, Susan, Sudbury, MA, UNITED STATES
PI US 2002174446 A1 20021121
AI US 2001-964899 A1 20010927 (9)
PRAI US 2000-236893P 20000929 (60)
US 2001-298309P 20010614 (60)
DT Utility
FS APPLICATION
LN.CNT 5722
INCL INCLM: 800/008.000
INCLS: 514/001.000
NCL NCLM: 800/008.000
NCLS: 514/001.000
IC [7]
ICM: A01K067-033
ICS: A61K031-00

L7 ANSWER 207 OF 266 USPATFULL on STN
AN 2002:308410 USPATFULL
TI 2-pyrrolidinone derivatives substituted at position 4 for reducing the extracellular glutamate level
IN Feurerstein, Thomas J., Horben, GERMANY, FEDERAL REPUBLIC OF
Knoerle, Rainer, Freiburg, GERMANY, FEDERAL REPUBLIC OF
PI US 2002173537 A1 20021121
AI US 2002-108879 A1 20020329 (10)
RLI Continuation-in-part of Ser. No. US 2000-554587, filed on 12 Jul 2000, GRANTED, Pat. No. US 6384069
DT Utility
FS APPLICATION
LN.CNT 1015
INCL INCLM: 514/424.000
NCL NCLM: 514/424.000
IC [7]
ICM: A61K031-4015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 208 OF 266 USPATFULL on STN
AN 2002:294612 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002164655 A1 20021107
AI US 2001-973941 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3277
INCL INCLM: 435/007.200
INCLS: 435/183.000; 530/388.260
NCL NCLM: 435/007.200
NCLS: 435/183.000; 530/388.260
IC [7]
ICM: G01N033-53
ICS: G01N033-567; C12N009-00; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 209 OF 266 USPATFULL on STN
AN 2002:280593 USPATFULL
TI Gene expression profiling of antidepressant action in the brain
IN Bonaventure, Pascal, San Diego, CA, UNITED STATES
Quo, Hongqing, San Diego, CA, UNITED STATES
Liu, Xuejun, San Diego, CA, UNITED STATES
Kamme, Fredrik, San Diego, CA, UNITED STATES
Meurers, Bernhard, La Jolla, CA, UNITED STATES
Leysen, Josepha E.M.F., Oud-Turnhout, BELGIUM
Bakker, Margot H.M., Breda, NETHERLANDS
PI US 2002156038 A1 20021024
AI US 2001-971900 A1 20011004 (9)
PRAI US 2000-238374P 20001006 (60)
US 2001-295782P 20010604 (60)
DT Utility
FS APPLICATION
LN.CNT 6849
INCL INCLM: 514/044.000
INCLS: 435/006.000; 435/287.200
NCL NCLM: 514/044.000
NCLS: 435/006.000; 435/287.200
IC [7]
ICM: A61K048-00
ICS: C12Q001-68; C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 210 OF 266 USPATFULL on STN
AN 2002:279740 USPATFULL
TI Methods and compounds for decreasing cell toxicity or death
IN Yuan, Junying, Newton, MA, UNITED STATES
Sanchez, Ivelisse, Watertown, MA, UNITED STATES
PI US 2002155172 A1 20021024

PRAI US 2000-195661P 20000407 (60)
DT Utility
FS APPLICATION
LN.CNT 1767
INCL INCLM: 424/692.000
INCLS: 514/150.000; 514/009.000; 514/179.000; 514/054.000; 514/034.000; 514/026.000; 514/250.000; 514/317.000; 424/725.000
NCL NCLM: 424/692.000
NCLS: 514/150.000; 514/009.000; 514/179.000; 514/054.000; 514/034.000; 514/026.000; 514/250.000; 514/317.000; 424/725.000
IC [7]
ICM: A61K031-704
ICS: A61K031-715; A61K031-655; A61K038-13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 211 OF 266 USPATFULL on STN
AN 2002:272765 USPATFULL
TI Novel fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof
IN Weber, Eckard, San Diego, CA, UNITED STATES
Cai, Sui Xiong, San Diego, CA, UNITED STATES
Keana, John F.W., Eugene, OR, UNITED STATES
Drewe, John A., Carlsbad, CA, UNITED STATES
Zhang, Han-Zhong, Irvine, CA, UNITED STATES
PA Cytovia, Inc. (U.S. corporation)
PI US 2002150885 A1 20021017
AI US 2001-947387 A1 20010907 (9)
RLI Division of Ser. No. US 1998-168888, filed on 9 Oct 1998, PATENTED
PRAI US 1998-145746P 19980303 (60)
US 1997-61582P 19971010 (60)
DT Utility
FS APPLICATION
LN.CNT 4773
INCL INCLM: 435/005.000
NCL NCLM: 435/005.000
IC [7]
ICM: C12Q001-70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 212 OF 266 USPATFULL on STN
AN 2002:231977 USPATFULL
TI Multiplexed analysis of clinical specimens apparatus and method
IN Chandler, Van S., Austin, TX, United States
Fulton, Jerrold R., Cedar Hill, TX, United States
Chandler, Mark B., Austin, TX, United States
PA Luminex Corporation, Austin, TX, United States (U.S. corporation)
PI US 6449562 B1 20020910
WO 9714028 19970417
AI US 1998-286 19980818 (9)
WO 1996-US16198 19961010
19980818 PCT 371 date
DT Utility
FS GRANTED
LN.CNT 4019
INCL INCLM: 702/019.000
INCLS: 702/020.000; 435/006.000; 707/001.000; 707/104.000
NCL NCLM: 702/019.000
NCLS: 435/006.000; 702/020.000; 707/001.000
IC [7]
ICM: G01N033-48
ICS: G01N033-50; C12Q001-68; G06F017-30
EXF 702/19; 702/20; 435/6; 707/104; 707/1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 213 OF 266 USPATFULL on STN
AN 2002:229107 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PI US 2002124273 A1 20020905
AI US 2001-973965 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)

FS APPLICATION
LN.CNT 3256
INCL INCLM: 800/003.000
INCLS: 435/007.930
NCL NCLM: 800/003.000
NCLS: 435/007.930
IC [7]
ICM: G01N033-00
ICS: G01N033-53; G01N033-542; G01N033-537; G01N033-543
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 214 OF 266 USPATFULL on STN
AN 2002:224705 USPATFULL
TI Hydrophobically-modified hedgehog protein compositions and methods
IN Pepinsky, R. Blake, Arlington, MA, United States
Baker, Darren P., Hingham, MA, United States
Wen, Dingyi, Waltham, MA, United States
Williams, Kevin P., Natick, MA, United States
Garber, Ellen A., Cambrdige, MA, United States
Taylor, Frederick R., Milton, MA, United States
Galdes, Alphonse, Lexington, MA, United States
Porter, Jeffrey, Cambridge, MA, United States
PA Curis, Inc., Cambridge, MA, United States (U.S. corporation)
Biogen, Inc., Cambridge, MA, United States (U.S. corporation)
PI US 6444793 B1 20020903
AI US 1999-325256 19990603 (9)
RLI Continuation of Ser. No. WO 1998-US25676, filed on 3 Dec 1998
PRAI US 1998-99800P 19980910 (60)
US 1998-89685P 19980617 (60)
US 1998-78935P 19980320 (60)
US 1997-67423P 19971203 (60)
DT Utility
FS GRANTED
LN.CNT 5426
INCL INCLM: 530/402.000
INCLS: 530/350.000; 530/399.000; 530/359.000; 436/071.000; 514/012.000; 514/506.000; 514/762.000
NCL NCLM: 530/402.000
NCLS: 436/071.000; 530/350.000; 530/359.000; 530/399.000
IC [7]
ICM: C07K014-435
ICS: C07K001-107
EXF 436/71; 530/350; 530/399; 530/402; 530/359; 514/12; 514/506; 514/762
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 215 OF 266 USPATFULL on STN
AN 2002:221785 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002119927 A1 20020829
AI US 2001-972757 A1 20011009 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3204
INCL INCLM: 514/012.000
INCLS: 424/146.100
NCL NCLM: 514/012.000
NCLS: 424/146.100
IC [7]
ICM: A61K039-395
ICS: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 216 OF 266 USPATFULL on STN
AN 2002:221300 USPATFULL
TI Genetic assays for trinucleotide repeat mutations in eukaryotic cells
IN Lahue, Robert S., Elkhorn, NE, UNITED STATES
Miret, Juan J., Stamford, CT, UNITED STATES
Pelletier, Richard, Omaha, NE, UNITED STATES
PI US 2002119439 A1 20020829
US 6489115 B2 20021203

DT Utility
FS APPLICATION
LN.CNT 1006
INCL INCLM: 435/004.000
INCLS: 435/006.000; 435/483.000
NCL NCLM: 435/006.000
NCLS: 435/029.000
IC [7]
ICM: C12N015-74
ICS: C12Q001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 217 OF 266 USPATFULL on STN
AN 2002:221020 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2002119155 A1 20020829
AI US 2001-972038 A1 20011009 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3081
INCL INCLM: 424/146.100
INCLS: 530/388.260; 435/226.000; 435/007.200; 435/006.000
NCL NCLM: 424/146.100
NCLS: 530/388.260; 435/226.000; 435/007.200; 435/006.000
IC [7]
ICM: A61K039-395
ICS: C12Q001-68; G01N033-53; C12N009-64; G01N033-567; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 218 OF 266 USPATFULL on STN
AN 2002:214220 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2002115607 A1 20020822
AI US 2001-975072 A1 20011012 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3574
INCL INCLM: 514/012.000
INCLS: 424/146.100; 435/226.000; 530/350.000; 435/194.000
NCL NCLM: 514/012.000
NCLS: 424/146.100; 435/226.000; 530/350.000; 435/194.000
IC [7]
ICM: A61K038-17
ICS: A61K039-395; C12N009-64; C07K014-435; C12N009-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 219 OF 266 USPATFULL on STN
AN 2002:214219 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002115606 A1 20020822
AI US 2001-973964 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3354
INCL INCLM: 514/012.000
NCL NCLM: 514/012.000
IC [7]

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 220 OF 266 USPATFULL on STN
AN 2002:213743 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Mark, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc. (U.S. corporation)
PI US 2002115119 A1 20020822
AI US 2001-973063 A1 20011010 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3133
INCL INCLM: 435/007.210
NCL NCLM: 435/007.210
IC [7]
ICM: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 221 OF 266 USPATFULL on STN
AN 2002:213426 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2002114799 A1 20020822
AI US 2001-973077 A1 20011010 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3207
INCL INCLM: 424/130.100
NCL NCLM: 424/130.100
IC [7]
ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 222 OF 266 USPATFULL on STN
AN 2002:206116 USPATFULL
TI Toxicant-induced differential gene expression
IN Reidhaar-Olson, John F., Montclair, NJ, UNITED STATES
PI US 2002110808 A1 20020815
AI US 2000-489220 A1 20000121 (9)
DT Utility
FS APPLICATION
LN.CNT 5161
INCL INCLM: 435/006.000
INCLS: 435/091.200; 536/023.100
NCL NCLM: 435/006.000
NCLS: 435/091.200; 536/023.100
IC [7]
ICM: C12Q001-68
ICS: C07H021-02; C07H021-04; C12P019-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 223 OF 266 USPATFULL on STN
AN 2002:199259 USPATFULL
TI Apaf-1, an activator of caspase-3
IN Wang, Xiaodong, Dallas, TX, UNITED STATES
PI US 2002107370 A1 20020808
AI US 2001-876667 A1 20010607 (9)
RLI Division of Ser. No. US 1999-435115, filed on 5 Nov 1999, PATENTED
Division of Ser. No. US 1998-92508, filed on 5 Jun 1998, PATENTED
PRAI US 1997-55258P 19970807 (60)
US 1997-48807P 19970605 (60)
DT Utility
FS APPLICATION
LN.CNT 3409
INCL INCLM: 530/388.260
INCLS: 435/226.000; 536/023.200; 435/069.100; 435/325.000; 435/320.100
NCL NCLM: 530/388.260

IC [7]
ICM: C07K016-40
ICS: C12N009-64; C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 224 OF 266 USPATFULL on STN
AN 2002:198673 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT, UNITED STATES (U.S. corporation)
PI US 2002106773 A1 20020808
AI US 2001-973064 A1 20011010 (9)
PRAI US 2000-240790P 20001017 (60)
DT Utility
FS APPLICATION
LN.CNT 3066
INCL INCLM: 435/196.000
INCLS: 435/007.100; 435/006.000; 530/388.260
NCL NCLM: 435/196.000
NCLS: 435/007.100; 435/006.000; 530/388.260
IC [7]
ICM: C12N009-16
ICS: C12Q001-68; G01N033-53; C07K016-40
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 225 OF 266 USPATFULL on STN
AN 2002:198576 USPATFULL
TI Protein-protein interactions in neurodegenerative diseases
IN Roch, Jean-Marc, Salt Lake City, UT, UNITED STATES
Bartel, Paul L., Salt Lake City, UT, UNITED STATES
Heichman, Karen, Salt Lake City, UT, UNITED STATES
PA Myriad Genetics, Inc., Salt Lake City, UT (U.S. corporation)
PI US 2002106676 A1 20020808
US 6653102 B2 20031125
AI US 2001-973963 A1 20011011 (9)
PRAI US 2000-240790P 20001017 (60)
US 2001-304775P 20010713 (60)
DT Utility
FS APPLICATION
LN.CNT 3181
INCL INCLM: 435/006.000
INCLS: 435/368.000; 435/320.100; 435/069.100; 536/023.200; 435/226.000
NCL NCLM: 435/069.100
NCLS: 435/183.000; 435/252.300; 435/254.110; 435/254.200; 435/320.100; 435/325.000; 536/023.500
IC [7]
ICM: C12Q001-68
ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 226 OF 266 USPATFULL on STN
AN 2002:191205 USPATFULL
TI Apoptosis marker antibodies and methods of use
IN Riss, Terry, Oregon, WI, UNITED STATES
PA Promega Corporation, Madison, WI, UNITED STATES (U.S. corporation)
PI US 2002102268 A1 20020801
AI US 2001-11321 A1 20011203 (10)
RLI Division of Ser. No. US 1999-445615, filed on 8 Dec 1999, PATENTED A 371 of International Ser. No. WO 1999-US22262, filed on 24 Sep 1999, UNKNOWN
PRAI US 1998-101920P 19980924 (60)
DT Utility
FS APPLICATION
LN.CNT 2192
INCL INCLM: 424/185.100
INCLS: 435/226.000; 435/199.000
NCL NCLM: 424/185.100
NCLS: 435/226.000; 435/199.000
IC [7]
ICM: A61K039-00
ICS: C12N009-22; C12N009-64
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:185606 USPATFULL
TI Rapid identification of conditions, compounds, or compositions that inhibit, prevent, induce, modify, or reverse transitions of physical state
IN Levinson, Douglas, Sherborn, MA, UNITED STATES
PI US 2002098518 A1 20020725
AI US 2001-994585 A1 20011127 (9)
PRAI US 2000-253629P 20001128 (60)
DT Utility
FS APPLICATION
LN.CNT 3080
INCL INCLM: 435/007.100
INCLS: 435/287.200
NCL NCLM: 435/007.100
NCLS: 435/287.200
IC [7]
ICM: G01N033-53
ICS: C12M001-34
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 228 OF 266 USPATFULL on STN
AN 2002:174785 USPATFULL
TI Assay for compounds which affect conformationally altered proteins
IN Prusiner, Stanley B., San Francisco, CA, United States
Supattapone, Surachai, San Francisco, CA, United States
Scott, Michael R., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6419916 B1 20020716
AI US 1999-406972 19990928 (9)
RLI Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, now patented, Pat. No. US 6214366
DT Utility
FS GRANTED
LN.CNT 1807
INCL INCLM: 424/078.320
INCLS: 424/078.350; 424/078.360; 424/078.370; 424/078.380; 424/DIG.016
NCL NCLM: 424/078.320
NCLS: 424/078.350; 424/078.360; 424/078.370; 424/078.380; 424/DIG.016
IC [7]
ICM: A61K031-785
EXF 424/78.16; 424/78.32; 424/78.35-78.38; 514/772.3-732.7; 435/238; 435/339; 523/105; 523/122
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 229 OF 266 USPATFULL on STN
AN 2002:164826 USPATFULL
TI PURIFIED 20 KDA PRESENILIN 2 C-TERMINAL FRAGMENT AND METHODS OF SCREENING FOR COMPOUNDS THAT INHIBIT PROTEOLYSIS OF PRESENILIN 2
IN TANZI, RUDOLPH E., HULL, MA, UNITED STATES
KIM, TAE-WAN, WALTHAM, MA, UNITED STATES
PI US 2002086444 A1 20020704
AI US 1998-65902 A1 19980424 (9)
PRAI US 1997-44262P 19970424 (60)
DT Utility
FS APPLICATION
LN.CNT 2012
INCL INCLM: 436/536.000
INCLS: 530/388.100; 530/388.850; 436/548.000
NCL NCLM: 436/536.000
NCLS: 530/388.100; 530/388.850; 436/548.000
IC [7]
ICM: G01N033-53
ICS: C07K016-00; C12P021-08; G01N033-536
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 230 OF 266 USPATFULL on STN
AN 2002:149205 USPATFULL
TI Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders
IN Peet, Malcolm, Sheffield, UNITED KINGDOM
Vaddadi, Krishna S., Melbourne, AUSTRALIA
PA Laxdale Limited (non-U.S. corporation)
PI US 2002077361 A1 20020620
US 6689812 B2 20040210

RLI Division of Ser. No. US 2000-492741, filed on 27 Jan 2000, PENDING
PRAI GB 1999-1809 19990127
DT Utility
FS APPLICATION
LN.CNT 1149
INCL INCLM: 514/560.000
INCLS: 514/549.000
NCL NCLM: 514/560.000
IC [7]
ICM: A61K031-232
ICS: A61K031-202
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 231 OF 266 USPATFULL on STN
AN 2002:133437 USPATFULL
TI Compositions and methods for the therapy and diagnosis of lung cancer
IN Lodes, Michael J., Seattle, WA, UNITED STATES
Wang, Tongtong, Medina, WA, UNITED STATES
Mohamath, Raodoh, Seattle, WA, UNITED STATES
Indirias, Carol Yoseph, Seattle, WA, UNITED STATES
PI US 2002068288 A1 20020606
AI US 2001-833790 A1 20010411 (9)
PRAI US 2000-196780P 20000411 (60)
US 2000-213361P 20000621 (60)
US 2000-229763P 20000901 (60)
US 2000-230629P 20000905 (60)
US 2000-232565P 20000914 (60)
US 2000-257037P 20001219 (60)
US 2001-260796P 20010108 (60)
DT Utility
FS APPLICATION
LN.CNT 12418
INCL INCLM: 435/006.000
INCLS: 435/069.100; 435/007.230; 435/325.000; 435/320.100; 435/183.000; 536/023.100
NCL NCLM: 435/006.000
NCLS: 435/069.100; 435/007.230; 435/325.000; 435/320.100; 435/183.000; 536/023.100
IC [7]
ICM: C12Q001-68
ICS: G01N033-574; C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 232 OF 266 USPATFULL on STN
AN 2002:112890 USPATFULL
TI Caspase inhibitors and the use thereof
IN Cai, Sui Xiong, San Diego, CA, UNITED STATES
Weber, Eckard, San Diego, CA, UNITED STATES
Wang, Yan, San Diego, CA, UNITED STATES
Mills, Gordon B., Houston, TX, UNITED STATES
Green, Douglas R., San Diego, CA, UNITED STATES
PA Cytovia, Inc. (U.S. corporation)
PI US 2002058631 A1 20020516
AI US 2001-987417 A1 20011114 (9)
RLI Continuation of Ser. No. US 2000-545565, filed on 7 Apr 2000, PENDING
PRAI US 1999-158370P 19991012 (60)
US 1999-128545P 19990409 (60)
DT Utility
FS APPLICATION
LN.CNT 1995
INCL INCLM: 514/019.000
INCLS: 514/400.000; 514/419.000; 514/397.000; 514/414.000; 514/449.000; 548/311.100; 548/338.100; 548/495.000; 548/485.000
NCL NCLM: 514/019.000
NCLS: 514/400.000; 514/419.000; 514/397.000; 514/414.000; 514/449.000; 548/311.100; 548/338.100; 548/495.000; 548/485.000
IC [7]
ICM: A61K038-05
ICS: A61K031-4178; A61K031-405; A61K031-335
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 233 OF 266 USPATFULL on STN
AN 2002:102526 USPATFULL
TI Highly purified EPA for treatment of schizophrenia and related disorders
IN Peet, Malcolm, Sheffield, UNITED KINGDOM

PA Laxdale Limited, Stirling, UNITED KINGDOM (non-U.S. corporation)
PI US 6384077 B1 20020507
AI US 2000-492741 20000127 (9)
PRAI GB 1999-1809 19990127
DT Utility
FS GRANTED
LN.CNT 1157
INCL INCLM: 514/560.000
NCL NCLM: 514/560.000
IC [7]
ICM: A61K031-20
EXF 514/560
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 234 OF 266 USPATFULL on STN
AN 2002:78209 USPATFULL
TI Method of sterilizing
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Supattapone, Surachai, San Francisco, CA, UNITED STATES
Scott, Michael R., San Francisco, CA, UNITED STATES
PI US 2002041862 A1 20020411
US 6517855 B2 20030211
AI US 2001-956705 A1 20010919 (9)
RLI Continuation of Ser. No. US 2000-494814, filed on 31 Jan 2000, GRANTED, Pat. No. US 6322802 Continuation-in-part of Ser. No. US 1999-447456, filed on 22 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, GRANTED, Pat. No. US 6214366
DT Utility
FS APPLICATION
LN.CNT 1727
INCL INCLM: 424/078.270
INCLS: 422/028.000
NCL NCLM: 424/408.000
NCLS: 424/078.080; 424/078.180; 424/078.270; 424/078.350; 424/456.000; 424/DIG.016; 514/578.000; 523/105.000; 523/122.000; 525/410.000; 525/419.000; 528/363.000
IC [7]
ICM: A61K031-74
ICS: A61L009-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 235 OF 266 USPATFULL on STN
AN 2002:78206 USPATFULL
TI Antiseptic compositions for inactivating prions
IN Prusiner, Stanley B., San Francisco, CA, UNITED STATES
Supattapone, Surachai, Hanover, NH, UNITED STATES
PI US 2002041859 A1 20020411
AI US 2001-904178 A1 20010711 (9)
RLI Continuation-in-part of Ser. No. US 2000-699284, filed on 26 Oct 2000, PENDING Continuation-in-part of Ser. No. US 2000-494814, filed on 31 Jan 2000, GRANTED, Pat. No. US 6322802 Continuation-in-part of Ser. No. US 1999-447456, filed on 22 Nov 1999, PENDING Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, GRANTED, Pat. No. US 6214366 Continuation-in-part of Ser. No. US 1999-235372, filed on 20 Jan 1999, GRANTED, Pat. No. US 6221614 Continuation-in-part of Ser. No. US 1998-151057, filed on 10 Sep 1998, ABANDONED Continuation-in-part of Ser. No. US 1998-26957, filed on 20 Feb 1998, ABANDONED Continuation-in-part of Ser. No. US 1997-804536, filed on 21 Feb 1997, GRANTED, Pat. No. US 5891641
DT Utility
FS APPLICATION
LN.CNT 3354
INCL INCLM: 424/070.240
INCLS: 424/451.000; 424/405.000; 424/709.000
NCL NCLM: 424/070.240
NCLS: 424/451.000; 424/405.000; 424/709.000
IC [7]
ICM: A61K007-075
ICS: A61K009-48; A61K007-08; A61K033-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 236 OF 266 USPATFULL on STN
AN 2002:69793 USPATFULL
TI Calcium binding protein
IN Tang, Y. Tom, San Jose, CA, United States

Corley, Neil C., Mountain View, CA, United States
Gorgone, Gina A., Boulder Creek, CA, United States
PA Incyte Genomics, Inc., Palo Alto, CA, United States (U.S. corporation)
PI US 6365371 B1 20020402
AI US 1999-470253 19991222 (9)
RLI Division of Ser. No. US 1998-190965, filed on 13 Nov 1998, now patented, Pat. No. US 6071721
DT Utility
FS GRANTED
LN.CNT 2562
INCL INCLM: 435/069.100
INCLS: 435/089.200; 435/006.000; 530/350.000; 530/023.100; 530/023.500; 514/012.000; 436/086.000
NCL NCLM: 435/069.100
NCLS: 435/006.000; 436/086.000; 514/012.000; 530/350.000; 536/023.100; 536/023.500
IC [7]
ICM: C12P021-06
ICS: C07K014-00
EXF 435/69.1; 435/6; 435/69.2; 530/350; 530/23.1; 530/23.5; 514/12; 436/86
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 237 OF 266 USPATFULL on STN
AN 2002:57807 USPATFULL
TI Method of using selective parp inhibitors to prevent or treat neurotoxicity
IN Eliasson, Mikael J., Baltimore, MD, United States
Sampei, Kenji, Baltimore, MD, United States
Mandir, Allen S., Baltimore, MD, United States
Hurn, Patricia D., Upperco, MD, United States
Traystman, Richard J., Ruxton, MD, United States
Bao, Jun, Baltimore, MD, United States
Pieper, Andrew, Baltimore, MD, United States
Dawson, Ted M., Baltimore, MD, United States
Snyder, Solomon, Baltimore, MD, United States
Dawson, Valina L., Baltimore, MD, United States
PA Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
PI US 6358975 B1 20020319
AI US 2000-502046 20000211 (9)
RLI Continuation of Ser. No. WO 1998-US16959, filed on 14 Aug 1998
PRAI US 1997-55866P 19970815 (60)
DT Utility
FS GRANTED
LN.CNT 1001
INCL INCLM: 514/309.000
INCLS: 514/617.000; 514/619.000
NCL NCLM: 514/309.000
NCLS: 514/617.000; 514/619.000
IC [7]
ICM: A61K031-47
ICS: A61K031-165
EXF 514/309; 514/617; 514/619
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 238 OF 266 USPATFULL on STN
AN 2002:50952 USPATFULL
TI Caspase inhibitors and the use thereof
IN Cai, Sui Xiong, San Diego, CA, United States
Weber, Eckard, San Diego, CA, United States
Wang, Yan, San Diego, CA, United States
Mills, Gordon B., Houston, TX, United States
Green, Douglas R., San Diego, CA, United States
PA Cytovia, Inc., Irvine, CA, United States (U.S. corporation)
PI US 6355618 B1 20020312
AI US 2000-545565 20000407 (9)
PRAI US 1999-158370P 19991012 (60)
US 1999-128545P 19990409 (60)
DT Utility
FS GRANTED
LN.CNT 2032
INCL INCLM: 514/019.000
INCLS: 546/335.000; 549/287.000; 549/405.000; 560/038.000; 560/039.000; 560/125.000; 560/169.000; 560/170.000; 562/450.000; 562/507.000; 562/561.000; 562/564.000; 514/237.500; 514/357.000; 514/456.000;

NCL NCLM: 514/019.000
NCLS: 514/237.500; 514/357.000; 514/456.000; 514/478.000; 514/557.000; 514/563.000; 546/335.000; 549/287.000; 549/405.000; 560/038.000; 560/039.000; 560/125.000; 560/169.000; 560/170.000; 562/450.000; 562/507.000; 562/561.000; 562/564.000
IC [7]
ICM: A61K038-05
ICS: C07D213-04; C07D311-06
EXF 514/19; 514/2; 514/237.5; 514/357; 514/456; 514/478; 514/563; 514/557; 260/998.2; 544/162; 546/335; 549/287; 549/405; 560/169; 560/170; 560/38; 560/39; 560/125; 562/564; 562/561; 562/567; 562/450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 239 OF 266 USPATFULL on STN
AN 2002:39659 USPATFULL
TI Apoptosis marker antibodies and methods of use
IN Riss, Terry, Oregon, WI, United States
PA Promega Corporation, Madison, WI, United States (U.S. corporation)
PI US 6350452 B1 20020226
WO 2000017648 20000330
AI US 1999-445615 19991208 (9)
WO 1999-US22262 19990924
19991208 PCT 371 date
PRAI US 1998-101920P 19980924 (60)
DT Utility
FS GRANTED
LN.CNT 2086
INCL INCLM: 424/185.100
INCLS: 530/388.100; 530/387.900; 435/069.100; 424/185.100
NCL NCLM: 424/185.100
NCLS: 435/069.100; 530/387.900; 530/388.100
IC [7]
ICM: A61K039-00
EXF 530/388.1; 530/387.9; 435/69.1; 424/185.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 240 OF 266 USPATFULL on STN
AN 2002:34458 USPATFULL
TI Remedies for motor dysfunction and GAPDH expression inhibitors
IN Ishitani, Ryoichi, Shiki, JAPAN
Katsube, Nobuo, Mishima-gun, JAPAN
PA Ono Pharmaceutical Co., Ltd., Osaka, JAPAN (non-U.S. corporation)
PI US 6348488 B1 20020219
WO 2000020387 20000413
AI US 2001-806572 20010402 (9)
WO 1999-JP5414 19991001
20010402 PCT 371 date
PRAI JP 1998-281498 19981002
DT Utility
FS GRANTED
LN.CNT 521
INCL INCLM: 514/422.000
NCL NCLM: 514/422.000
IC [7]
ICM: A61K031-40
EXF 514/422
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 241 OF 266 USPATFULL on STN
AN 2002:29458 USPATFULL
TI APAF-1 an activator of caspase-3
IN Wang, Xiaodong, Dallas, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
PI US 6346607 B1 20020212
AI US 1999-435115 19991105 (9)
RLI Division of Ser. No. US 1998-92508, filed on 5 Jun 1998
PRAI US 1997-55258P 19970807 (60)
US 1997-48807P 19970605 (60)
DT Utility
FS GRANTED
LN.CNT 3330
INCL INCLM: 530/350.000
INCLS: 530/409.000; 435/183.000; 435/004.000
NCL NCLM: 530/350.000

IC [7]
ICM: C07K014-00
ICS: C08H001-00; C12N009-00; C12Q001-00
EXF 530/350; 530/409; 435/183; 435/4
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 242 OF 266 USPATFULL on STN
AN 2002:27095 USPATFULL
TI Method for treatment of neurodegenerative diseases
IN Kim, Tae-Wan, Fort Lee, NJ, UNITED STATES
Tanzi, Rudolph E., Hull, MA, UNITED STATES
Yoo, Andrew S., Fort Lee, NJ, UNITED STATES
PA The General Hospital Corporation (U.S. corporation)
PI US 2002015941 A1 20020207
AI US 2001-814179 A1 20010322 (9)
RLI Continuation of Ser. No. WO 2000-US20138, filed on 25 Jul 2000, UNKNOWN
PRAI US 2000-191109P 20000322 (60)
DT Utility
FS APPLICATION
LN.CNT 1637
INCL INCLM: 435/004.000
INCLS: 514/002.000
NCL NCLM: 435/004.000
NCLS: 514/002.000
IC [7]
ICM: A01N037-18
ICS: A61K038-00; C12Q001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 243 OF 266 USPATFULL on STN
AN 2002:19420 USPATFULL
TI Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
IN Weber, Eckard, San Diego, CA, United States
Cai, Sui Xiong, San Diego, CA, United States
Keana, John F. W., Eugene, OR, United States
Drewe, John A., Costa Mesa, CA, United States
Zhang, Han-Zhong, Irvine, CA, United States
PA Cytovia, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6342611 B1 20020129
AI US 1998-168888 19981009 (9)
PRAI US 1997-61582P 19971010 (60)
DT Utility
FS GRANTED
LN.CNT 4372
INCL INCLM: 549/227.000
NCL NCLM: 549/227.000
IC [7]
ICM: C07D311-88
EXF 549/227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 244 OF 266 USPATFULL on STN
AN 2002:1317 USPATFULL
TI Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof
IN Cai, Sui Xiong, San Diego, CA, United States
Keana, John F. W., Eugene, OR, United States
Drewe, John A., Costa Mesa, CA, United States
Zhang, Han-Zhong, Irvine, CA, United States
PA Cytovia, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6335429 B1 20020101
AI US 2000-521650 20000308 (9)
RLI Division of Ser. No. US 1998-168888, filed on 9 Oct 1998
PRAI US 1998-145746P 19980303 (60)
US 1997-61582P 19971010 (60)
DT Utility
FS GRANTED
LN.CNT 4329
INCL INCLM: 530/402.000
INCLS: 436/546.000; 435/018.000; 435/024.000
NCL NCLM: 530/402.000
NCLS: 435/018.000; 435/024.000; 436/546.000

ICM: C07K017-02
ICS: G01N033-533
EXF 436/546; 530/402
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 245 OF 266 USPATFULL on STN
AN 2001:231048 USPATFULL
TI Food additives which affect conformationally altered proteins
IN Prusiner, Stanley B., 400 Pacheco St., San Francisco, CA, United States 94116
Supattapone, Surachai, 225 Buckingham Way #702, San Francisco, CA, United States 94132
Scott, Michael R., 1200 Clayton St., #9, San Francisco, CA, United States 94114
PI US 6331296 B1 20011218
AI US 1999-447456 19991122 (9)
RLI Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, now patented, Pat. No. US 6214366
DT Utility
FS GRANTED
LN.CNT 1764
INCL INCLM: 424/078.080
INCLS: 424/078.170; 424/078.180; 424/078.270; 424/078.310; 424/078.320; 424/405.000; 424/439.000; 424/442.000; 424/438.000; 424/078.330; 424/078.340; 424/078.350; 426/271.000; 426/532.000; 525/512.000; 525/513.000; 525/514.000; 523/122.000
NCL NCLM: 424/078.080
NCLS: 424/078.170; 424/078.180; 424/078.270; 424/078.310; 424/078.320; 424/078.330; 424/078.340; 424/078.350; 424/405.000; 424/438.000; 424/439.000; 424/442.000; 426/271.000; 426/532.000; 523/122.000; 525/512.000; 525/513.000; 525/514.000
IC [7]
ICM: A01N025-10
EXF 424/DIG.76; 424/78.32; 424/78.35-78.38; 424/438-442; 424/405; 424/78.08; 424/78.17; 424/78.18; 424/78.27; 424/78.31; 514/772.3-772.7; 523/122; 525/512-514; 426/271; 426/286; 426/326; 426/335; 426/532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 246 OF 266 USPATFULL on STN
AN 2001:214671 USPATFULL
TI Method of sterilizing
IN Prusiner, Stanley B., San Francisco, CA, United States
Supattapone, Surachai, San Francisco, CA, United States
Scott, Michael R., San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6322802 B1 20011127
AI US 2000-494814 20000131 (9)
RLI Continuation-in-part of Ser. No. US 1999-447456, filed on 22 Nov 1999
Continuation-in-part of Ser. No. US 1999-322903, filed on 1 Jun 1999, now patented, Pat. No. US 6214366
DT Utility
FS GRANTED
LN.CNT 1702
INCL INCLM: 424/405.000
INCLS: 424/078.080; 424/078.180; 424/078.270; 424/078.350; 424/DIG.016; 528/363.000; 128/114.100; 128/832.000; 128/899.000; 600/003.000; 600/029.000; 600/030.000; 600/036.000; 600/372.000; 602/508.000; 604/890.100; 623/001.100; 623/920.000
NCL NCLM: 424/405.000
NCLS: 128/114.100; 128/832.000; 128/899.000; 422/027.000; 424/078.080; 424/078.180; 424/078.270; 424/078.350; 424/DIG.016; 528/363.000; 600/003.000; 600/029.000; 600/030.000; 600/036.000; 600/372.000; 604/890.100; 623/001.100; 623/920.000
IC [7]
ICM: A01N025-10
EXF 424/DIG.16; 424/405; 424/76.8; 424/78.07; 424/78.08; 424/78.17; 424/78.18; 424/78.26; 424/78.27; 424/78.31; 424/78.35; 424/78.37; 623/920; 623/11.11; 623/1.1; 623/2.1; 623/3.1; 623/4.1; 623/7; 623/9; 623/10; 604/890.1; 602/48; 602/508; 128/114.1; 128/832; 128/842; 128/899; 600/372; 600/478; 600/462; 600/488; 600/466; 600/3; 600/29; 600/30; 600/36
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 247 OF 266 USPATFULL on STN

TI Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
IN Zoghbi, Huda Y., Houston, TX, United States
Orr, Harry T., Minneapolis, MN, United States
Cummings, Christopher J., San Francisco, CA, United States
PI US 2001032339 A1 20011018
AI US 2001-884384 A1 20010619 (9)
RLI Division of Ser. No. US 1999-321916, filed on 28 May 1999, PENDING
PRAI US 1998-87128P 19980529 (60)
DT Utility
FS APPLICATION
LN.CNT 1226
INCL INCLM: 800/013.000
INCLS: 800/018.000
NCL NCLM: 800/013.000
NCLS: 800/018.000
IC [7]
ICM: A01K067-00
ICS: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 248 OF 266 USPATFULL on STN
AN 2001:178878 USPATFULL
TI Antisense modulation of caspase 3 expression
IN Zhang, Hong, Carlsbad, CA, United States
Cowsert, Lex M., Carlsbad, CA, United States
PA Isis Pharmaceuticals Inc., Carlsbad, CA, United States (U.S. corporation)
PI US 6303374 B1 20011016
AI US 2000-484617 20000118 (9)
DT Utility
FS GRANTED
LN.CNT 2749
INCL INCLM: 435/375.000
INCLS: 435/006.000; 435/455.000; 435/458.000; 536/023.100; 536/024.100; 536/024.500
NCL NCLM: 435/375.000
NCLS: 435/006.000; 435/455.000; 435/458.000; 536/023.100; 536/024.100; 536/024.500
IC [7]
ICM: C07H021-04
ICS: C12Q001-68; C12N015-85
EXF 435/6; 435/455; 435/458; 435/375; 536/23.1; 536/24.1; 536/24.5; 514/44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 249 OF 266 USPATFULL on STN
AN 2001:171132 USPATFULL
TI CHAPERONE SUPPRESSION OF ATAXIN-1 AGGREGATION AND ALTERED SUBCELLULAR PROTEASOME LOCALIZATION IMPLY PROTEIN MISFILIND IN SCA1
IN ZOGHBI, HUDA Y., HOUSTON, TX, United States
ORR, HARRY T., MINNEAPOLIS, MN, United States
DEFRANCO, DONALD B., PITTSBURGH, PA, United States
MANCINI, MICHAEL A., HOUSTON, TX, United States
STENOIEN, DAVID, HOUSTON, TX, United States
CUMMINGS, CHRISTOPHER J., HOUSTON, TX, United States
PI US 2001027182 A1 20011004
AI US 1999-321916 A1 19990528 (9)
PRAI US 1998-87128P 19980529 (60)
DT Utility
FS APPLICATION
LN.CNT 1227
INCL INCLM: 514/044.000
INCLS: 514/002.000; 800/013.000
NCL NCLM: 514/044.000
NCLS: 514/002.000; 800/013.000
IC [7]
ICM: A61K048-00
ICS: A01K067-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 250 OF 266 USPATFULL on STN
AN 2001:158461 USPATFULL
TI Apaf-1 an activator of caspase-3
IN Zou, Hua, Dallas, TX, United States
Henzel, William J., San Mateo, CA, United States

PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)
Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6291643 B1 20010918
AI US 1998-92508 19980605 (9)
PRAI US 1997-48807P 19970605 (60)
US 1997-55258P 19970807 (60)
DT Utility
FS GRANTED
LN.CNT 2840
INCL INCLM: 530/350.000
INCLS: 536/023.100; 435/006.000; 435/320.100; 435/325.000
NCL NCLM: 530/350.000
NCLS: 435/006.000; 435/320.100; 435/325.000; 536/023.100
IC [7]
ICM: C07R014-00
ICS: C12Q001-68; C07H021-00; C12N015-00; C12N005-00
EXF 530/350; 536/23.1; 435/6
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 251 OF 266 USPATFULL on STN
AN 2001:145063 USPATFULL
TI Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
IN Pulst, Stefan M., Los Angeles, CA, United States
Shibata, Hiroki, Los Angeles, CA, United States
PA CEDARS-SINAI MEDICAL CENTER (U.S. corporation)
PI US 2001018198 A1 20010830
US 6617430 B2 20030909
AI US 2001-794591 A1 20010226 (9)
RLI Division of Ser. No. US 1998-145391, filed on 1 Sep 1998, GRANTED, Pat. No. US 6194171
DT Utility
FS APPLICATION
LN.CNT 1599
INCL INCLM: 435/069.100
INCLS: 435/325.000; 435/320.100; 536/023.500; 435/006.000
NCL NCLM: 530/350.000
IC [7]
ICM: C12P021-02
ICS: C07H021-04; C12N005-06; C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 252 OF 266 USPATFULL on STN
AN 2001:123570 USPATFULL
TI DNA fragmentation factor involved in apoptosis
IN Wang, Xiaodong, Dallas, TX, United States
Liu, Xueson, Dallas, TX, United States
PA Board of Regents, The University of Texas System (U.S. corporation)
PI US 2001011078 A1 20010802
AI US 2000-748451 A1 20001222 (9)
RLI Division of Ser. No. US 1998-61702, filed on 16 Apr 1998, GRANTED, Pat. No. US 6165737
DT Utility
FS APPLICATION
LN.CNT 5190
INCL INCLM: 514/044.000
INCLS: 435/320.100; 435/196.000; 435/006.000; 530/388.260; 536/023.200; 424/094.600; 424/093.200
NCL NCLM: 514/044.000
NCLS: 435/320.100; 435/196.000; 435/006.000; 530/388.260; 536/023.200; 424/094.600; 424/093.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04; C07K016-40; A61K038-46; C12N009-16; A61K031-713
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 253 OF 266 USPATFULL on STN
AN 2001:93669 USPATFULL
TI Fluorescence dyes and their applications for whole-cell fluorescence screening assays for caspases, peptidases, proteases and other enzymes and the use thereof
IN Zhang, Han-Zhong, San Diego, CA, United States
Cai, Sui Xiong, San Diego, CA, United States

PI US 6248904 B1 20010619
AI US 1999-357952 19990721 (9)
PRAI US 1998-93642P 19980721 (60)
DT Utility
FS GRANTED
LN.CNT 2970
INCL INCLM: 549/227.000
INCLS: 435/015.000; 435/023.000; 435/024.000; 436/093.000
NCL NCLM: 549/227.000
NCLS: 435/015.000; 435/023.000; 435/024.000; 436/093.000
IC [7]
ICM: C07D311-88
ICS: G01N033-15; C12Q001-48; C12Q001-37
EXF 549/227
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 254 OF 266 USPATFULL on STN
AN 2001:51590 USPATFULL
TI Clearance and ***inhibition*** of conformationally altered proteins
IN Prusiner, Stanley B., San Francisco, CA, United States
Supattapone, Surachai, San Francisco, CA, United States
Scott, Michael, San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 6214366 B1 20010410
AI US 1999-322903 19990601 (9)
DT Utility
FS Granted
LN.CNT 1037
INCL INCLM: 424/405.000
INCLS: 424/438.000; 424/442.000; 424/484.000; 424/DIG.016; 424/078.320; 424/078.350; 424/078.360; 424/078.370; 424/078.380; 514/772.300; 514/772.400; 514/772.500; 514/772.600; 514/772.700
NCL NCLM: 424/405.000
NCLS: 424/078.320; 424/078.350; 424/078.360; 424/078.370; 424/078.380; 424/438.000; 424/442.000; 424/484.000; 424/DIG.016; 514/772.300; 514/772.400; 514/772.500; 514/772.600; 514/772.700
IC [7]
ICM: A01N025-10
EXF 424/78.32; 424/78.35; 424/78.38; 424/405; 424/438; 424/442; 424/DIG.16; 514/772.3-772.7
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 255 OF 266 USPATFULL on STN
AN 2001:29324 USPATFULL
TI Nucleic acids encoding ataxin-2 binding proteins
IN Pulst, Stefan M., Los Angeles, CA, United States
Shibata, Hiroki, Los Angeles, CA, United States
PA Cedard-Sinai Medical Center, Los Angeles, CA, United States (U.S. corporation)
PI US 6194171 B1 20010227
AI US 1998-145391 19980901 (9)
DT Utility
FS Granted
LN.CNT 1573
INCL INCLM: 435/069.100
INCLS: 435/243.000; 435/320.100; 435/325.000; 435/410.000; 536/023.500
NCL NCLM: 435/069.100
NCLS: 435/243.000; 435/320.100; 435/325.000; 435/410.000; 536/023.500
IC [7]
ICM: C12P021-02
ICS: C12N001-00; C12N005-10; C12N015-12; C12N015-63
EXF 536/23.5; 435/320.1; 435/243; 435/325; 435/420; 435/69.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 256 OF 266 USPATFULL on STN
AN 2001:18457 USPATFULL
TI Dipeptide apoptosis inhibitors and the use thereof
IN Keana, John F. W., Eugene, OR, United States
Cai, Sui Xiong, San Diego, CA, United States
Guastella, John, Irvine, CA, United States
Yang, Wu, Irvine, CA, United States
Drewe, John A., Costa Mesa, CA, United States
PA Cytovia, Inc., San Diego, CA, United States (U.S. corporation)
PI US 6184210 B1 20010206

RLI Continuation-in-part of Ser. No. US 1998-168945, filed on 9 Oct 1998, now abandoned
PRAI US 1997-61676P 19971010 (60)
DT Utility
FS Granted
LN.CNT 1500
INCL INCLM: 514/019.000
INCLS: 514/002.000; 260/998.200
NCL NCLM: 514/019.000
NCLS: 260/998.200; 514/002.000
IC [7]
ICM: A61K038-05
ICS: C07K004-00
EXF 514/219; 514/20; 548/496; 560/9; 560/37; 560/38; 560/39; 560/41; 560/42; 560/169; 562/426; 562/442; 562/443; 562/444; 562/448; 562/450; 564/153; 564/155; 564/157; 564/158; 564/159; 424/85.1; 435/1.1; 435/1.2; 435/2; 435/260; 435/366; 435/374; 435/404; 260/998.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 257 OF 266 USPATFULL on STN
AN 2001:10721 USPATFULL
TI Assays and kits for ***inhibition*** of polyglutamine-induced cell death
IN Yuan, Junying, Newton, MA, United States
Sanchez, Ivelisse, Watertown, MA, United States
PA President and Fellows of Harvard College, Cambridge, MA, United States (U.S. corporation)
PI US 6177259 B1 20010123
AI US 1999-368540 19990805 (9)
DT Utility
FS Granted
LN.CNT 1839
INCL INCLM: 435/023.000
INCLS: 435/004.000; 435/183.000
NCL NCLM: 435/023.000
NCLS: 435/004.000; 435/183.000
IC [7]
ICM: C12Q001-37
ICS: C12Q001-00; C12N009-00
EXF 435/4; 435/23; 435/183
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 258 OF 266 USPATFULL on STN
AN 2000:174366 USPATFULL
TI DNA fragmentation factor involved in apoptosis
IN Wang, Xiaodong, Dallas, TX, United States
Liu, Xuesong, Dallas, TX, United States
PA The University of Texas System Board of Regents, Austin, TX, United States (U.S. corporation)
PI US 6165737 20001226
AI US 1998-61702 19980416 (9)
DT Utility
FS Granted
LN.CNT 5176
INCL INCLM: 435/007.600
INCLS: 435/007.910; 435/023.000; 435/252.300; 435/252.330; 435/320.100; 536/023.200
NCL NCLM: 435/007.600
NCLS: 435/007.910; 435/023.000; 435/252.300; 435/252.330; 435/320.100; 536/023.200
IC [7]
ICM: C12Q001-00
ICS: C12Q001-37; C12N009-64; C12N015-70; C12N015-74
EXF 435/23; 435/69.1; 435/252.3; 435/252.33; 435/320.1; 435/7.6; 536/23.5; 536/23.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 259 OF 266 USPATFULL on STN
AN 2000:160988 USPATFULL
TI Dipeptide caspase inhibitors and the use thereof
IN Cai, Sui Xiong, San Diego, CA, United States
Drewe, John, Costa Mesa, CA, United States
Wang, Yan, San Diego, CA, United States
Weber, Eckard, San Diego, CA, United States
PA Cytovia, Inc., San Diego, CA, United States (U.S. corporation)

AI US 1999-270735 19990316 (9)
DT Utility
FS Granted
LN.CNT 1571
INCL INCLM: 514/019.000
INCLS: 435/001.100; 435/001.200; 435/002.000; 548/200.000; 549/076.000; 549/077.000; 549/493.000; 549/494.000; 560/037.000; 560/038.000; 560/039.000; 560/040.000; 560/041.000; 560/042.000; 560/125.000; 560/169.000; 562/442.000; 562/443.000; 562/444.000; 562/445.000; 562/448.000; 562/449.000
NCL NCLM: 514/019.000
NCLS: 435/001.100; 435/001.200; 435/002.000; 548/200.000; 549/076.000; 549/077.000; 549/493.000; 549/494.000; 560/037.000; 560/038.000; 560/039.000; 560/040.000; 560/041.000; 560/042.000; 560/125.000; 560/169.000; 562/442.000; 562/443.000; 562/444.000; 562/445.000; 562/448.000; 562/449.000
IC [7]
ICM: A01N001-02
ICS: A01N003-00; A61K038-05; C07K005-06
EXF 514/19; 435/1.1; 435/1.2; 435/1.3; 435/2; 549/76; 549/77; 549/493; 549/494; 549/37; 549/38; 549/39; 549/40; 549/41; 549/42; 549/125; 549/169; 562/442; 562/443; 562/444; 562/445; 562/448; 562/449; 562/451; 562/507; 562/561; 562/564; 548/200
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 260 OF 266 USPATFULL on STN
AN 2000:137814 USPATFULL
TI Allelic polygene diagnosis of reward deficiency syndrome and treatment
IN Blum, Kenneth, San Antonio, TX, United States
PA City of Hope National Medical Center, Duarte, CA, United States (U.S. corporation)
The University of Texas System AMD Board of Regents, Austin, TX, United States (U.S. corporation)
PI US 6132724 20001017
AI US 1998-69886 19980429 (9)
DT Utility
FS Granted
LN.CNT 20845
INCL INCLM: 424/195.100
INCLS: 514/188.000; 514/561.000
NCL NCLM: 424/725.000
NCLS: 514/188.000; 514/561.000
IC [7]
ICM: A61K035-78
EXF 514/188; 514/561; 424/195.1

L7 ANSWER 261 OF 266 USPATFULL on STN
AN 2000:106055 USPATFULL
TI CAPON: a protein associated with neuronal nitric oxide synthase
IN Snyder, Solomon H., Baltimore, MD, United States
Jaffrey, Samie R., Baltimore, MD, United States
PA The Johns Hopkins University, Baltimore, MD, United States (U.S. corporation)
PI US 6103872 20000815
AI US 1998-10998 19980122 (9)
DT Utility
FS Granted
LN.CNT 1968
INCL INCLM: 530/350.000
INCLS: 530/326.000; 530/327.000; 530/328.000
NCL NCLM: 530/350.000
NCLS: 530/326.000; 530/327.000; 530/328.000
IC [7]
ICM: C07K007-06
ICS: C07K007-08; C07K014-47
EXF 530/300; 530/324; 530/325; 530/326; 530/327; 530/328; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 262 OF 266 USPATFULL on STN
AN 2000:70651 USPATFULL
TI Calcium binding protein
IN Tang, Y. Tom, San Jose, CA, United States
Guegler, Karl J., Menlo Park, CA, United States
Corley, Neil C., Mountain View, CA, United States
Gorgone, Gina A., Boulder Creek, CA, United States

corporation)
PI US 6071721 20000606
AI US 1998-190965 19981113 (9)
DT Utility
FS Granted
LN.CNT 2567
INCL INCLM: 435/069.100
INCLS: 435/006.000; 530/350.000; 536/023.100; 536/023.200
NCL NCLM: 435/069.100
NCLS: 435/006.000; 530/350.000; 536/023.100; 536/023.200
IC [7]
ICM: C12N015-12
EXF 435/69.1; 435/6; 530/350; 536/23.1; 536/23.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 263 OF 266 USPATFULL on STN
AN 2000:53891 USPATFULL
TI Methods and compositions for flow cytometric determination of DNA sequences
IN Fulton, R. Jerrold, Cedar Hill, TX, United States
PA Luminex Corporation, Austin, TX, United States (U.S. corporation)
PI US 6057107 20000502
AI US 1998-55329 19980406 (9)
RLI Continuation of Ser. No. US 1995-542401, filed on 11 Oct 1995, now patented, Pat. No. US 5736330
DT Utility
FS Granted
LN.CNT 876
INCL INCLM: 435/006.000
INCLS: 435/091.100; 435/091.200
NCL NCLM: 435/006.000
NCLS: 435/091.100; 435/091.200
IC [7]
ICM: C12Q001-68
EXF 422/68.1; 435/6; 435/91.1; 435/91.2; 935/77; 935/78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 264 OF 266 USPATFULL on STN
AN 1998:36541 USPATFULL
TI Method and compositions for flow cytometric determination of DNA sequences
IN Fulton, R. Jerrold, Cedar Hill, TX, United States
PA Luminex Corporation, Austin, TX, United States (U.S. corporation)
PI US 5736330 19980407
AI US 1995-542401 19951011 (8)
DT Utility
FS Granted
LN.CNT 850
INCL INCLM: 435/006.000
INCLS: 435/005.000; 435/091.200; 435/007.100; 435/007.200; 435/007.900; 435/210.000; 536/024.300
NCL NCLM: 435/006.000
NCLS: 435/005.000; 435/007.100; 435/007.200; 435/007.900; 435/091.200; 435/210.000; 536/024.300
IC [6]
ICM: C12P001-68
ICS: C12P019-34; C12Q001-70; C07H021-04
EXF 435/6; 435/5; 435/210; 435/91.2; 435/7.1-7.9; 436/523; 536/24.3; 536/26.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 265 OF 266 USPATFULL on STN
AN 1998:22065 USPATFULL
TI Method to screen compounds that affect GAPDH binding to polyglutamine
IN Burke, James R., Chapel Hill, NC, United States
Vance, Jeffery M., Durham, NC, United States
Enghild, Jan, Durham, NC, United States
Strittmatter, Warren J., Durham, NC, United States
PA Duke University, Durham, NC, United States (U.S. corporation)
PI US 5723301 19980303
AI US 1995-553110 19951103 (8)
DT Utility
FS Granted
LN.CNT 1286
INCL INCLM: 435/007.100

IC [6]
ICM: G01N033-68
EXF 435/7.1; 435/7.8
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 266 OF 266 WPIDS COPYRIGHT 2004 THOMSON DERWENT on STN
AN 2004-035757 [04] WPIDS
DNC C2004-014384
TI Use of exogenous ***huntingtin*** protein for modulating cell survival, treating cell degenerative or proliferative disease e.g. Alzheimer's disease, cancer or psoriasis, or ameliorating cytotoxic effects of a therapeutic compound.
DC B04 D16
IN CHAN, E; HAYDEN, M; LEAVITT, B R
PA (UYBR-N) UNIV BRITISH COLUMBIA
CYC 1
PI CA 2424577 A1 20031022 (200404)* EN 42p A61K038-17
ADT CA 2424577 A1 CA 2003-2424577 20030422
PRAI US 2002-374156P 20020422
IC ICM A61K038-17
ICS A61K031-138; A61K031-7088; A61K039-395; A61K048-00; A61P025-00; A61P025-28; A61P035-00; C12Q001-48
STN INTERNATIONAL LOGOFF AT 13:03:03 ON 12 MAR 2004